

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
21 October 2004 (21.10.2004)

PCT

(10) International Publication Number  
**WO 2004/090145 A2**

(51) International Patent Classification<sup>7</sup>: C12N 15/864, A61K 48/00

(21) International Application Number:  
PCT/US2004/010045

(22) International Filing Date: 31 March 2004 (31.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/459,323 31 March 2003 (31.03.2003) US  
60/512,347 16 October 2003 (16.10.2003) US

(71) Applicants (for all designated States except US): UNIVERSITY OF IOWA RESEARCH FOUNDATION [US/US]; Oakdale Research Center, 100 Oakdale Campus #214 TIC, Iowa City, Iowa 52242-5000 (US). TARGETED GENETICS CORPORATION [US/US]; 1100 Olive Way, Suite 100, Seattle, Washington 98101 (US).

(71) Applicants and

(72) Inventors: ENGELHARDT, John, F. [US/US]; 8 Laredo Court, Iowa City, Iowa 52246 (US). MUNSON, Keith, L. [US/US]; 29 Eturia Street, #308, Seattle, Washington 98109 (US).

(74) Agents: STEFFEY, Charles, E. et al.; Schwegman, Lundberg, Woessner & Kluth P.A., P.O. Box 2938, Minneapolis, Minnesota 55402 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.



(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS AND METHODS TO ENHANCE RAAV TRANSDUCTION



(57) Abstract: Agents and methods to alter rAAV transduction are provided.

WO 2004/090145 A2

## COMPOUNDS AND METHODS TO ENHANCE rAAV TRANSDUCTION

### Cross-Reference to Related Applications

5           The present application claims the benefit of the filing date of U.S. application Serial No. 60/459,323, filed March 31, 2003, and U.S. application Serial No. 60/512,347, filed October 16, 2003, the disclosures of which are incorporated by reference herein.

### Statement of Government Rights

10           This invention was made, at least in part, with a grant from the Government of the United States of America (grant HL58340 from the National Institutes of Health). The Government may have certain rights in the invention.

### Background of the Invention

15           Recombinant adeno-associated virus (rAAV) has several characteristics that underscore its potential as a gene therapy vector for numerous target organs and inherited or acquired diseases, a vaccine vector or for diagnostics. Moreover, rAAV vector systems potentially offer major advantages over other  
20           gene delivery vehicles, including adenoviruses and retroviruses. These include the ability of rAAV to readily transduce non dividing or slowly dividing cells and persist essentially for the lifetime of the cell, the lack of undesirable cellular immune responses since all viral genes can be deleted from the vector, and the fact that AAV has never been associated with human disease.

25           A serotype 2 rAAV (rAAV-2) vector expressing the CFTR gene was the first AAV vector to be utilized in clinical trials. This vector has demonstrated promise in patients with cystic fibrosis and has advanced to phase II trials (Flotte et al., 1996; Wagner et al., 1999; Wagner et al., 2002; Aitken et al., 2001). In recent years, additional rAAV 2 vectors have been or are currently being  
30           advanced to clinical trials to treat a number of disease states including a rAAV2 factor IX vector in phase I clinical trials in patients with hemophilia B (Kay et al., 2000), and a rAAV2 sarcoglycan vector in phase I clinical trials of patients with CNS disease. Additionally, clinical trials for rAAV expressing proteins to treat Parkinsons disease (RDAC, 2001), and Canavan's disease (Janson et al.,  
35           2001), have been proposed.

Other serotypes of AAV are known to exist, although they are all closely related at the functional, structural, and genetic level (see, e.g., Blacklow, 1988; and Rose, 1974). All AAV serotypes exhibit very similar replication properties mediated by homologous rep genes; all bear three related capsid proteins such as those expressed in AAV-2, and all contain 5'-3' ITR sequences. Currently, 8 serotypes of AAV have been described with the complete genome sequence information available for AAV-1-AAV-6 (Srivastava et al., 1983; Miramatsu et al., 1996; Chiorini et al., 1967; Xiao et al., 1999; Chiorini et al., 1999; Bantel-Schaal et al., 1999; Rutledge et al., 1998) and capsid gene sequence for AAV-7 and AAV-8 (Gao et al., 2002). AAV-6 has been shown to be a recombinant between AAV-1 and AAV-2. In addition, there are two isolates and sequences of AAV-3 that differ from each other in a number of amino acids in both rep and cap (Rutledge et al., 1998). AAV-5 is the most distantly related of the serotypes, and displays a serotype-specific terminal resolution site (trs) in its ITR (Chiorini et al., 1999). Even though rep proteins from other serotypes bind the AAV-5 ITR, they do not efficiently cleave at the trs. In addition to recent developments in AAV and rAAV serotypes, numerous groups are experimenting with rAAV pseudotypes.

Variations in cell surface receptor usage for binding of rAAV to cell membranes exists among various serotypes and may be in part responsible for the differences in transduction efficiencies in various tissue and cell types. Although conflicting data exists, it has become apparent that there are differences among the serotypes in the efficiency of transgene expression in various tissues and cell types. For example, rAAV-1 and rAAV-7 overall appear several orders of magnitude superior for transduction of murine muscle tissue although rAAV-5 also demonstrates enhancement compared to rAAV-2 (Gao et al., 2002; Chao et al., 2000; Rabinowitz et al., 2002; Hildinger et al., 2001). rAAV-8 transduces murine liver up to 100-fold higher (Gao et al., 2002) than rAAV-2, and rAAV-5 appears superior in transduction of cells of the murine respiratory tract (Zabner et al., 2000; Aurichio et al., 2002). rAAV-5 generally appears to be superior to rAAV-2-based vectors in all tissue types tested so far including CNS, muscle, liver and retina (Chao et al., 2000; Rabinowitz et al., 2002; Hildinger et al., 2001; Aurichio et al., 2002; Davidson et al., 2000; Mingozzi et al., 2002). Similarly, rAAV-6 is more efficient than rAAV-2 in

transducing murine airway epithelia and alveoli, while rAAV-3 is superior in transducing smooth muscle cells (Halbert et al., 2001; Halbert et al., 2000). rAAV-4 transduces ependymal cells in the murine CNS almost exclusively, while rAAV-5 transduces both neurons and astrocytes (Davidson et al., 2000).

- 5 In retina, a number of studies have demonstrated large differences among serotypes in the ability to transduce photoreceptor cells and the retinal pigmented epithelium (Walters et al., 2001; Auricchio et al., 2001; Yang et al., 2002).

- Despite the fact that rAAV has a very broad host tropism in a variety of human, simian, and rodent cell lines (Lebkowski et al., 1988; Muzyczka, 1992),
- 10 the overall transduction efficiency in human airway epithelia and other tissues seems to be quite low. Previous studies have suggested that single to double strand conversion of the rAAV genome may be the rate-limiting step for AAV-mediated gene transfer (Ferrari et al., 1996; Fisher et al., 1996). These studies demonstrated that adenovirus E4orf6 enhances the conversion of single-stranded
- 15 DNA genomes to linear, double-stranded replication form dimers (Rfd) and monomers (Rfm), through a pathway characteristic of the lytic phase of rAAV replication. The structure of these replication forms consists of head-to-head and tail-to-tail orientated linear concatamers with one covalently linked end (Ferrari et al., 1996; Fisher et al., 1996). In contrast, recent studies have elucidated an
- 20 alternative pathway for the conversion of rAAV genomes to double-stranded circular intermediates with head-to-tail monomer and concatamer structures (Duan et al., 1999; Duan et al., 1998; Sanlioglu et al., 1999). The distinct pathways leading to the formation of either circular AAV genomes or Rf intermediates appear to be regulated by different cellular factors. For example,
- 25 adenoviral E4orf6 expression decreases circular genome formation while adenovirus E2a enhances its formation (Duan et al., 1999). Similarly, UV irradiation also enhances AAV circular intermediate formation but not Rf intermediates (Sanlioglu et al., 1999).

- More recently, when cellular binding protein FK506- (FKBP-52) was
- 30 phosphorylated at tyrosine residues (by the epidermal growth factor receptor protein tyrosine kinase), FKBP-52 was demonstrated to be bound to the single-stranded D-sequence of the AAV ITR causing an impairment in second strand synthesis (Qing et al., 2001; Qing et al., 2003). The efficiency of rAAV transduction in a number of cell types *in vitro* and *in vivo* correlates with the

phosphorylation state of FKBP-52. For example, in HeLa cells, overexpression of a cellular phosphatase (TC-PTP), led to dephosphorylation of the FKBP-52, an increase in AAV second-strand DNA synthesis, and an increase in transgene expression. Transgenic mice expressing either the wild type (wt) or a

5 catalytically mutant form of TC-PTP, were created. Hematopoietic stem cells from transgenic mice expressing the wt TC-PTP phosphatase were transduced by a rAAV2, but those from the phosphatase-negative mutant were not. These results suggest that the block to second-strand DNA synthesis is due to binding of FKBP-52 to the D-sequence of infecting vector genomic DNA and that this

10 binding is regulated by phosphorylation. Thus, numerous strategies aimed at increasing the transduction frequency for AAV have focused on enhancing the molecular conversion of nonfunctional viral genomes to expressible forms (Fisher et al., 1996; Sanlioglu et al., 1999) or by increasing transcription and translation efficiencies by altering the transgene expression cassettes (Zabner et

15 al., 1996; Xiao et al., 1998).

A second approach aimed at improving transduction efficiencies of rAAV has focused on the binding of rAAV to cell surface receptors. Many primary and secondary cell surface receptor molecules have been identified for the various AAV serotypes. The primary receptors identified (heparin sulfate

20 and sialic acid) are found on many cell types and are also utilized by a large number of viruses besides AAV. This suggests that additional receptors that lend more specificity to attachment and penetration of cells might exist and several such co-receptors have been identified. Thus, additional strategies to improve rAAV transduction efficiency have focused on manipulation of cell

25 surface receptors (Qing et al., 1997) and/or receptor ligands in the virus coat proteins (Wickham et al., 1996a; Wickham et al., 1996b; Bartlett et al., 1999).

While binding to the cell surface membrane and successful conversion to a double stranded DNA genome are important, the efficiency of these events does not necessarily correlate with the overall ability or efficiency of rAAV to

30 transduce a given cell type. This has been increasingly apparent in recent years as a more detailed understanding of the trafficking and uncoating of rAAV has been accumulated (Duan et al., 1998; Seisenberger et al., 2001; Hanson et al., 2001; Bantel-Schaal et al., 2002; Yan et al., 2002). For example, polarized human airway epithelial cells are transduced with varying efficiencies by rAAV-

2 depending on the route of delivery; entry from the basolateral surface results in  
about a 200-fold increase in gene expression in the cells compared to vector  
administered from the apical surface (Duan et al., 1998; Duan et al., 2000).  
Surprisingly, the difference in rAAV cell surface binding between two cell  
5 surfaces is only about 5-fold. This finding led to the discovery that the vectors  
traffic differently in these cells depending on the route of delivery (Duan et al.,  
1998; Duan et al., 2000).

Previous reports have clearly demonstrated that intracellular trafficking  
to the nucleus for rAAV-2 and canine parvovirus is a slow, rate-limiting process  
10 for certain cell types (Parker et al., 2000; Hanson et al., 2001; Hanson et al.,  
2000; Duan et al., 2000). Canine parvovirus and rAAV-2 have also been  
demonstrated to be endocytosed through clathrin-dependent receptor endocytosis  
and processed through endosomal compartments in a similar fashion to  
transferrin, but not a fluid phase marker such as dextran (Parker et al., 2000;  
15 Bartlett et al., 2000; Benson et al., 2000; Duan et al., 1999). Transferrin  
trafficking has been extensively studied and shown to move through the early  
endosome to perinuclear recycling endosome (PNRE) (Sonnichsen et al., 2000;  
Ren et al., 1998). The recycling of transferrin through the PNRE requires the  
coordinated interactions of several small GTPases (Rab5, Rab4, and Rab11)  
20 which direct the movement and fusion of early endosomes to the PNRE  
compartment (Sonnichsen et al., 2000).

Studies designed to develop agents to improve the efficiency of rAAV  
transduction have demonstrated that proteasome inhibitors such as the  
tripeptides LLnL and Z-LLL can enhance transduction of rAAV. Agents of this  
25 class affect ubiquitination of rAAV by inhibiting calpains, cathepsins, cysteine  
proteases as well as the chymotrypsin-like protease activity of proteasomes in  
polarized cell types (Duan et al., 2000; Yan et al., 2002). Additionally, agents  
affecting DNA metabolism including hydroxyurea, novobiocin, amsacrine, and  
etoposide were tested for the ability to enhance rAAV transduction based on the  
30 hypothesis that these drugs would increase the rate of conversion of the single  
stranded rAAV genome to a double stranded form. Results demonstrated that  
etoposide, hydroxyurea, and camptothecin were effective at enhancing rAAV  
transduction when utilized singularly but when used in combination produced no  
additive or synergistic effects (Russel et al., 1995). Furthermore, these agents

were only stated as effective in enhancing rAAV transduction in cell types for which gene conversion is rate limiting. Steps which proceed gene conversion (i.e., intracellular trafficking and processing of virions) appear to be critical rate-limiting steps in primary cells and differentiated tissues such as the airway  
5 (Hansen et al., 2000; Duan et al., 2000).

There exists a need for improved transduction efficiencies for rAAV vectors.

Thus, what is needed is the identification of agents that can alter, e.g., increase or enhance, rAAV transduction or rAAV transduction frequencies *in vivo*. What is  
10 also needed is the identification of agents that increase or enhance the expression of a rAAV heterologous transgene in non-dividing or slowly dividing cells or tissues, such as those in the liver and the airway.

#### **Summary of the Invention**

15 The invention provides a method to identify an agent, or a combination of agents, that alters adeno-associated virus (AAV) transduction of a eukaryotic cell, e.g., a mammalian cell such as a mammalian lung or liver cell, or a population of eukaryotic cells, e.g., in tissues or organs. For example, the invention provides a method to identify agents that enhance rAAV transduction,  
20 e.g., enhance rAAV endocytosis, enhance trafficking and processing of the rAAV through the intracellular compartments, including without limitation proteosomes, endosomes, and trans-golgi, decrease viral nucleic acid or protein degradation, increase viral uncoating and/or increase nuclear transport of virus or the viral genome, e.g., via cytoskeletal components such as microtubules or  
25 microfilaments. The method comprises contacting the cell or population of cells with one or more agents and virus. Then it is determined whether virus transduction is altered. Preferred cells include those of mammals, birds, fish, and reptiles, especially domesticated mammals and birds such as humans, non-human primates, cattle, sheep, pigs, horses, dogs, cats, mice, rats, rabbits,  
30 chickens, and turkeys. For example, polarized human airway epithelial cells grown at an air-liquid interface or human bronchial xenografts are useful to identify agents which alter viral transduction.

In one embodiment, agents to be tested are selected from agents including those having desirable properties, e.g., therapeutic properties or

functional and/or structural properties of other agents identified as altering rAAV transduction. An agent or library of agents may be randomly screened in the methods of the invention. Alternatively, agents to be tested may be selected from agents having desirable properties for a particular cell type, tissue type or disease type to be treated with rAAV. Moreover, agents may be selected from agents that modulate the proteasome, e.g., agents that bind to a proteasome, alter the interaction of virus and the proteasome, alter a function of the proteasome, stabilize the proteasome, or alter the trafficking of the proteasome, but do not inhibit the proteolytic activity of the proteasome. As used herein, agents that are “proteasome modulating agents” do not include agents that inhibit the proteolytic activity of the proteasome. For example, to identify an agent useful to enhance transduction of a CFTR rAAV vector for delivery to the lungs of patients with cystic fibrosis, agents may be selected from agents used or approved for use in cystic fibrosis patient populations, agents in clinical trials or having FDA approval, and/or agents associated with viral transduction, e.g., rAAV endocytosis, trafficking and processing of the rAAV through intracellular compartment(s), e.g., endosomal compartments, decreased viral nucleic acid or protein degradation, increased viral uncoating, or increased nuclear transport of virus or the viral genome, agents that interact with cytoskeletal elements, e.g., microtubules or microfilaments. In one embodiment, the agent is not an agent inhibits proteolytic activity of the proteasome. In one embodiment, the agent alters, e.g., enhances, transduction of a mammalian cell by rAAV after viral binding to the cell membrane and before second strand synthesis which yields an expressible form of the viral genome. Randomized screening may be performed using a transgene expressing rAAV, e.g., a reporter transgene encoding GFP, or high throughput screening of chemical libraries on indicator cell lines. Transduction may be assessed using expression of the rAAV encoded reporter transgene. In one embodiment, chemical libraries are selected based on chemical structures known to interact with the proteasome, virus, or other intracellular processing pathways, e.g., endosomal compartments, through which virus is processed. Alternatively, peptide libraries may be screened to identify agents that enhance rAAV transduction, for instance, via an interaction with a proteasome that affects rAAV transduction.



The agents of the inventions may be tested and/or used with any serotype or pseudotype of rAAV vectors. It is envisioned that agents identified as enhancing rAAV transduction may function with all AAV serotypes and pseudotypes although there may be variations in the degree of enhancement, cell or tissue type specificities or concentrations employed for enhancement.

Agents of the invention may be used alone or in combination to produce additive or synergistic transduction effects, to increase the efficiency of transduction for multiple cell or tissue types, to increase the time period of rAAV heterologous transgene expression, to shorten the time period to expression of the transgene, or to reduce the amount of virus needed to achieve a therapeutic or prophylactic effect compared to transduction by or expression of the same vector in the absence of the agent or agents, or when an agent is used singularly. It is also contemplated that one or more agents of invention may be used in combination with agents that increase binding to cellular receptors, promote conversion of the single stranded rAAV vector to the double stranded form, or inhibit proteosome proteolytic functions, to produce additive or synergistic transduction effects, to increase the efficiency of transduction for multiple cell or tissue types, to increase the time period of rAAV heterologous transgene expression, to decrease lag time between contact of the host cell with rAAV and expression of the transgene, or to reduce the amount of virus needed to achieve a desired effect, compared to transduction by or expression of the same vector in the absence of the agent, a single agent or less than all of the agents. Agents of the invention used in combination may be synergistic or additive in enhancing rAAV transduction. Examples of additive effects of rAAV transduction include, e.g., a shortened lag time between infection and expression of the transgene and an overall longer time period of expression.

Accordingly the invention provides a method to enhance rAAV transduction of a mammalian cell. The method includes contacting the mammalian cell with at least one rAAV and at least two agents, e.g., in an amount effective to additively or synergistically enhance rAAV transduction.

Agents of the invention may be employed with a rAAV vector that contains only a single heterologous transgene, i.e., one not derived from AAV sequences, e.g., not encoding a AAV protein, or with dual vector strategies wherein the rAAV vectors contain more than one heterologous transgene and/or

transcriptional regulatory elements as described in Duan et al. (2000); Yan et al. (2000); and Duan et al. (2001). The gene being expressed can be either a DNA segment encoding a polypeptide, catalytic RNA, or antisense RNA, with whatever control elements (e.g., promoters, operators) are desired.

5           The invention includes agents that modulate proteasomes including agents that bind to, and/or alter one or more activities of a proteasome, the association of virus with the proteasome, and/or subcellular positioning of the proteasome. Proteasomes are the main proteolytic complex in the cytosol and nucleus, and can be transported between the cytoplasm and nucleus. For  
10 instance, the 26S proteasome complex comprises a 19S regulatory unit and a 20S catalytic core which has chymotrypsin-like activity, i.e., cleavage after large hydrophobic residues, trypsin-like activity, i.e., cleavage after basic residues, post-glutamyl hydrolase activity, i.e., cleavage after acidic residues, branched amino acid cleavage activity and small neutral amino acid cleavage activity. As  
15 described herein, doxorubicin, an approved antibiotic, also enhances rAAV transduction. Doxorubin may facilitate viral binding to the proteasome and/or subsequent transportation into the nucleus. In contrast, proteasome inhibitors such as LLnL and Z-LLL more significantly inhibit core proteolytic activity of the proteasome.

20           Hence, the combined use of agents that individually have different or overlapping properties that alter rAAV transduction, as well as agents with similar or identical properties, can result in an additive and/or synergistic effect and so enhance rAAV transduction. Thus, agents that enhance virus transduction are particularly useful in gene therapy that employs rAAV to  
25 introduce and/or express a therapeutic peptide or polypeptide, or in vaccines that employ rAAV to introduce and/or express an immunogenic prophylactic polypeptide or peptide, such as one from a virus, fungus, bacterium, yeast or cancer cell, so as to induce an immune response to that polypeptide or peptide. The agents of the invention are also useful for the development of diagnostic  
30 markers to aide in *in vivo* cellular marking of cells or tissue, or to track and/or target chemotherapeutic strategies. Further, agents of the invention may enhance rAAV transduction of cells, tissues, or animals employed for the production of therapeutic proteins, e.g., growth hormone, cytokines or other recombinant proteins.

Further, the cells to be transduced may be contacted with one or more agents prior to viral infection, concurrently with viral infection, subsequent to viral infection, or any combination thereof. Cells to be transduced may be contacted with one or more agents at a single time point, e.g., a single dose of one agent or a single dose of two or more agents, or at multiple time points, as described above, e.g., multiple doses of one agent, multiple doses of a combination of two or more agents, sequential or alternating doses of two or more agents.

As described hereinbelow, virus binding, e.g., the restricted distribution of viral receptors, and endocytosis of AAV-2 at the apical membrane of airway epithelia is not the major rate limiting step in transduction of this tissue type. In fact, differentiated human airway epithelia internalize rAAV-2 quite efficiently from the apical surface. Rather, endosomal processing and trafficking of internalized virus to the nucleus is the major obstacle encountered by AAV-2 following infection from the apical membrane of the airway. In contrast to basolateral infection that led to the efficient conversion of single stranded AAV DNA to circular form genomes, apical infection gave rise to persistent intracellular single stranded viral DNA in a transcriptionally inactive state for up to 50 days. Using proteasome inhibitors which increase the efficiency of endosomal processing of AAV-2 and intracellular routing to the nucleus, a significantly enhanced transduction from the apical surface of more than 200-fold was observed, to nearly that of transduction from the basolateral surface. It was also found that AAV capsid proteins are ubiquitinated following endocytosis, and that ubiquitin-mediated proteasome degradation of incoming virus can be blocked by treatment with either proteasome or ubiquitin ligase inhibitors.

Moreover, importantly, *in vivo* application of proteasome inhibitor in mouse lung augmented rAAV gene transfer from undetectable levels to a mean of 10.4 +/- 1.6% of the epithelial cells in large bronchioles. Thus, the use of one or more agents that alter rAAV endocytosis, trafficking and processing of the rAAV through the intracellular compartments, including without limitation proteosomes, endosomes, and trans-golgi, viral nucleic acid or protein degradation, viral uncoating and/or nuclear transport of virus or viral genome, e.g., via cytoskeletal components such as microtubules or microfilaments, to

circumvent the major endosomal processing barriers to transduction in the airway may provide clinically useful strategies for *in vivo* AAV-mediated gene therapy of respiratory disorders such as cystic fibrosis, as well as for other tissues in which viral processing appears to be a rate limiting event, or strategies for *in vivo* rAAV-mediated vaccines.

As also described hereinbelow, the transduction efficiency of a recombinant AAV-2 construct with an RSV LTR promoter driving a luciferase reporter that was packaged into both AAV-2 and AAV-5 capsid particles was compared in a number of cell lines and in lung *in vivo*. Co-administration of the viruses with agents of the invention including a proteasome modulator and/or a proteasome inhibitor *in vitro* not only increased the transduction efficiency of AAV-2, it also augmented AAV-5 mediated gene transfer although often to a slightly lower extent. Increased transgene expression in the presence of proteasome inhibitor was independent of viral genome degradation since no significant difference of the amount of internalized viral DNA was detected 24 hours after infection. Western blot assays of immunoprecipitated viral proteins from infected HeLa cell lysates and *in vitro* reconstitution experiments revealed evidence for ubiquitin conjugation of both AAV-2 and AAV-5 capsids. These studies suggest that the previously reported barrier involving the ubiquitin/proteasome pathway for rAAV-2 is also active for rAAV-5 capsid entry pathways. *In vivo* co-administration of a pseudotyped rAAV and the proteasome inhibitor Z-LLL induced whole lung luciferase expression 17.2- and 2.1-fold at 14 and 42 days post-infection, respectively, while co-administration of rAAV and a different rAAV transduction enhancing agent, doxorubicin, induced tracheal and bronchial luciferase expression at higher levels at 14, 42 and 90 days post-infection relative to expression levels induced by Z-LLL. Surprisingly, at 42 days, luciferase expression in trachea and bronchi in mice co-administered virus and Z-LLL and doxorubicin was more than additive when administered by endotracheal instillation. In human polarized airway epithelia, combined doxorubicin and LLnL enhanced luciferase expression from rAAV synergistically more than 1000-fold while individually doxorubicin and LLnL enhanced transduction by 100- and 10-fold, respectively. As also described herein, other agents that bind to proteasomes and/or modulate proteasome activity, can alter rAAV transduction efficiency.

Further, the activity of agents that alter virus transduction, e.g., a modulator of rAAV endocytosis, trafficking and processing of rAAV through the intracellular compartment, viral nucleic acid or protein degradation, viral uncoating and nuclear transport, may be enhanced by the addition of agents, such as EDTA or EGTA, which may alter molecules in pathways associated with virus transduction, e.g., agents such as calcium chelators or modulators of intracellular calcium levels. Thus, one or more agents that alter virus transduction may be employed with an agent that enhances the activity of, or acts synergistically with, the one or more agents that alter virus transduction. Thus, the invention also provides for compositions or kits comprising two or more agents, e.g., a first agent that alters virus transduction and a second agent which enhances the activity of the first agent or acts synergistically with the first agent.

Therefore, the invention also provides a method to alter adeno-associated virus transduction of a eukaryotic cell or a population of cells. The method comprises contacting the cell or a population of cells with an amount of virus and an amount of at least one agent of the invention effective to alter virus transduction. The agent may be contacted with the cell concurrently with the virus, prior to contacting the cell with virus or after contacting the cell with virus. In one embodiment, the invention provides a method in which a mammalian cell is contacted with at least one rAAV and at least one agent that alters rAAV endocytosis, rAAV trafficking or processing in intracellular compartments, viral nucleic acid or protein degradation, and/or nuclear transport of virus or viral genomes. In one embodiment, the agent is not an inhibitor of proteasome proteolytic activity. The agent(s) and/or virus may each be administered once, or in repeated dosing, so as to achieve the desired effect, i.e., to enhance rAAV transduction. Since AAV has been shown to have a broad host range (e.g., for pulmonary expression) and persists in muscle, rAAV may be employed to express a gene in any animal, and particularly in mammals, birds, fish, and reptiles, especially domesticated mammals and birds such as cattle, sheep, pigs, horses, dogs, cats, chickens, and turkeys. Both human and veterinary uses are particularly preferred.

In one embodiment, at least one rAAV and/or pseudotyped rAAV and one or more agents of the invention may be employed in methods to alter, e.g.,

increase, transduction efficiency and transgene expression, methods to detect or determine transgene expression efficiency, methods to screen for promoter strength and/or RNA stability, as well as in therapeutic or prophylactic therapies in which the vectors are useful include blood disorders (e.g., sickle cell anemia, thalassemias, hemophilias, and Fanconi anemias), neurological disorders, such as Alzheimer's disease and Parkinson's disease, and muscle disorders involving skeletal, cardiac or smooth muscle, as well as diseases of the lung, e.g., cystic fibrosis and asthma. In particular, therapeutic genes useful in the vectors of the invention include a  $\alpha$ -globin gene,  $\beta$ -globin gene,  $\gamma$ -globin gene, Factor VIII gene, Factor IX gene, cystic fibrosis transmembrane conductance regulator gene (CFTR), Fanconi anemia complementation group, dystrophin gene, an antisense gene, low density lipoprotein (LDL) gene, tyrosine hydroxylase gene (Parkinson's disease), glucocerebrosidase gene (Gaucher's disease), arylsulfatase A gene (metachromatic leukodystrophies), erythropoietin gene, as well as genes encoding immunogenic polypeptides or peptide, such as those useful for vaccines, or genes encoding other gene products such as other peptides, polypeptides or proteins. In one embodiment, the rAAV encodes a catalytic RNA, e.g., a ribozyme or siRNA, e.g., one useful to decrease expression of a particular RNA expressed in a cell.

Also within the scope of the invention is the inclusion of more than one open reading frame in a rAAV vector, i.e., a plurality of genes may be present in an individual vector. Further, as rAAV may form concatamers after infection, each monomer of that concatamer may comprise a different gene, or a portion thereof.

Circularized intermediates of recombinant adeno-associated virus may impart episomal persistence to linked sequences.

Further, co-infection with two or more different rAAV may, through intermolecular recombination, yield a concatamer having one or more copies of any particular rAAV. The implications of intermolecular recombination of rAAV genomes to form a single molecule, e.g., a nuclear episome, which may be a concatamer comprising at least two different rAAV genomes, is particularly relevant for gene therapy with rAAV, as large regulatory elements and genes beyond the packaging capacity of rAAV can be brought together by co-infecting cells or tissue of an organism with two independent rAAV vectors. For example,

enhancers and/or promoters may be introduced into one vector while DNA comprising an open reading frame, e.g., a gene of interest, with or without a minimal promoter, is introduced into a second vector. Thus, after co-infection with the two vectors, the transgene cassette size is increased beyond that for a single AAV vector alone and the DNA comprising the opening reading frame is linked to the enhancer and/or promoter. In another embodiment of the invention, vectors encoding two independent regions of a gene are brought together to form an intact splicing unit. Without being bound by theory, agents of the invention may increase concatamerization and/or intermolecular recombination of rAAV by increasing the steady state abundance of viral genomes resulting in enhanced transduction frequencies of rAAV compared to cells not treated with agents of the invention. Agents of the invention that alter processing of rAAV virions in the cytoplasm and/or nucleus may also influence the presentation of viral DNA in the nucleus and hence alter gene conversion products. Such altered presentation may affect concatamerization by allowing for more localized accumulation of virions at specific sites within the nucleus. Alternatively, ubiquitination of associated factors with viral DNA (i.e., Rep or host cell proteins) may affect the biologic properties of these associated factors and influence linear, circular, and/or concatamerization processes. Thus, agents of this invention may influence intramolecular concatamerization and the efficiency of multiple vector technologies by the mechanisms discussed above.

Accordingly, the use of multiple rAAV vectors is useful to overcome the current size limitation for transgenes within rAAV vectors, and allows for the incorporation of a larger transcriptional regulatory region, e.g., a stronger heterologous promoter or an endogenous promoter, e.g., the CFTR endogenous promoter, or one or more enhancer sequences.

Therefore, two or more, e.g., a plurality, of DNA segments, each in an individual rAAV vector, may be delivered to a cell, so as to result in a single DNA molecule having DNA segments from more than one rAAV. In one embodiment of the invention, one rAAV may comprise a first recombinant DNA molecule comprising linked: a first DNA segment comprising a 5' ITR of AAV; a second DNA segment which does not comprise AAV sequences (nonAAV sequences), i.e., heterologous sequences; and a third DNA segment comprising a 3' ITR of AAV. A second recombinant AAV comprises a second recombinant

DNA molecule comprising linked: a first DNA segment comprising a 5' ITR of AAV; a second DNA segment which does not comprise AAV sequences and which second DNA segment has sequences which are different than the sequences in the second DNA segment of the first recombinant DNA molecule; and a third DNA segment comprising a 3' ITR of AAV. One of the rAAV may be a pseudotype.

In one embodiment of the invention, one rAAV vector comprises a first DNA segment comprising a 5' ITR linked to a second DNA segment comprising the 5' end of an open reading frame (but optionally not an entire open reading frame), optionally operably linked to a promoter, e.g., a heterologous promoter, and a 5' splice site linked to a third DNA segment comprising a 3' ITR. The second rAAV vector comprises a first DNA segment comprising a 5' ITR linked to a second DNA segment comprising a 3' splice site and the 3' end (the remainder) of an open reading frame, i.e., the second DNA segment of the second vector together with the second DNA segment of the first vector encodes a functional gene product linked to a third DNA segment comprising a 3' ITR. A "functional" gene product is one which has a detectable activity or is capable of having a detectable activity when present in an appropriate cell, tissue or organism, e.g., has at least one activity, and preferably substantially the same activity, as a reference, e.g., corresponding, gene product, for example, a wild-type (full-length) polypeptide or ribozyme. Preferably, the second DNA segments together comprise DNA encoding, for example, CFTR, factor VIII, dystrophin, or erythropoietin. The second DNA segments may be obtained or derived from cDNA, genomic DNA or a combination thereof. For example, the second DNA segment of the first vector may comprise one or more, but not all of the exons of a gene comprising more than one exon and the second DNA segment of the second vector may comprise at least one exon of the gene that is not present in the first vector, or one or more exons from a different gene (thereby coding for a chimeric polypeptide). The second DNA segment of the first vector may comprise the endogenous promoter of the respective gene, e.g., the epo promoter, or a heterologous promoter.

In another embodiment, one rAAV vector comprises a first DNA segment comprising a 5' ITR linked to a second DNA segment comprising a promoter and/or enhancer linked to a third DNA segment comprising a 3' ITR.



Optionally, the first rAAV vector does not include a splice donor and/or a splice acceptor. A second rAAV vector comprises a first DNA segment comprising a 5' ITR linked to a second DNA segment comprising at least a portion of an open reading frame optionally linked to a promoter (a different promoter than in the first vector or a second copy of the promoter in the first vector) linked to a third DNA segment comprising a 3' ITR. For example, the second DNA segment of the first recombinant DNA molecule comprises at least one heterologous enhancer and/or at least one heterologous promoter, i.e., the enhancer and/or promoter sequences are not derived from AAV sequences. Preferably, the second DNA segment of the second recombinant DNA molecule comprises a portion of an open reading frame which encodes a functional gene product.

In one embodiment, co-infection of a cell with at least one pseudotyped rAAV, e.g., a transgene containing vector, and a second vector comprising at least one, preferably at least two or more, enhancer sequences, may result in an enhancement of transgene expression from a minimal promoter. Furthermore, an enhancement can also be achieved by *cis*-activation of ITRs in transgene-containing vectors without a promoter. Thus, large regulatory elements including tissue-specific enhancers can be introduced into cells by a separate rAAV vector to regulate the expression of a second transgene-containing AAV vector in *cis* following intracellular concatamerization.

In yet another embodiment of the invention, the second DNA segment of the first recombinant DNA molecule comprises a *cis*-acting integration sequence(s) for a recombinase and also encodes a recombinase or integrase that is specific for the integration sequence(s), e.g., Cre/lox system of bacteriophage P1 (U.S. Patent No. 5,658,772), the FLP/FRT system of yeast, the Gin recombinase of phage Mu, the Pin recombinase of *E. coli*, the R/RS system of the pSR1 plasmid, a retrotransposase or the integrase from a lentivirus or retrovirus. The second DNA segment in the second recombinant DNA molecule comprises at least a portion of an open reading frame, and preferably a promoter operably linked to the open reading frame. The formation of a concatamer comprising the first and the second recombinant DNA molecules, and the expression of the recombinase or integrase, will enhance the integration of the concatamer, or a portion thereof, into the host genome. Also, rAAV vectors comprising *cis*-acting integration sequences and the corresponding recombinase

or integrase are useful to drive directional recombination, which, as discussed above, may be particularly useful when employing two or more rAAV vectors.

Accordingly, the vectors of the invention are useful in a method of delivering and/or expressing one or more genes in a host cell, to prepare host  
5 cells having the vector(s), and in the preparation of a composition comprising rAAV(s). A host cell may be contacted with each rAAV individually, e.g., sequentially, with or without an agent of the invention. To deliver the gene(s) to the host cell, a recombinant adenovirus helper virus may be employed.

Thus, the invention also provides a method to express a gene product in a  
10 host cell. The host cell is preferably a mammalian host cell, e.g., a murine, canine, feral or human cell, and may be a lung, neuron or muscle cell. The method comprises contacting the host cell with at least one rAAV vector and at least one agent of the invention. In one embodiment, the host cell is contacted with at least two different rAAV vectors. In one embodiment, one of the rAAV  
15 vectors is a pseudotyped rAAV. The host cell is preferably contacted with the vectors concurrently, although it is envisioned that the host cell may be contacted with each vector at a different time relative to the contact with the other vector(s), as discussed herein. Two or more agents of the invention may also be employed in the method, and may be contacted with the cell prior to,  
20 concurrent with, or subsequent to contact of the cell with the vector(s). In one embodiment, the agent modulates microfilament or microtubule synthesis, formation or degradation, modulates rAAV endocytosis, modulates rAAV trafficking in a cell, modulates rAAV processing in a cell, modulates rAAV nucleic acid degradation in a cell, modulates rAAV protein degradation in a cell,  
25 modulates rAAV transport to the nucleus and/or modulates viral genome transport to the nucleus. In one embodiment, two agents that modulate microfilament or microtubule synthesis, formation or degradation, rAAV endocytosis, rAAV trafficking in a cell, rAAV processing in a cell, rAAV nucleic acid degradation in a cell, rAAV protein degradation in a cell, rAAV  
30 transport to the nucleus and/or viral genome transport to the nucleus, are employed.

Also provided is a method to detect expression of a transgene in a cell. The method comprises contacting a host cell with a rAAV of the invention which comprises a transgene comprising a non-AAV promoter linked to an open

reading frame, e.g., a marker gene or an open reading frame having one or more genetic modifications relative to a corresponding wild-type open reading frame. One or more agents of the invention may also be employed in the method, and may be contacted with the cell prior to, concurrent with, or subsequent to contact of the cell with the vector(s). The expression of the transgene is then detected or determined, e.g., relative to a host cell contacted with a rAAV comprising a transgene linked to a different promoter or a transgene with the same promoter but linked to a wild-type open reading frame or one not contacted with an agent of the invention.

Thus, one embodiment, the invention provides a method to prevent, inhibit or treat a condition associated with aberrant expression of an endogenous gene product. The method includes contacting a mammal at risk of or having the condition, with an effective amount of at least one agent that enhances AAV transduction and an effective amount at least one rAAV comprising a transgene encoding at least a portion of a functional gene product, the expression of which in the mammal inhibits the aberrant expression of the corresponding endogenous gene product, e.g., via a dominant negative, antisense or catalytic RNA, or encodes a functional gene product, thereby preventing or inhibiting one or more symptoms of the condition. In one embodiment, the agent is a chemotherapeutic, a lipid lowering agent, an antibiotic or a food additive. In one embodiment, the agent is not camptothecin. In another embodiment, the agent is not cisplatin.

The invention provides use of two or more agents that enhance rAAV transduction of a mammalian cell for the preparation of a medicament to additively or synergistically enhance rAAV transduction in a mammal in need of rAAV mediated gene therapy. Further provided is use of a chemotherapeutic, a lipid lowering agent, an antibiotic or a food additive, or use of at least one agent that alters rAAV endocytosis, rAAV trafficking or processing in intracellular compartments, viral nucleic acid or protein degradation, nuclear transport of virus or viral genome, for the preparation of a medicament to enhance transduction of at least one rAAV comprising a transgene encoding at least a portion of a functional gene product in a mammal having a condition associated with aberrant expression of an endogenous gene product that is capable of being inhibited or treated with the transgene.

**Brief Description of the Figures**

Figures 1A-E. Luciferase activity in HeLa cells transfected with rAAV FLAG-Luc in the presence or absence of various agents. HeLa cells were contacted with 100 ppc AAV FLAG-Luc for 2 hours, and cells were harvested  
 5 48 hours later. N=3, average  $\pm$  standard deviation.

Figure 2. *In vivo* enhancement of rAAV transduction with Doxil. Male Balb/c mice intravenously administered Doxil were endotracheally instilled with  $1 \times 10^{11}$  DRP AAV2FLAG-Luc (01:004)

Figure 3. *In vivo* enhancement of rAAV transduction of Factor VIII in  
 10 Rag-1 mice treated with Doxil. Rag-1 mice intravenously administered Doxil (20 mg/kg) were infected with  $1 \times 10^{12}$  DRP AAV5-FVIII, and Factor VIII levels at sacrifice determined. Data are the average  $\pm$  standard deviation.

Figure 4. Luciferase activity in HeLa cells after infection with A) AV2.RSVLuc or AV2.RSVlucCap5 (100 or 1000 ppc) or B) AV2CMVluc or  
 15 AV2CMVluc Cap5 (500 ppc), and co-administration of LLnL (40, 200 or 400  $\mu$ M), Z-LLL (4  $\mu$ M), or doxorubicin (0.5, 1.0 or 5.0  $\mu$ M) or a combination of LLnL (4, 10, 20 or 200  $\mu$ M) and doxorubicin (0.5, 1.0 or 5.0  $\mu$ M). C) Comparison of CMV and RSV promoters in AAV-2 vectors in HeLa cells.

Figure 5. Luciferase activity in A549 cells after infection with  
 20 AV2CMVluc or AV2CMVluc Cap5 (500 ppc), and co-administration of LLnL (40, 200 or 400  $\mu$ M), Z-LLL (4  $\mu$ M), or doxorubicin (5  $\mu$ M). A) Comparison of AV2CMVluc and AV2CMVlucCap5. B) Dose response for varying amounts of LLnL in A549 cells infected with AV2CMVluc.

Figure 6. Luciferase activity in ferret fibroblasts after infection with  
 25 AV2CMVluc or AV2CMVluc Cap5 (500 ppc), and co-administration of LLnL (40, 200 or 400  $\mu$ M), Z-LLL (4  $\mu$ M), or doxorubicin (1  $\mu$ M). A) Comparison of AV2CMVluc and AV2CMVlucCap5. B) RLU at 1 and 5 days for AV2CMVluc and AV2CMVlucCap5 in ferret fibroblasts.

Figure 7. Comparison of luciferase activity in HeLa (A), ferret fibroblast  
 30 (B) and A549 (C) cells with one or two proteasome modulators.

Figure 8. Luciferase activity in polarized airway epithelial cells at 3 days and 15 days after apical infection with  $5 \times 10^9$  AV2RSVLuc or AV2RSVlucCap5 and co-administration of LLnL (40  $\mu$ M) or doxorubicin (1.0 or 5.0  $\mu$ M) or a combination of LLnL (40  $\mu$ M) and doxorubicin (1.0 or 5.0  $\mu$ M).

Figure 9. Luciferase activity in C57Bl6 mouse lung or trachea and bronchi at 2 weeks (A) or 6 weeks (B) after infection (via nasal aspiration) with AV2RSVlucCap5 (3 times with 10  $\mu$ l of  $2 \times 10^9$  particles/ $\mu$ l in 40  $\mu$ l, for a total of  $6 \times 10^{10}$  particles) and co-administration of Z-LLL (200  $\mu$ M), doxorubicin (200  $\mu$ M), or a combination of Z-LLL (200  $\mu$ M) and doxorubicin (200  $\mu$ M). For each group, n = 12. Lung and trachea with some bronchial tissue was isolated and, after extraction, luciferase activity/total protein in the tissue extraction determined.

Figure 10. Luciferase activity in mouse lung or trachea and bronchi at 2 weeks, 6 weeks or 3 months after infection with AV2RSVlucCap5 and co-administration of Z-LLL (200  $\mu$ M), doxorubicin (200  $\mu$ M) or a combination of Z-LLL (200  $\mu$ M) and doxorubicin (200  $\mu$ M). The luciferase assay was performed at 80% sensitivity. Lung and trachea with some bronchial tissue was isolated and, after extraction, luciferase activity/total protein in the tissue extraction determined.

Figure 11. The effects of proteasome inhibitors LLnL and Doxorubicin (Dox) on AV2Luc and AV2/5Luc transduction of immortalized human airway cell lines IB3 (panel A) and A549 (panel B) were evaluated. Proteasome-modulating agents were co-administered with each rAAV vector (MOI of 500 particles per cell) at the time of infection and transduction was evaluated 24 hours later. Various concentrations of each chemical were evaluated as indicated in each graph. Data represent the mean ( $\pm$ -SEM) relative luciferase activity experiment (N=4).

Figure 12. LLnL and Dox both facilitate translocation of rAAV to the nucleus. IB3 cells were infected with AV2eGFP (MOI = 1000 particles/cell) in the presence or absence 40  $\mu$ M LLnL or 1  $\mu$ M Dox. At 24 hours post-infection, cytoplasmic (Cyt) and nuclear (Nuc) fractions were isolated. (A) Viral DNA in each fraction was detected by slot-blot hybridization against a  $P^{32}$  labeled eGFP probe and visualized using a BioRad phosphorimager (N = 3 isolations are shown for each condition).  $P^{32}$  signal was quantified using BioRad software. (B) The percentage distribution of the signals in nuclear and cytoplasmic fractions was calculated based on the mean signal for the three experimental points. (C) Results of  $S^{35}$ -capsid labeled rAAV2 localization in polarized human airway epithelia by *in situ* autoradiography. Infections were performed in the presence

and absence of LLnL treatment.

Figure 13. Dox and LLnL provide additive induction of rAV2 transduction. Hela cells (left panel) and A549 cells (right panel) were infected with rAAV (MOI 500 particles/cell) in the presence of the indicated drug combinations and the expressed transgene was assessed at 24 hours post-infection (Mean  $\pm$  SEM, N = 4). Fold induction relative to vehicle-treated rAAV-infected cells is indicated above each bar.

Figure 14. The effect of proteasome inhibitor LLnL on (A) AV2Luc and (B) AV2/5Luc transduction was evaluated following apical and basolateral infection of human polarized airway epithelia at an MOI of 10,000 particles/cell in the presence and absence of LLnL (40  $\mu$ M). Luciferase activity was measured at 5 and 14 days post-infection. Values represent the mean ( $\pm$  SEM) relative luciferase activity for three independent tissue samples (N = 6-9 total transwells).

Figure 15. Analysis of full-length and self-complementary eGFP-expressing AAV vectors. HeLa cells were infected at an MOI = 1000 particles/cell. (A) Quantification of relative eGFP-expressing area for AV2eGFP and scAV2eGFP vectors. The values represent the mean ( $\pm$  SEM) for three independent infections and quantification of 10 random fields for each experimental point. (B) Response of AV2eGFP and scAV2eGFP vectors to treatment with hydroxyurea (5 mM) with gene expression analyzed at 24 hours post-infection. (C) Southern blot analysis of Hirt DNA harvested from AV2eGFP-infected (lanes 1 and 2) and scAV2eGFP-infected (lanes 3 and 4) HeLa cells at 24 hours post-infection. A  $^{32}$ P-labeled eGFP DNA probe was used for Southern blots.

Figure 16. Quantification of eGFP expression following apical infection of polarized human airway epithelia with self-complementary and full-length eGFP vectors. The relative mean area of fluorescence was evaluated following transduction with AV2eGFP and scAV2eGFP vectors in the presence or absence of LLnL (40  $\mu$ M) at an MOI of 10,000 particles/cell on 1, 3, 7, 15 and 30 days post-infection. The values represent the mean ( $\pm$  SEM) for three independent tissue samples. For each tissue sample, 3 transwells were evaluated by imaging 10 random fields in each sample at the various time points (N = 9 total transwells for each experimental point).

Figure 17. Combined administration of proteasome-modulating agents can synergistically induce rAAV transduction from the apical surface of polarized human airway epithelia. (A)  $1 \times 10^9$  particles of AV2Luc were applied to the apical surface of polarized human airway epithelia cultures in the absence and presence of various combinations of LLnL (40  $\mu$ M) and/or Dox (5  $\mu$ M). Luciferase expression was assayed at 3 and 17 days post-infection (B-E). Similar results were observed following apical infection with a self complementary (2.3 kb) scAV2eGFP vector at 15 days post-infection. (F) Combined administration of LLnL and Dox augments dual vector heterodimer-mediated delivery of a *trans*-spliced LacZ gene product.  $10^{10}$  particles of AV2LacZdonor (indicated by D) and/or AV2LacZacceptor (indicated by A) were used to infect each transwell of the polarized airway epithelia in the presence or absence of co-administered LLnL (40  $\mu$ M) and Dox (5  $\mu$ M).  $\beta$ -galactosidase activity was evaluated at 15 days post-infection. Data represents the mean ( $\pm$ -SEM) relative luciferase or  $\beta$ -galactosidase activity (per 1/10 sample) for 3 independent experiments.

Figure 18. *In vivo* gene transfer to the mouse lung. AV2 and AV2/5 luciferase vectors were used to evaluate the ability of proteasome-modulating agents to induce transduction. Results depict the mean ( $\pm$ -SEM) luciferase expression from (N = 5) mouse lungs at 14 days post-infection for each condition.

Figure 19. Complementation of CFTR chloride transport abnormalities in CF airway epithelia using combined CFTR rAAV and proteasome inhibitor treatment. Results depict the mean  $\pm$ -SEM (N=9) delta I<sub>sc</sub> response to IBMX/forskolin in CF airway epithelia treated under the indicated conditions. Assays were performed at 15 days post-infection and a non-CF untreated control is given as a reference for fully functional CFTR.

Figure 20. Screening for anthracycline proteasome modulators. A) Graph of luciferase activity versus concentration of tested agent. B) Fold change in luciferase activity for various treatments.

Figure 21. *In vivo* results for anthracycline proteasome modulators.

### **Detailed Description of the Invention**

#### **Definitions**

A "vector" as used herein refers to a macromolecule or association of macromolecules that comprises or associates with a polynucleotide and which can be used to mediate delivery of the polynucleotide to a cell, either *in vitro* or *in vivo*. Illustrative vectors include, for example, plasmids, viral vectors, liposomes and other gene delivery vehicles. The polynucleotide to be delivered, sometimes referred to as a "target polynucleotide" or "transgene," may comprise a coding sequence of interest in gene therapy (such as a gene encoding a protein of therapeutic or interest), a coding sequence of interest in vaccine development (such as a polynucleotide expressing a protein, polypeptide or peptide suitable for eliciting an immune response in a mammal), and/or a selectable or detectable marker.

"AAV" is adeno-associated virus, and may be used to refer to the naturally occurring wild-type virus itself or derivatives thereof. The term covers all subtypes, serotypes and pseudotypes, and both naturally occurring and recombinant forms, except where required otherwise. As used herein, the term "serotype" refers to an AAV which is identified by and distinguished from other AAVs based on capsid protein reactivity with defined antisera, e.g., there are eight serotypes of primate AAVs, AAV-1 to AAV-8. For example, serotype AAV2 is used to refer to an AAV which contains capsid proteins encoded from the cap gene of AAV 2 and a genome containing 5' and 3' ITR sequences from the same AAV2 serotype. Pseudotyped AAV as refers to an AAV that contains capsid proteins from one serotype and a viral genome including 5'-3' ITRs of a second serotype. Pseudotyped rAAV would be expected to have cell surface binding properties of the capsid serotype and genetic properties consistent with the ITR serotype. Pseudotyped rAAV are produced using standard techniques described in the art. As used herein, for example, rAAV5 may be used to refer to an AAV having both capsid proteins and 5'-3' ITRs from the same serotype or it may refer to an AAV having capsid proteins from serotype 5 and 5'-3' ITRs from a different AAV serotype, e.g., AAV serotype 2. For each example illustrated herein the description of the vector design and production describes the serotype of the capsid and 5'-3' ITR sequences. The abbreviation "rAAV" refers to recombinant adeno-associated virus, also referred to as a recombinant AAV vector (or "rAAV vector").



“Transduction” or “transducing” as used herein, are terms referring to a process for the introduction of an exogenous polynucleotide, e.g., a transgene in rAAV vector, into a host cell leading to expression of the polynucleotide, e.g., the transgene in the cell. The process includes 1) endocytosis of the AAV after  
5 it has bound to a cell surface receptor, 2) escape from endosomes or other intracellular compartments in the cytosol of a cell, 3) trafficking of the viral particle or viral genome to the nucleus, 4) uncoating of the virus particles, and generation of expressible double stranded AAV genome forms, including circular intermediates. The rAAV expressible double stranded form may persist  
10 as a nuclear episome or optionally may integrate into the host genome. The alteration of any or a combination of endocytosis of the AAV after it has bound to a cell surface receptor, escape from endosomes or other intracellular compartments to the cytosol of a cell, trafficking of the viral particle or viral genome to the nucleus, or uncoating of the virus particles, and generation of  
15 expressive double stranded AAV genome forms, including circular intermediates, by an agent of the invention, may result in altered expression levels or persistence of expression, or altered trafficking to the nucleus, or altered types or relative numbers of host cells or a population of cells expressing the introduced polynucleotide. Altered expression or persistence of a  
20 polynucleotide introduced via rAAV can be determined by methods well known to the art including, but not limited to, protein expression, e.g., by ELISA, flow cytometry and Western blot, measurement of and DNA and RNA production by hybridization assays, e.g., Northern blots, Southern blots and gel shift mobility assays. The agents of the invention preferably alter, enhance or increase viral  
25 endocytosis, escape from endosomes or other intracellular cytosolic compartments, and trafficking into or to the nucleus, uncoating of the viral particles in the nucleus, and/or increasing concatamerization or generation of double stranded expressible forms of the rAAV genome in the nucleus, so as to alter expression of the introduced polynucleotide, e.g., a transgene in a rAAV  
30 vector, *in vitro* or *in vivo*. Methods used for the introduction of the exogenous polynucleotide include well-known techniques such as transfection, lipofection, viral infection, transformation, and electroporation, as well as non-viral gene delivery techniques. The introduced polynucleotide may be stably or transiently maintained in the host cell.

“Increased transduction or transduction frequency”, “altered transduction or transduction frequency”, or “enhanced transduction or transduction frequency” refers to an increase in one or more of the activities described above in a treated cell relative to an untreated cell. Agents of the invention which  
5 increase transduction efficiency may be determined by measuring the effect on one or more transduction activities, which may include measuring the expression of the transgene, measuring the function of the transgene, or determining the number of rAAV vector particles necessary to yield the same transgene effect compared to host cells not treated with the agents.

10 “Proteosome modulator” refers to an agent or class of agents which alter or enhance rAAV transduction or rAAV transduction frequencies by interacting with, binding to, or altering the function of, and/or trafficking or location of the proteosome. Proteosome modulators may have other cellular functions as described in the art, e.g., such as doxyrubicin, an antibiotic. Proteosome  
15 modulators of the current invention do not include proteosome inhibitors, e.g., such as tripeptidyl aldehydes (Z-LLL or LLnL), agents that inhibit calpains, cathepsins, cysteine proteases, and/or chymotrypsin-like protease activity of proteasomes (Wagner et al., 2002; Young et al., 2000; Seisenberger et al., 2001).

“Generation of double stranded expressible forms” or “conversion of  
20 single to double strand rAAV genomes” refers to the process of replicating in the nucleus of an rAAV infected host cell a complimentary strand of the rAAV single stranded vector DNA genome and annealing of the complimentary strand to the vector genome to produce a double stranded DNA rAAV genome. Agents of the invention described herein to increase, alter, or enhance rAAV  
25 transduction include agents which increase the rate of nuclear transport or the steady state of single stranded viral DNA genomes in the nucleus which can drive gene conversion events via steady state mechanisms. For the purposes of the invention described herein, agents which enhance conversion of single to double strands do not include agents which increase the concentration of DNA  
30 repair enzymes or activate alternate DNA repair mechanism described by Russel et al. (1995).

“Gene delivery” refers to the introduction of an exogenous polynucleotide into a cell for gene transfer, and may encompass targeting, binding, uptake, transport, localization, replicon integration and expression.

“Gene transfer” refers to the introduction of an exogenous polynucleotide into a cell which may encompass targeting, binding, uptake, transport, localization and replicon integration, but is distinct from and does not imply subsequent expression of the gene.

5 “Gene expression” or “expression” refers to the process of gene transcription, translation, and post-translational modification.

A “detectable marker gene” is a gene that allows cells carrying the gene to be specifically detected (e.g., distinguished from cells which do not carry the marker gene). A large variety of such marker genes are known in the art.

10 A “selectable marker gene” is a gene that allows cells carrying the gene to be specifically selected for or against, in the presence of a corresponding selective agent. By way of illustration, an antibiotic resistance gene can be used as a positive selectable marker gene that allows a host cell to be positively selected for in the presence of the corresponding antibiotic. A variety of positive  
15 and negative selectable markers are known in the art, some of which are described below.

An “rAAV vector” as used herein refers to an AAV vector comprising a polynucleotide sequence not of AAV origin (i.e., a polynucleotide heterologous to AAV), typically a sequence of interest for the genetic transformation of a cell.  
20 In preferred vector constructs of this invention, the heterologous polynucleotide is flanked by at least one, preferably two AAV inverted terminal repeat sequences (ITRs). The term rAAV vector encompasses both rAAV vector particles and rAAV vector plasmids.

An “AAV virus” or “AAV viral particle” refers to a viral particle  
25 composed of at least one AAV capsid protein (preferably by all of the capsid proteins of a wild-type AAV) and an encapsidated polynucleotide. If the particle comprises a heterologous polynucleotide (i.e., a polynucleotide other than a wild-type AAV genome such as a transgene to be delivered to a mammalian cell), it is typically referred to as “rAAV”.

30 A “rAAV vaccine” as used herein refers to an AAV vector comprising a polynucleotide sequence not of AAV origin (i.e., a polynucleotide heterologous to AAV), that encodes a peptide, polypeptide, or protein capable of eliciting an immune response in a host contacted with the vector. Expression of the polynucleotide may result in generation of a neutralizing antibody response

and/or a cell mediated response, e.g., a cytotoxic T cell response. In preferred vector constructs of this invention, the heterologous polynucleotide is flanked by at least one, preferably two AAV inverted terminal repeat sequences (ITRs).

5 A "helper virus" for AAV refers to a virus that allows AAV (e.g., wild-type AAV) to be replicated and packaged by a mammalian cell. A variety of such helper viruses for AAV are known in the art, including adenoviruses, herpes viruses and poxviruses such as vaccinia. The adenoviruses encompass a number of different subgroups, although Adenovirus type 5 of subgroup C is most commonly used. Numerous adenoviruses of human, non-human  
10 mammalian and avian origin are known and available from depositories such as the ATCC. Viruses of the herpes family include, for example, herpes simplex viruses (HSV) and Epstein-Barr viruses (EBV), as well as cytomegaloviruses (CMV) and pseudorabies viruses (PRV); which are also available from depositories such as ATCC.

15 An "infectious" virus or viral particle is one that comprises a polynucleotide component which it is capable of delivering into a cell for which the viral species is trophic. The term does not necessarily imply any replication capacity of the virus.

A "replication-competent" virus (e.g., a replication-competent AAV, sometimes abbreviated as "RCA") refers to a phenotypically wild-type virus that is  
20 infectious, and is also capable of being replicated in an infected cell (i.e., in the presence of a helper virus or helper virus functions). In the case of AAV, replication competence generally requires the presence of functional AAV packaging genes. Preferred rAAV vectors as described herein are replication-  
25 incompetent in mammalian cells (especially in human cells) by virtue of the lack of one or more AAV packaging genes. Preferably, such rAAV vectors lack any AAV packaging gene sequences in order to minimize the possibility that RCA are generated by recombination between AAV packaging genes and an incoming  
30 rAAV vector. Preferred rAAV vector preparations as described herein are those which contain few if any RCA (preferably less than about 1 RCA per  $10^2$  rAAV particles, more preferably less than about 1 RCA per  $10^4$  rAAV particles, still more preferably less than about 1 RCA per  $10^8$  rAAV particles, even more preferably less than about 1 RCA per  $10^{12}$  rAAV particles, most preferably no RCA).

The term "polynucleotide" refers to a polymeric form of nucleotides of any length, including deoxyribonucleotides or ribonucleotides, or analogs thereof. A polynucleotide may comprise modified nucleotides, such as methylated or capped nucleotides and nucleotide analogs, and may be interrupted by non-nucleotide components. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The term polynucleotide, as used herein, refers interchangeably to double- and single-stranded molecules. Unless otherwise specified or required, any embodiment of the invention described herein that is a polynucleotide encompasses both the double-stranded form and each of two complementary single-stranded forms known or predicted to make up the double-stranded form.

A "transcriptional regulatory sequence" or "TRS," as used herein, refers to a genomic region that controls the transcription of a gene or coding sequence to which it is operably linked. Transcriptional regulatory sequences of use in the present invention generally include at least one transcriptional promoter and may also include one or more enhancers and/or terminators of transcription.

"Operably linked" refers to an arrangement of two or more components, wherein the components so described are in a relationship permitting them to function in a coordinated manner. By way of illustration, a transcriptional regulatory sequence or a promoter is operably linked to a coding sequence if the TRS or promoter promotes transcription of the coding sequence. An operably linked TRS is generally joined in cis with the coding sequence, but it is not necessarily directly adjacent to it.

"Heterologous" means derived from a genotypically distinct entity from that of the rest of the entity to which it is compared. For example, a polynucleotide introduced by genetic engineering techniques into a different cell type is a heterologous polynucleotide (and, when expressed, can encode a heterologous polypeptide). Similarly, a TRS or promoter that is removed from its native coding sequence and operably linked to a different coding sequence is a heterologous TRS or promoter.

"Packaging" as used herein refers to a series of subcellular events that results in the assembly and encapsidation of a viral vector, particularly an AAV vector. Thus, when a suitable vector is introduced into a packaging cell line under appropriate conditions, it can be assembled into a viral particle. Functions

associated with packaging of viral vectors, particularly AAV vectors, are described herein and in the art.

A "terminator" refers to a polynucleotide sequence that tends to diminish or prevent read-through transcription (i.e., it diminishes or prevent transcription originating on one side of the terminator from continuing through to the other side of the terminator). The degree to which transcription is disrupted is typically a function of the base sequence and/or the length of the terminator sequence. In particular, as is well known in numerous molecular biological systems, particular DNA sequences, generally referred to as "transcriptional termination sequences" are specific sequences that tend to disrupt read-through transcription by RNA polymerase, presumably by causing the RNA polymerase molecule to stop and/or disengage from the DNA being transcribed. Typical example of such sequence-specific terminators include polyadenylation ("polyA") sequences, e.g., SV40 polyA. In addition to or in place of such sequence-specific terminators, insertions of relatively long DNA sequences between a promoter and a coding region also tend to disrupt transcription of the coding region, generally in proportion to the length of the intervening sequence. This effect presumably arises because there is always some tendency for an RNA polymerase molecule to become disengaged from the DNA being transcribed, and increasing the length of the sequence to be traversed before reaching the coding region would generally increase the likelihood that disengagement would occur before transcription of the coding region was completed or possibly even initiated. Terminators may thus prevent transcription from only one direction ("uni-directional" terminators) or from both directions ("bi-directional" terminators), and may be comprised of sequence-specific termination sequences or sequence-non-specific terminators or both. A variety of such terminator sequences are known in the art; and illustrative uses of such sequences within the context of the present invention are provided below.

"Host cells," "cell lines," "cell cultures," "packaging cell line" and other such terms denote higher eukaryotic cells, preferably mammalian cells, most preferably human cells, useful in the present invention. These cells can be used as recipients for recombinant vectors, viruses or other transfer polynucleotides, and include the progeny of the original cell that was transduced. It is understood

that the progeny of a single cell may not necessarily be completely identical (in morphology or in genomic complement) to the original parent cell.

A "therapeutic gene," "prophylactic gene," "target polynucleotide," "transgene," "gene of interest" and the like generally refer to a gene or genes to be transferred using a vector. Typically, in the context of the present invention, such genes are located within the rAAV vector (which vector is flanked by inverted terminal repeat (ITR) regions and thus can be replicated and encapsidated into rAAV particles). Target polynucleotides can be used in this invention to generate rAAV vectors for a number of different applications. Such polynucleotides include, but are not limited to: (i) polynucleotides encoding proteins useful in other forms of gene therapy to relieve deficiencies caused by missing, defective or sub-optimal levels of a structural protein or enzyme; (ii) polynucleotides that are transcribed into anti-sense molecules; (iii) polynucleotides that are transcribed into decoys that bind transcription or translation factors; (iv) polynucleotides that encode cellular modulators such as cytokines; (v) polynucleotides that can make recipient cells susceptible to specific drugs, such as the herpes virus thymidine kinase gene; and (vi) polynucleotides for cancer therapy, such as E1A tumor suppressor genes or p53 tumor suppressor genes for the treatment of various cancers. To effect expression of the transgene in a recipient host cell, it is preferably operably linked to a promoter, either its own or a heterologous promoter. A large number of suitable promoters are known in the art, the choice of which depends on the desired level of expression of the target polynucleotide; whether one wants constitutive expression, inducible expression, cell-specific or tissue-specific expression, etc. The rAAV vector may also contain a selectable marker.

A "gene" refers to a polynucleotide containing at least one open reading frame that is capable of encoding a particular protein after being transcribed and translated.

"Recombinant," as applied to a polynucleotide means that the polynucleotide is the product of various combinations of cloning, restriction and/or ligation steps, and other procedures that result in a construct that is distinct from a polynucleotide found in nature. A recombinant virus is a viral particle comprising a recombinant polynucleotide. The terms respectively

include replicates of the original polynucleotide construct and progeny of the original virus construct.

A "control element" or "control sequence" is a nucleotide sequence involved in an interaction of molecules that contributes to the functional regulation of a polynucleotide, including replication, duplication, transcription, splicing, translation, or degradation of the polynucleotide. The regulation may affect the frequency, speed, or specificity of the process, and may be enhancing or inhibitory in nature. Control elements known in the art include, for example, transcriptional regulatory sequences such as promoters and enhancers. A promoter is a DNA region capable under certain conditions of binding RNA polymerase and initiating transcription of a coding region usually located downstream (in the 3' direction) from the promoter. Promoters include AAV promoters, e.g., P5, P19, P40 and AAV ITR promoters, as well as heterologous promoters.

An "expression vector" is a vector comprising a region which encodes a polypeptide of interest, and is used for effecting the expression of the protein in an intended target cell. An expression vector also comprises control elements operatively linked to the encoding region to facilitate expression of the protein in the target. The combination of control elements and a gene or genes to which they are operably linked for expression is sometimes referred to as an "expression cassette," a large number of which are known and available in the art or can be readily constructed from components that are available in the art.

"Genetic alteration" refers to a process wherein a genetic element is introduced into a cell other than by mitosis or meiosis. The element may be heterologous to the cell, or it may be an additional copy or improved version of an element already present in the cell. Genetic alteration may be effected, for example, by transfecting a cell with a recombinant plasmid or other polynucleotide through any process known in the art, such as electroporation, calcium phosphate precipitation, or contacting with a polynucleotide-liposome complex. Genetic alteration may also be effected, for example, by transduction or infection with a DNA or RNA virus or viral vector. Preferably, the genetic element is introduced into a chromosome or mini-chromosome in the cell; but any alteration that changes the phenotype and/or genotype of the cell and its progeny is included in this term.



A cell is said to be “stably” altered, transduced or transformed with a genetic sequence if the sequence is available to perform its function during extended culture of the cell *in vitro*. In preferred examples, such a cell is “inheritably” altered in that a genetic alteration is introduced which is also inheritable by progeny of the altered cell.

The terms “polypeptide” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, acetylation, phosphorylation, lipidation, or conjugation with a labeling component. Polypeptides such as “CFTR” and the like, when discussed in the context of gene therapy and compositions therefor, refer to the respective intact polypeptide, or any fragment or genetically engineered derivative thereof, that retains the desired biochemical function of the intact protein. Similarly, references to CFTR, and other such genes for use in gene therapy (typically referred to as “transgenes” to be delivered to a recipient cell), include polynucleotides encoding the intact polypeptide or any fragment or genetically engineered derivative possessing the desired biochemical function.

An “isolated” plasmid, virus, or other substance refers to a preparation of the substance devoid of at least some of the other components that may also be present where the substance or a similar substance naturally occurs or is initially prepared from. Thus, for example, an isolated substance may be prepared by using a purification technique to enrich it from a source mixture. Enrichment can be measured on an absolute basis, such as weight per volume of solution, or it can be measured in relation to a second, potentially interfering substance present in the source mixture. Increasing enrichments of the embodiments of this invention are increasingly more preferred. Thus, for example, a 2-fold enrichment is preferred, 10-fold enrichment is more preferred, 100-fold enrichment is more preferred, 1000-fold enrichment is even more preferred.

A preparation of AAV is said to be “substantially free” of helper virus if the ratio of infectious AAV particles to infectious helper virus particles is at least about  $10^2:1$ ; preferably at least about  $10^4:1$ , more preferably at least about  $10^6:1$ ; still more preferably at least about  $10^8:1$ . Preparations are also preferably free of equivalent amounts of helper virus proteins (i.e., proteins as would be present as a result of such a level of helper virus if the helper virus particle impurities noted

above were present in disrupted form). Viral and/or cellular protein contamination can generally be observed as the presence of Coomassie staining bands on SDS gels (e.g., the appearance of bands other than those corresponding to the AAV capsid proteins VP1, VP2 and VP3).

5       “Efficiency” when used in describing viral production, replication or packaging refers to useful properties of the method: in particular, the growth rate and the number of virus particles produced per cell. “High efficiency” production indicates production of at least 100 viral particles per cell; preferably at least about 10,000 and more preferably at least about 100,000 particles per  
10 cell, over the course of the culture period specified.

An “individual” or “subject” treated in accordance with this invention refers to vertebrates, particularly members of a mammalian species, and includes but is not limited to domestic animals, sports animals, and primates, including humans.

15       “Treatment” of an individual or a cell is any type of intervention in an attempt to alter the natural course of the individual or cell at the time the treatment is initiated, e.g., eliciting a prophylactic, curative or other beneficial effect in the individual. For example, treatment of an individual may be undertaken to decrease or limit the pathology caused by any pathological  
20 condition, including (but not limited to) an inherited or induced genetic deficiency, infection by a viral, bacterial, or parasitic organism, a neoplastic or aplastic condition, or an immune system dysfunction such as autoimmunity or immunosuppression. Treatment includes (but is not limited to) administration of a composition, such as a pharmaceutical composition, and administration of  
25 compatible cells that have been treated with a composition. Treatment may be performed either prophylactically or therapeutically; that is, either prior or subsequent to the initiation of a pathologic event or contact with an etiologic agent.

The practice of the present invention will employ, unless otherwise  
30 indicated, conventional techniques of molecular biology, virology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook et al., 1989; Gait, 1984; Freshney, 1987; the series Methods in Enzymology (Academic

Press, Inc.); Miller et al., 1987; Weir et al., 1996; Ausubel et al., 1998; Coligan et al., 1991; Coligan et al., 1995; and Scopes 1994.

#### I. rAAV vectors

Recombinant AAV vectors are potentially powerful tools for human gene  
5 therapy, particularly for diseases such as cystic fibrosis and sickle cell anemia. A major advantage of rAAV vectors over other approaches to gene therapy is that they generally do not require ongoing replication of the target cell in order to become stably integrated into the host cell.

rAAV vectors and/or viruses are also potentially powerful for the  
10 development of therapeutic or prophylactic vaccines to prevent infection, progression, and/or severity of disease. A major advantage of rAAV vectors for vaccine development is that they are capable of persisting for essentially the lifetime of the cell as a nuclear episome and therefore provide long term expression of the peptide, polypeptide, or protein of immunologic interest.  
15 Transgenes of interest include viral gene e.g. the envelope (env) or gag genes of HIV; bacterial genes e.g., streptococcal cell wall proteins; fungi, e.g., coccidiomycosis; parasites, e.g., Leishmaniasis, or cancer genes, e.g. p53.

rAAV vectors and/or viruses may also contain one or more detectable  
markers. A variety of such markers are known, including, by way of illustration,  
20 the bacterial beta-galactosidase (lacZ) gene; the human placental alkaline phosphatase (AP) gene and genes encoding various cellular surface markers which have been used as reporter molecules both *in vitro* and *in vivo*. The rAAV vectors and/or viruses may also contain one or more selectable markers.

Recombinant AAV vectors and/or viruses can also comprise  
25 polynucleotides that do not encode proteins, including, e.g., polynucleotides encoding for antisense mRNA (the complement of mRNA) which can be used to block the translation of normal mRNA by forming a duplex with it, and polynucleotides that encode ribozymes (RNA catalysts).

#### II. Selection and Preparation of AAV Vector

30 Adeno-associated viruses of any serotype are suitable to prepare rAAV, since the various serotypes are functionally and structurally related, even at the genetic level (see, e.g., Blacklow, 1988; and Rose, 1974). All AAV serotypes apparently exhibit similar replication properties mediated by homologous rep genes; and all generally bear three related capsid proteins such as those

expressed in AAV2. The degree of relatedness is further suggested by heteroduplex analysis which reveals extensive cross-hybridization between serotypes along the length of the genome; and the presence of analogous self-annealing segments at the termini that correspond to ITRs. The similar  
5 infectivity patterns also suggest that the replication functions in each serotype are under similar regulatory control. Among the various AAV serotypes, AAV2 is most commonly employed.

An AAV vector of the invention typically comprises a polynucleotide that is heterologous to AAV. The polynucleotide is typically of interest because  
10 of a capacity to provide a function to a target cell in the context of gene therapy, such as up- or down-regulation of the expression of a certain phenotype. Such a heterologous polynucleotide or "transgene," generally is of sufficient length to provide the desired function or encoding sequence.

Where transcription of the heterologous polynucleotide is desired in the  
15 intended target cell, it can be operably linked to its own or to a heterologous promoter, depending for example on the desired level and/or specificity of transcription within the target cell, as is known in the art. Various types of promoters and enhancers are suitable for use in this context. Constitutive promoters provide an ongoing level of gene transcription, and are preferred  
20 when it is desired that the therapeutic or prophylactic polynucleotide be expressed on an ongoing basis. Inducible promoters generally exhibit low activity in the absence of the inducer, and are up-regulated in the presence of the inducer. They may be preferred when expression is desired only at certain times or at certain locations, or when it is desirable to titrate the level of expression  
25 using an inducing agent. Promoters and enhancers may also be tissue-specific: that is, they exhibit their activity only in certain cell types, presumably due to gene regulatory elements found uniquely in those cells.

Illustrative examples of promoters are the SV40 late promoter from simian virus 40, the Baculovirus polyhedron enhancer/promoter element, Herpes  
30 Simplex Virus thymidine kinase (HSV tk), the immediate early promoter from cytomegalovirus (CMV) and various retroviral promoters including LTR elements. Inducible promoters include heavy metal ion inducible promoters (such as the mouse mammary tumor virus (mMTV) promoter or various growth hormone promoters), and the promoters from T7 phage which are active in the

presence of T7 RNA polymerase. By way of illustration, examples of tissue-specific promoters include various surfactin promoters (for expression in the lung), myosin promoters (for expression in muscle), and albumin promoters (for expression in the liver). A large variety of other promoters are known and  
5 generally available in the art, and the sequences of many such promoters are available in sequence databases such as the GenBank database.

Where translation is also desired in the intended target cell, the heterologous polynucleotide will preferably also comprise control elements that facilitate translation (such as a ribosome binding site or "RBS" and a  
10 polyadenylation signal). Accordingly, the heterologous polynucleotide generally comprises at least one coding region operatively linked to a suitable promoter, and may also comprise, for example, an operatively linked enhancer, ribosome binding site and poly-A signal. The heterologous polynucleotide may comprise one encoding region, or more than one encoding regions under the control of the  
15 same or different promoters. The entire unit, containing a combination of control elements and encoding region, is often referred to as an expression cassette.

The heterologous polynucleotide is integrated by recombinant techniques into or preferably in place of the AAV genomic coding region (i.e., in place of  
20 the AAV rep and cap genes), but is generally flanked on either side by AAV inverted terminal repeat (ITR) regions. This means that an ITR appears both upstream and downstream from the coding sequence, either in direct juxtaposition, preferably (although not necessarily) without any intervening sequence of AAV origin in order to reduce the likelihood of recombination that  
25 might regenerate a replication-competent AAV genome. However, a single ITR may be sufficient to carry out the functions normally associated with configurations comprising two ITRs (see, for example, WO 94/13788), and vector constructs with only one ITR can thus be employed in conjunction with the packaging and production methods of the present invention.

30 The native promoters for rep are self-regulating, and can limit the amount of AAV particles produced. The rep gene can also be operably linked to a heterologous promoter, whether rep is provided as part of the vector construct, or separately. Any heterologous promoter that is not strongly down-regulated by rep gene expression is suitable; but inducible promoters are preferred because

constitutive expression of the rep gene can have a negative impact on the host cell. A large variety of inducible promoters are known in the art; including, by way of illustration, heavy metal ion inducible promoters (such as metallothionein promoters); steroid hormone inducible promoters (such as the MMTV promoter or growth hormone promoters); and promoters such as those from T7 phage which are active in the presence of T7 RNA polymerase. An especially preferred sub-class of inducible promoters are those that are induced by the helper virus that is used to complement the replication and packaging of the rAAV vector. A number of helper-virus-inducible promoters have also been described, including the adenovirus early gene promoter which is inducible by adenovirus E1A protein; the adenovirus major late promoter; the herpesvirus promoter which is inducible by herpesvirus proteins such as VP16 or 1CP4; as well as vaccinia or poxvirus inducible promoters.

Methods for identifying and testing helper-virus-inducible promoters have been described (see, e.g., WO 96/17947). Thus, methods are known in the art to determine whether or not candidate promoters are helper-virus-inducible, and whether or not they will be useful in the generation of high efficiency packaging cells. Briefly, one such method involves replacing the p5 promoter of the AAV rep gene with the putative helper-virus-inducible promoter (either known in the art or identified using well-known techniques such as linkage to promoter-less "reporter" genes). The AAV rep-cap genes (with p5 replaced), preferably linked to a positive selectable marker such as an antibiotic resistance gene, are then stably integrated into a suitable host cell (such as the HeLa or A549 cells exemplified below). Cells that are able to grow relatively well under selection conditions (e.g., in the presence of the antibiotic) are then tested for their ability to express the rep and cap genes upon addition of a helper virus. As an initial test for rep and/or cap expression, cells can be readily screened using immunofluorescence to detect Rep and/or Cap proteins. Confirmation of packaging capabilities and efficiencies can then be determined by functional tests for replication and packaging of incoming rAAV vectors. Using this methodology, a helper-virus-inducible promoter derived from the mouse metallothionein gene has been identified as a suitable replacement for the p5 promoter, and used for producing high titers of rAAV particles (as described in WO 96/17947).

Given the relative encapsidation size limits of various AAV genomes, insertion of a large heterologous polynucleotide into the genome necessitates removal of a portion of the AAV sequence. Removal of one or more AAV genes is in any case desirable, to reduce the likelihood of generating replication-competent AAV ("RCA"). Accordingly, encoding or promoter sequences for rep, cap, or both, are preferably removed, since the functions provided by these genes can be provided in trans.

The resultant vector is referred to as being "defective" in these functions. In order to replicate and package the vector, the missing functions are complemented with a packaging gene, or a plurality thereof, which together encode the necessary functions for the various missing rep and/or cap gene products. The packaging genes or gene cassettes are preferably not flanked by AAV ITRs and preferably do not share any substantial homology with the rAAV genome. Thus, in order to minimize homologous recombination during replication between the vector sequence and separately provided packaging genes, it is desirable to avoid overlap of the two polynucleotide sequences. The level of homology and corresponding frequency of recombination increase with increasing length of homologous sequences and with their level of shared identity. The level of homology that will pose a concern in a given system can be determined theoretically and confirmed experimentally, as is known in the art. Typically, however, recombination can be substantially reduced or eliminated if the overlapping sequence is less than about a 25 nucleotide sequence if it is at least 80% identical over its entire length, or less than about a 50 nucleotide sequence if it is at least 70% identical over its entire length. Of course, even lower levels of homology are preferable since they will further reduce the likelihood of recombination. It appears that, even without any overlapping homology, there is some residual frequency of generating RCA. Even further reductions in the frequency of generating RCA (e.g., by nonhomologous recombination) can be obtained by "splitting" the replication and encapsidation functions of AAV, as described by Allen et al., WO 98/27204).

The rAAV vector construct, and the complementary packaging gene constructs can be implemented in this invention in a number of different forms.

Viral particles, plasmids, and stably transformed host cells can all be used to introduce such constructs into the packaging cell, either transiently or stably.

In certain embodiments of this invention, the AAV vector and complementary packaging gene(s), if any, are provided in the form of bacterial plasmids, AAV particles, or any combination thereof. In other embodiments, either the AAV vector sequence, the packaging gene(s), or both, are provided in the form of genetically altered (preferably inheritably altered) eukaryotic cells. The development of host cells inheritably altered to express the AAV vector sequence, AAV packaging genes, or both, provides an established source of the material that is expressed at a reliable level.

A variety of different genetically altered cells can thus be used in the context of this invention. By way of illustration, a mammalian host cell may be used with at least one intact copy of a stably integrated rAAV vector. An AAV packaging plasmid comprising at least an AAV rep gene operably linked to a promoter can be used to supply replication functions (as described in U.S. Patent 5,658,776). Alternatively, a stable mammalian cell line with an AAV rep gene operably linked to a promoter can be used to supply replication functions (see, e.g., Trempe et al., WO 95/13392); Burstein et al. (WO 98/23018); and Johnson et al. (U.S. No. 5,656,785). The AAV cap gene, providing the encapsidation proteins as described above, can be provided together with an AAV rep gene or separately (see, e.g., the above-referenced applications and patents as well as Allen et al. (WO 98/27204). Other combinations are possible and included within the scope of this invention.

### III. Generating rAAV

To generate recombinant AAV particles useful for such purposes as gene therapy, the packaging cell line is preferably supplied with a recombinant AAV vector comprising AAV inverted terminal repeat (ITR) regions surrounding one or more polynucleotides of interest (or "target" polynucleotides).

The target polynucleotide is generally operably linked to a promoter, either its own or a heterologous promoter. A large number of suitable promoters are known in the art, the choice of which depends on the desired level of expression of the target polynucleotide (i.e., whether one wants constitutive expression, inducible expression, cell-specific or tissue-specific expression, etc.).



Preferably, the rAAV vector also contains a positive selectable marker in order to allow for selection of cells that have been infected by the rAAV vector. Negative selectable markers can also be included; as a means of selecting against those same cells should that become necessary or desirable. In a preferred  
5 embodiment, one can make use of the "bifunctional selectable fusion genes" described by S. D. Lupton; see, e.g., PCT/US91/08442 and PCT/US94/05601. Briefly, those constructs involve direct translational fusions between a dominant positive selectable marker and a negative selectable marker. Preferred positive selectable markers are derived from genes selected from the group consisting of  
10 hph, neo, and gpt, and preferred negative selectable markers are derived from genes selected from the group consisting of cytosine deaminase, HSV-I TK, VZV TK, HPRT, APRT and gpt. Especially preferred markers are bifunctional selectable fusion genes wherein the positive selectable marker is derived from hph or neo, and the negative selectable marker is derived from cytosine  
15 deaminase or a TK gene.

Useful target polynucleotides can be employed in rAAV vectors for a number of different applications. Such polynucleotides include, but are not limited to: (i) polynucleotides encoding proteins useful in other forms of gene therapy to relieve deficiencies caused by missing, defective or sub-optimal levels  
20 of a structural protein or enzyme; (ii) polynucleotides that are transcribed into anti-sense molecules; (iii) polynucleotides that are transcribed into decoys that bind transcription or translation factors; (iv) polynucleotides that encode cellular modulators such as cytokines; (v) polynucleotides that can make recipient cells susceptible to specific drugs, such as the herpes virus thymidine kinase gene;  
25 and (vi) polynucleotides for cancer therapy, such as the wild-type p53 tumor suppressor cDNA for replacement of the missing or damaged p53 gene associated with some lung and breast cancers, or the E1A tumor suppressor gene which is capable of inhibiting tumorigenesis and/or metastasis of a variety of different cancers including breast and ovarian cancers.

30 Since the therapeutic or prophylactic specificity of the resulting recombinant AAV particle is determined by the particular vector or pro-vector introduced, the same basic packaging cell line can be modified for any of these applications. For example, a vector comprising a specific target polynucleotide can be introduced into the packaging cell for production of the AAV vector by

any of several possible methods; including, for example, electroporation or transfection of a plasmid comprising an rAAV pro-vector, or infection with an rAAV or helper virus comprising an rAAV vector or pro-vector.

5 Helper virus can be introduced before, during or after introduction of the rAAV vector. For example, the plasmid can be co-infected into the culture along with the helper virus; and the cells can then be cultured for a sufficient period, typically 2-5 days, in conditions suitable for replication and packaging as known in the art (see references above and examples below). Lysates are prepared, and the recombinant AAV vector particles are purified by techniques known in the art.

10 In a preferred embodiment, also illustrated in the Examples below, a recombinant AAV vector is itself stably integrated into a mammalian cell to be used for packaging. Such rAAV "producer cells" can then be grown and stored until ready for use. To induce production of rAAV particles from such producer cells, the user need only infect the cells with helper virus and culture the cells under conditions suitable for replication and packaging of AAV (as described below).

Alternatively, one or more of the AAV split-packaging genes or the rAAV vector can be introduced as part of a recombinant helper virus. For example, the E1, E3 and/or the E4 genes of adenovirus can be replaced with one or more split-packaging genes or an rAAV vector. Techniques for facilitating cloning into adenovirus vectors, e.g., into the E1 and/or E3 regions, are known in the art (see, e.g., Bett, A. J. et al., Proc. Natl. Acad. Sci. USA, 91, 8802-8806 (1994)). Thus, a helper virus such as a recombinant adenovirus, can be used to provide helper virus functions as well as AAV packaging genes and/or an rAAV pro-vector, since (as is known in the art) a number of genes in such a helper virus (e.g., the E3 gene of adenovirus) can be replaced without eliminating helper virus activity. Additional genes can be inserted into such a helper virus by providing any necessary helper virus functions in trans. For example, human 293 cells contain adenoviral genes that can complement adenoviral E1 mutants. Thus, heterologous genes can also be cloned into an adenovirus in which the E1 genes have been deleted, for use in cells that can effectively provide such adenoviral functions in trans. Alternatively, the use of a helper virus can be

eliminated by providing all necessary helper virus functions in the packaging cell.

#### IV. Introduction of Genetic Material Into Cells

As is described in the art, and illustrated both herein and in the references cited above, genetic material can be introduced into cells (such as mammalian “producer” cells for the production of AAV) using any of a variety of means to transform or transduce such cells. By way of illustration, such techniques include, for example, transfection with bacterial plasmids, infection with viral vectors, electroporation, calcium phosphate precipitation, and introduction using any of a variety of lipid-based compositions (a process often referred to as “lipofection”). Methods and compositions for performing these techniques have been described in the art and are widely available.

Selection of suitably altered cells may be conducted by any technique in the art. For example, the polynucleotide sequences used to alter the cell may be introduced simultaneously with or operably linked to one or more detectable or selectable markers as is known in the art. By way of illustration, one can employ a drug-resistance gene as a selectable marker. Drug-resistant cells can then be picked and grown, and then tested for expression of the desired sequence, i.e., a packaging gene product, or a product of the heterologous polynucleotide, as appropriate. Testing for acquisition, localization and/or maintenance of an introduced polynucleotide can be performed using DNA hybridization-based techniques (such as Southern blotting and other procedures as is known in the art). Testing for expression can be readily performed by Northern analysis of RNA extracted from the genetically altered cells, or by indirect immunofluorescence for the corresponding gene product. Testing and confirmation of packaging capabilities and efficiencies can be obtained by introducing to the cell the remaining functional components of AAV and a helper virus, to test for production of AAV particles. Where a cell is inheritably altered with a plurality of polynucleotide constructs, it is generally more convenient (though not essential) to introduce them to the cell separately, and validate each step seriatim. References describing such techniques include those cited herein.

#### V. Selection and Preparation of Helper Virus

As discussed above, AAV is a parvovirus that is defective for self-replication, and must generally rely on a helper virus to supply certain replicative functions. A number of such helper viruses have been identified, including adenoviruses, herpes viruses (including but not limited to HSV1, cytomegalovirus and HHV-6), and pox viruses (particularly vaccinia). Any such virus may be used with this invention.

Frequently, the helper virus is an adenovirus of a type and subgroup that can infect the intended host cell. Human adenovirus of subgroup C, particularly serotypes 1, 2, 4, 6, and 7, are commonly used. Serotype 5 is generally preferred.

The features and growth patterns of adenovirus are known in the art. The reader may refer, for example, to Horowitz (1985). The packaged adenovirus genome is a linear DNA molecule, linked through adenovirus ITRs at the left- and right-hand termini through a terminal protein complex to form a circle. Control and encoding regions for early, intermediate, and late components overlap within the genome. Early region genes are implicated in replication of the adenovirus genome, and are grouped depending on their location into the E1, E2, E3, and E4 regions.

Although not essential, in principle it is desirable that the helper virus strain be defective for replication in the subject ultimately to receive the genetic therapy. Thus, any residual helper virus present in an rAAV preparation will be replication-incompetent. Adenoviruses from which the E1A or both the E1A and the E3 region have been removed are not infectious for most human cells. They can be replicated in a permissive cell line (e.g., the human 293 cell line) which is capable of complementing the missing activity. Regions of adenovirus that appear to be associated with helper function, as well as regions that do not, have been identified and described in the art (see, e.g., P. Colosi et al., WO97/17458, and references cited therein).

#### VI. Uses of rAAV for Gene Therapy

AAV vectors can be used for administration to an individual for purposes of gene therapy or vaccination. Suitable diseases for rAAV therapy include but are not limited to those induced by viral, bacterial, or parasitic infections, various malignancies and hyperproliferative conditions, autoimmune conditions, and congenital deficiencies.

Gene therapy can be conducted to enhance the level of expression of a particular protein either within or secreted by the cell. Vectors of this invention may be used to genetically alter cells either for gene marking, replacement of a missing or defective gene, or insertion of a therapeutic gene. Alternatively, a polynucleotide may be provided to the cell that decreases the level of expression. This may be used for the suppression of an undesirable phenotype, such as the product of a gene amplified or overexpressed during the course of a malignancy, or a gene introduced or overexpressed during the course of a microbial infection. Expression levels may be decreased by supplying a therapeutic or prophylactic polynucleotide comprising a sequence capable, for example, of forming a stable hybrid with either the target gene or RNA transcript (antisense therapy), capable of acting as a ribozyme to cleave the relevant mRNA or capable of acting as a decoy for a product of the target gene.

The introduction of rAAV vectors by the methods of the present invention may involve use of any number of delivery techniques (both surgical and non-surgical) which are available and well known in the art. Such delivery techniques, for example, include vascular catheterization, cannulization, injection, inhalation, endotracheal, subcutaneous, inunction, topical, oral, percutaneous, intra-arterial, intravenous, and/or intraperitoneal administrations. Vectors can also be introduced by way of bioprostheses, including, by way of illustration, vascular grafts (PTFE and dacron), heart valves, intravascular stents, intravascular paving as well as other non-vascular prostheses. General techniques regarding delivery, frequency, composition and dosage ranges of vector solutions are within the skill of the art.

In particular, for delivery of a vector of the invention to a tissue, any physical or biological method that will introduce the vector to a host animal can be employed. Vector means both a bare recombinant vector and vector DNA packaged into viral coat proteins, as is well known for AAV administration. Simply dissolving an AAV vector in phosphate buffered saline has been demonstrated to be sufficient to provide a vehicle useful for muscle tissue expression, and there are no known restrictions on the carriers or other components that can be coadministered with the vector (although compositions that degrade DNA should be avoided in the normal manner with vectors). Pharmaceutical compositions can be prepared as injectable formulations or as

topical formulations to be delivered to the muscles by transdermal transport.

Numerous formulations for both intramuscular injection and transdermal transport have been previously developed and can be used in the practice of the invention. The vectors can be used with any pharmaceutically acceptable carrier  
5 for ease of administration and handling.

For purposes of intramuscular injection, solutions in an adjuvant such as sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions. Such aqueous solutions can be buffered, if desired, and the liquid diluent first rendered isotonic with saline or glucose. Solutions of  
10 the AAV vector as a free acid (DNA contains acidic phosphate groups) or a pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. A dispersion of AAV viral particles can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof and in oils. Under ordinary conditions of storage and use, these  
15 preparations contain a preservative to prevent the growth of microorganisms. In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous  
20 preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for  
25 example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of a dispersion and by the use of surfactants. The prevention of the action of  
30 microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable

compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the AAV vector in the required amount in the appropriate solvent with various of the other  
5 ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred  
10 methods of preparation are vacuum drying and the freeze drying technique which yield a powder of the active ingredient plus any additional desired ingredient from the previously sterile-filtered solution thereof.

For purposes of topical administration, dilute sterile, aqueous solutions (usually in about 0.1% to 5% concentration), otherwise similar to the above  
15 parenteral solutions, are prepared in containers suitable for incorporation into a transdermal patch, and can include known carriers, such as pharmaceutical grade dimethylsulfoxide (DMSO).

Of particular interest is the correction of the genetic defect of cystic fibrosis, by supplying a properly functioning cystic fibrosis transmembrane  
20 conductance regulator (CFTR) to the airway epithelium. Thus, rAAV vectors encoding native CFTR protein, and mutants and fragments thereof, are all preferred embodiments of this invention.

Compositions of this invention may be used *in vivo* as well as *ex vivo*. *In vivo* gene therapy comprises administering the vectors of this invention directly  
25 to a subject. Pharmaceutical compositions can be supplied as liquid solutions or suspensions, as emulsions, or as solid forms suitable for dissolution or suspension in liquid prior to use. For administration into the respiratory tract, a preferred mode of administration is by aerosol, using a composition that provides either a solid or liquid aerosol when used with an appropriate  
30 aerosolubilizer device. Another preferred mode of administration into the respiratory tract is using a flexible fiberoptic bronchoscope to instill the vectors. Typically, the viral vectors are in a pharmaceutically suitable pyrogen-free buffer such as Ringer's balanced salt solution (pH 7.4). Although not required,

pharmaceutical compositions may optionally be supplied in unit dosage form suitable for administration of a precise amount.

An effective amount of virus is administered, depending on the objectives of treatment. An effective amount may be given in single or divided  
5 doses. Where a low percentage of transduction can cure a genetic deficiency, then the objective of treatment is generally to meet or exceed this level of transduction. In some instances, this level of transduction can be achieved by transduction of only about 1 to 5% of the target cells, but is more typically 20% of the cells of the desired tissue type, usually at least about 50%, preferably at  
10 least about 80%, more preferably at least about 95%, and even more preferably at least about 99% of the cells of the desired tissue type. As a guide, the number of vector particles present in a single dose given by bronchoscopy will generally be at least about  $1 \times 10^8$ , and is more typically  $5 \times 10^8$ ,  $1 \times 10^{10}$ , and on some occasions  $1 \times 10^{11}$  particles, including both DNase-resistant and DNase-  
15 susceptible particles. In terms of DNase-resistant particles, the dose will generally be between  $1 \times 10^6$  and  $1 \times 10^{14}$  particles, more generally between about  $1 \times 10^8$  and  $1 \times 10^{12}$  particles. The treatment can be repeated as often as every two or three weeks, as required, although treatment once in 180 days may be sufficient.

20 To confirm the presence of the desired DNA sequence in the host cell, a variety of assays may be performed. Such assays include, for example, "molecular biological" assays well known to those of skill in the art, such as Southern and Northern blotting, RT-PCR and PCR; "biochemical" assays, such as detecting the presence of a polypeptide expressed from a gene present in the  
25 vector, e.g., by immunological means (immunoprecipitations, immunoaffinity columns, ELISAs and Western blots) or by any other assay useful to identify the presence and/or expression of a particular nucleic acid molecule falling within the scope of the invention.

To detect and quantitate RNA produced from introduced DNA segments,  
30 RT-PCR may be employed. In this application of PCR, it is first necessary to reverse transcribe RNA into DNA, using enzymes such as reverse transcriptase, and then through the use of conventional PCR techniques amplify the DNA. In most instances PCR techniques, while useful, will not demonstrate integrity of the RNA product. Further information about the nature of the RNA product may



be obtained by Northern blotting. This technique demonstrates the presence of an RNA species and gives information about the integrity of that RNA. The presence or absence of an RNA species can also be determined using dot or slot blot Northern hybridizations. These techniques are modifications of Northern blotting and only demonstrate the presence or absence of an RNA species.

While Southern blotting and PCR may be used to detect the DNA segment in question, they do not provide information as to whether the DNA segment is being expressed. Expression may be evaluated by specifically identifying the polypeptide products of the introduced DNA sequences or evaluating the phenotypic changes brought about by the expression of the introduced DNA segment in the host cell.

Thus, the effectiveness of the genetic alteration can be monitored by several criteria, including analysis of physiological fluid samples, e.g., urine, plasma, serum, blood, cerebrospinal fluid or nasal or lung washes. Samples removed by biopsy or surgical excision may be analyzed by in situ hybridization, PCR amplification using vector-specific probes, RNase protection, immunohistology, or immunofluorescent cell counting. When the vector is administered by bronchoscopy, lung function tests may be performed, and bronchial lavage may be assessed for the presence of inflammatory cytokines. The treated subject may also be monitored for clinical features, and to determine whether the cells express the function intended to be conveyed by the therapeutic or prophylactic polynucleotide.

The decision of whether to use *in vivo* or *ex vivo* therapy, and the selection of a particular composition, dose, and route of administration will depend on a number of different factors, including but not limited to features of the condition and the subject being treated. The assessment of such features and the design of an appropriate therapeutic or prophylactic regimen is ultimately the responsibility of the prescribing physician.

The foregoing description provides, *inter alia*, methods for generating high titer preparations of recombinant AAV vectors that are substantially free of helper virus (e.g., adenovirus) and cellular proteins. It is understood that variations may be applied to these methods by those of skill in this art without departing from the spirit of this invention.

## VII. Exemplary Methods to Identify Useful Agents

The utility of rAAV as a gene therapy vector is based on its transduction properties. Methods to detect AAV transduction are known in the art, including those described herein, and are useful to screen libraries, types and classes of agents for the ability to improve AAV transduction by means other than by affecting binding to cell surface receptors, or the rate of intra-nuclear genome conversion of the single stranded rAAV vector to a double stranded genome.

Transduction may be defined by protein expression of a heterologous transgene contained in the vector or steady state levels thereof. Hence, transduction is a measurable functional endpoint of successful gene delivery with a viral vector, e.g., rAAV. A variety of transgenes have been expressed from cells infected with AAV vectors, and include intracellularly expressed proteins such as the green fluorescent protein (GFP), cell membrane associated proteins such as the cystic fibrosis transmembrane protein (CFTR), and secretory proteins such as Epo, FVIII, and FIX. However, not all transgenes are capable of fully assessing the extent of transduction with a given vector and tissue target. For example, secreted proteins do not give indication of the number of cell types expressing a given transgene. Furthermore, functional markers of gene expression are dependent on the ability of a given transgene protein product to function properly within a given target cell type.

#### VIII. Agents Useful in the Practice of the Invention

rAAV must undergo a number of complex intracellular events between binding and conversion to dsDNA that may be rate limiting for transduction efficiency including but not limited to rAAV endocytosis, trafficking and processing of the rAAV through the appropriate intracellular compartments (including without limitation proteosomes, endosomes, and trans-golgi), transport into the nucleus, and viral uncoating. Furthermore, agents that alter the efficiency of these intracellular processing events can also have an end result of increasing the amount of viral DNA in the nucleus and hence, through steady state, the abundance of gene conversion products. Thus, an increase in genome conversion products following enhancement of rAAV intracellular processing does not necessarily indicate an increased rate of gene conversion. Methods of enhancing transduction with rAAV are expected to increase the extent of double stranded genome conversion products in the nucleus. This is an important distinction with previous methods aimed at directly enhancing genome

conversion using DNA damaging agents, topoisomerase inhibitors, or adenoviral early gene products (Alexander et al., 1997; Alexander et al., 1996; Ferrari et al., 1996; Fisher et al., 1996; Halbert et al., 1997; Russel et al., 1995) which essentially change the level of gene conversion enzymes in the nucleus.

- 5 However, in cases where gene conversion in the nucleus is not rate limiting, intracellular viral processing events that limit transduction may predominate.

Thus, agents useful in the practice of the invention include agents which alter rAAV transduction efficiency, e.g., rAAV endocytosis, trafficking and processing of rAAV through the intracellular compartment, viral nucleic acid or  
10 protein degradation, viral uncoating and nuclear transport of virus or viral genomes or otherwise modulate proteasomes. Preferred agents are those which enhance or increase rAAV transduction. Classes of agents useful in the invention include but are not limited to antibiotics, chemotherapeutics, e.g., anthracyclines, proteasome modulators, lipid lowering agents, and food  
15 additives. Exemplary agents include proteasomes (Wagner et al., 2002; Young et al., 2000; Seisenberger et al., 2001), as well as agents that modulate the proteasome and ubiquitin pathways, e.g., bind to proteasomes and/or modulate the activity of proteasomes, ubiquitin, ubiquitin carrier protein, or ubiquitin ligase, but do not substantially alter the activity of the proteasome, e.g., the  
20 proteolytic activity of the proteasome or of ubiquitin, ubiquitin carrier protein, or ubiquitin ligase. Examples of these agents include without limitation antibiotics, e.g., epoxomicin, lipid lowering drugs, e.g., simvastatin, food additives, e.g., tannic acid, and chemotherapeutics, e.g., cisplatin, anthracyclines such as doxorubicin, and camptothecin.

25 IX. Dosages, Formulations and Routes of Administration of the Agents of the

Invention

Administration of the agents identified in accordance with the present invention may be continuous or intermittent, depending, for example, upon the  
30 recipient's physiological condition, whether the purpose of the administration is therapeutic or prophylactic, and other factors known to skilled practitioners. The administration of the agents of the invention may be essentially continuous over a preselected period of time or may be in a series of spaced doses. Both local and systemic administration is contemplated. When the agents of the invention

are employed for prophylactic purposes, agents of the invention are amenable to chronic use, preferably by systemic administration.

One or more suitable unit dosage forms comprising the agents of the invention, which, as discussed below, may optionally be formulated for sustained release, can be administered by a variety of routes including oral, or parenteral, including by rectal, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, intrathoracic, intrapulmonary and intranasal routes. For example, for administration to the liver, intravenous administration is preferred. For administration to the lung, airway administration is preferred.

10 The formulations may, where appropriate, be conveniently presented in discrete unit dosage forms and may be prepared by any of the methods well known to pharmacy. Such methods may include the step of bringing into association the agent with liquid carriers, solid matrices, semi-solid carriers, finely divided solid carriers or combinations thereof, and then, if necessary, introducing or shaping

15 the product into the desired delivery system.

When the agents of the invention are prepared for oral administration, they are preferably combined with a pharmaceutically acceptable carrier, diluent or excipient to form a pharmaceutical formulation, or unit dosage form. The total active ingredients in such formulations comprise from 0.1 to 99.9% by weight of the formulation. By "pharmaceutically acceptable" it is meant the carrier, diluent, excipient, and/or salt must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof. The active ingredient for oral administration may be present as a powder or as granules; as a solution, a suspension or an emulsion; or in achievable base such as a synthetic resin for ingestion of the active ingredients from a chewing gum.

20

25 The active ingredient may also be presented as a bolus, electuary or paste.

Pharmaceutical formulations containing the agents of the invention can be prepared by procedures known in the art using well known and readily available ingredients. For example, the agent can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and the like. Examples of excipients, diluents, and carriers that are suitable for such formulations include the following fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose, HPMC and other cellulose derivatives, alginates,

30

gelatin, and polyvinyl-pyrrolidone; moisturizing agents such as glycerol; disintegrating agents such as calcium carbonate and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate, and solid polyethyl glycols.

For example, tablets or caplets containing the agents of the invention can include buffering agents such as calcium carbonate, magnesium oxide and magnesium carbonate. Caplets and tablets can also include inactive ingredients such as cellulose, pregelatinized starch, silicon dioxide, hydroxy propyl methyl cellulose, magnesium stearate, microcrystalline cellulose, starch, talc, titanium dioxide, benzoic acid, citric acid, corn starch, mineral oil, polypropylene glycol, sodium phosphate, and zinc stearate, and the like. Hard or soft gelatin capsules containing an agent of the invention can contain inactive ingredients such as gelatin, microcrystalline cellulose, sodium lauryl sulfate, starch, talc, and titanium dioxide, and the like, as well as liquid vehicles such as polyethylene glycols (PEGs) and vegetable oil. Moreover, enteric coated caplets or tablets of an agent of the invention are designed to resist disintegration in the stomach and dissolve in the more neutral to alkaline environment of the duodenum.

The agents of the invention can also be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for parenteral administration, for instance by intramuscular, subcutaneous or intravenous routes.

The pharmaceutical formulations of the agents of the invention can also take the form of an aqueous or anhydrous solution or dispersion, or alternatively the form of an emulsion or suspension.

Thus, the therapeutic agent may be formulated for parenteral administration (e.g., by injection, for example, bolus injection or continuous infusion) and may be presented in unit dose form in ampules, pre-filled syringes, small volume infusion containers or in multi-dose containers with an added preservative. The active ingredients may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively,

the active ingredients may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.

These formulations can contain pharmaceutically acceptable vehicles and  
5    adjuvants which are well known in the prior art. It is possible, for example, to prepare solutions using one or more organic solvent(s) that is/are acceptable from the physiological standpoint, chosen, in addition to water, from solvents such as acetone, ethanol, isopropyl alcohol, glycol ethers such as the products sold under the name "Dowanol", polyglycols and polyethylene glycols, C<sub>1</sub>-C<sub>4</sub>  
10    alkyl esters of short-chain acids, preferably ethyl or isopropyl lactate, fatty acid triglycerides such as the products marketed under the name "Miglyol", isopropyl myristate, animal, mineral and vegetable oils and polysiloxanes.

The compositions according to the invention can also contain thickening agents such as cellulose and/or cellulose derivatives. They can also contain  
15    gums such as xanthan, guar or carbo gum or gum arabic, or alternatively polyethylene glycols, bentones and montmorillonites, and the like.

It is possible to add, if necessary, an adjuvant chosen from antioxidants, surfactants, other preservatives, film-forming, keratolytic or comedolytic agents, perfumes and colorings. Also, other active ingredients may be added, whether  
20    for the conditions described or some other condition.

For example, among antioxidants, t-butylhydroquinone, butylated hydroxyanisole, butylated hydroxytoluene and  $\alpha$ -tocopherol and its derivatives may be mentioned. The galenical forms chiefly conditioned for topical application take the form of creams, milks, gels, dispersion or microemulsions,  
25    lotions thickened to a greater or lesser extent, impregnated pads, ointments or sticks, or alternatively the form of aerosol formulations in spray or foam form or alternatively in the form of a cake of soap.

Additionally, the agents are well suited to formulation as sustained release dosage forms and the like. The formulations can be so constituted that  
30    they release the active ingredient only or preferably in a particular part of the intestinal or respiratory tract, possibly over a period of time. The coatings, envelopes, and protective matrices may be made, for example, from polymeric substances, such as polylactide-glycolates, liposomes, microemulsions, microparticles, nanoparticles, or waxes. These coatings, envelopes, and

protective matrices are useful to coat indwelling devices, e.g., stents, catheters, peritoneal dialysis tubing, and the like.

The agents of the invention can be delivered via patches for transdermal administration. See U.S. Patent No. 5,560,922 for examples of patches suitable  
5 for transdermal delivery of an agent. Patches for transdermal delivery can comprise a backing layer and a polymer matrix which has dispersed or dissolved therein an agent, along with one or more skin permeation enhancers. The backing layer can be made of any suitable material which is impermeable to the agent. The backing layer serves as a protective cover for the matrix layer and  
10 provides also a support function. The backing can be formed so that it is essentially the same size layer as the polymer matrix or it can be of larger dimension so that it can extend beyond the side of the polymer matrix or overlay the side or sides of the polymer matrix and then can extend outwardly in a manner that the surface of the extension of the backing layer can be the base for  
15 an adhesive means. Alternatively, the polymer matrix can contain, or be formulated of, an adhesive polymer, such as polyacrylate or acrylate/vinyl acetate copolymer. For long-term applications it might be desirable to use microporous and/or breathable backing laminates, so hydration or maceration of the skin can be minimized.

20 Examples of materials suitable for making the backing layer are films of high and low density polyethylene, polypropylene, polyurethane, polyvinylchloride, polyesters such as poly(ethylene phthalate), metal foils, metal foil laminates of such suitable polymer films, and the like. Preferably, the materials used for the backing layer are laminates of such polymer films with a  
25 metal foil such as aluminum foil. In such laminates, a polymer film of the laminate will usually be in contact with the adhesive polymer matrix.

The backing layer can be any appropriate thickness which will provide the desired protective and support functions. A suitable thickness will be from about 10 to about 200 microns.

30 Generally, those polymers used to form the biologically acceptable adhesive polymer layer are those capable of forming shaped bodies, thin walls or coatings through which agents can pass at a controlled rate. Suitable polymers are biologically and pharmaceutically compatible, nonallergenic and insoluble in and compatible with body fluids or tissues with which the device is contacted.

The use of soluble polymers is to be avoided since dissolution or erosion of the matrix by skin moisture would affect the release rate of the agents as well as the capability of the dosage unit to remain in place for convenience of removal.

Exemplary materials for fabricating the adhesive polymer layer include

5 polyethylene, polypropylene, polyurethane, ethylene/propylene copolymers, ethylene/ethylacrylate copolymers, ethylene/vinyl acetate copolymers, silicone elastomers, especially the medical-grade polydimethylsiloxanes, neoprene rubber, polyisobutylene, polyacrylates, chlorinated polyethylene, polyvinyl chloride, vinyl chloride-vinyl acetate copolymer, crosslinked polymethacrylate

10 polymers (hydrogel), polyvinylidene chloride, poly(ethylene terephthalate), butyl rubber, epichlorohydrin rubbers, ethylene vinyl alcohol copolymers, ethylene-vinyloxyethanol copolymers; silicone copolymers, for example, polysiloxane-polycarbonate copolymers, polysiloxane-polyethylene oxide copolymers, polysiloxane-polymethacrylate copolymers, polysiloxane-alkylene

15 copolymers (e.g., polysiloxane-ethylene copolymers), polysiloxane-alkylenesilane copolymers (e.g., polysiloxane-ethylenesilane copolymers), and the like; cellulose polymers, for example methyl or ethyl cellulose, hydroxy propyl methyl cellulose, and cellulose esters; polycarbonates; polytetrafluoroethylene; and the like.

20 Preferably, a biologically acceptable adhesive polymer matrix should be selected from polymers with glass transition temperatures below room temperature. The polymer may, but need not necessarily, have a degree of crystallinity at room temperature. Cross-linking monomeric units or sites can be incorporated into such polymers. For example, cross-linking monomers can be

25 incorporated into polyacrylate polymers, which provide sites for cross-linking the matrix after dispersing the agent into the polymer. Known cross-linking monomers for polyacrylate polymers include polymethacrylic esters of polyols such as butylene diacrylate and dimethacrylate, trimethylol propane trimethacrylate and the like. Other monomers which provide such sites include

30 allyl acrylate, allyl methacrylate, diallyl maleate and the like.

Preferably, a plasticizer and/or humectant is dispersed within the adhesive polymer matrix. Water-soluble polyols are generally suitable for this purpose. Incorporation of a humectant in the formulation allows the dosage unit to absorb moisture on the surface of skin which in turn helps to reduce skin



irritation and to prevent the adhesive polymer layer of the delivery system from failing.

Agents released from a transdermal delivery system must be capable of penetrating each layer of skin. In order to increase the rate of permeation of an agent, a transdermal drug delivery system must be able in particular to increase  
5 the permeability of the outermost layer of skin, the stratum corneum, which provides the most resistance to the penetration of molecules. The fabrication of patches for transdermal delivery of agents is well known to the art.

For administration to the upper (nasal) or lower respiratory tract by  
10 inhalation, the agents of the invention are conveniently delivered from an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a  
15 pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount.

Alternatively, for administration by inhalation or insufflation, the composition may take the form of a dry powder, for example, a powder mix of the agent and a suitable powder base such as lactose or starch. The powder  
20 composition may be presented in unit dosage form in, for example, capsules or cartridges, or, e.g., gelatine or blister packs from which the powder may be administered with the aid of an inhalator, insufflator or a metered-dose inhaler.

For intra-nasal administration, the agent may be administered via nose drops, a liquid spray, such as via a plastic bottle atomizer or metered-dose  
25 inhaler. Typical of atomizers are the Mistometer (Wintrop) and the Medihaler (Riker).

The local delivery of the agents of the invention can also be by a variety of techniques which administer the agent at or near the site of disease. Examples of site-specific or targeted local delivery techniques are not intended to be  
30 limiting but to be illustrative of the techniques available. Examples include local delivery catheters, such as an infusion or indwelling catheter, e.g., a needle infusion catheter, shunts and stents or other implantable devices, site specific carriers, direct injection, or direct applications.

For topical administration, the agents may be formulated as is known in the art for direct application to a target area. Conventional forms for this purpose include wound dressings, coated bandages or other polymer coverings, ointments, creams, lotions, pastes, jellies, sprays, and aerosols. Ointments and  
5 creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents. The active ingredients can also be  
10 delivered via iontophoresis, e.g., as disclosed in U.S. Patent Nos. 4,140,122; 4,383,529; or 4,051,842. The percent by weight of an agent of the invention present in a topical formulation will depend on various factors, but generally will be from 0.01% to 95% of the total weight of the formulation, and typically 0.1-25% by weight.

15 Drops, such as eye drops or nose drops, may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilizing agents or suspending agents. Liquid sprays are conveniently delivered from pressurized packs. Drops can be delivered via a simple eye dropper-capped bottle, or via a plastic bottle adapted to deliver liquid contents  
20 dropwise, via a specially shaped closure.

The agent may further be formulated for topical administration in the mouth or throat. For example, the active ingredients may be formulated as a lozenge further comprising a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the composition in an inert base such as gelatin  
25 and glycerin or sucrose and acacia; and mouthwashes comprising the composition of the present invention in a suitable liquid carrier.

The formulations and compositions described herein may also contain other ingredients such as antimicrobial agents, or preservatives. Furthermore, the active ingredients may also be used in combination with other agents, for  
30 example, bronchodilators.

The agents of this invention may be administered to a mammal alone or in combination with pharmaceutically acceptable carriers. As noted above, the relative proportions of active ingredient and carrier are determined by the

solubility and chemical nature of the compound, chosen route of administration and standard pharmaceutical practice.

5 The dosage of the present agents will vary with the form of administration, the particular compound chosen and the physiological characteristics of the particular patient under treatment. Generally, small dosages will be used initially and, if necessary, will be increased by small increments until the optimum effect under the circumstances is reached.

10 The invention will be further described by, but is not limited to, the following examples. In particular, the following Examples are provided to exemplify various methods to detect rAAV transduction, which methods are described in WO 00/75365.

### Example 1

#### Endosomal Processing Inhibitors May Increase rAAV

##### Transduction in Polarized Airway Cells

###### Materials and Methods

###### 5       Primary culture of human bronchial epithelia and reagents utilized.

Primary human airway epithelial cells were collected by enzymatic digestion of bronchial samples from lung transplants, as previously described (Kondo et al., 1991; Zabner et al., 1996). Isolated primary airway cells were seeded at a density of  $5 \times 10^5$  cells/cm<sup>2</sup> onto collagen-coated Millicell-HA culture inserts  
10 (Millipore Corp., Bedford, MA). Primary cultures were grown at the air-liquid interface for more than 2 weeks, by which time differentiation into a mucociliary epithelium occurs. The culture medium, used to feed only the basolateral side of the cells, contained 49% DMEM, 49% Ham's F12 and 2% Ultraser G (BioSeptra, Cédex, France). Dimethyl Sulphoxide (DMSO), camptothecin (Camp),  
15 etoposide (Etop), aphidicolin (Aphi), hydroxyurea (HU) and genistein (Geni) were purchased from Sigma (St. Louis, MO). Tripeptidyl aldehyde proteasome inhibitors N-Acetyl-L-Leucyl-L-Leucyl-Norleucine (LLnL) and benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal (Z-LLL) were purchased from Calbiochem-Novabiochem Corporation (La Jolla, CA). Ubiquitin ligase (E3)  
20 inhibitors were obtained from Bachem Bioscience Inc. (King of Prussia, PA). Anti-AAV capsid monoclonal antibody (Anti-VP1,2 and 3) was purchased from American Research Products (Belmont, MA) and anti-ubiquitin antibody was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).

Production of recombinant AAV viral stocks. Recombinant AAV was  
25 produced by a CaPO<sub>4</sub> co-transfection protocol and purified through three rounds of isopycnic cesium chloride ultracentrifugation. The proviral plasmid pCisAV.GFP3ori is described in Duan et al. (1998). The proviral plasmid pCisRSV.Alkphos, which encodes the alkaline phosphatase reporter gene under the transcriptional control of the RSV promoter and SV40 poly-adenylation  
30 signal, was used to generate AV.Alkphos (Yang et al., 1999). The proviral plasmid pCisRSV.LacZ used for AV.LacZ production was generated by first inserting 3474 bp Not I digested  $\beta$ -galactosidase gene (from pCMV $\beta$ , Clontech) into the Not I site of the pRep4 (Invitrogen). The entire  $\beta$ -galactosidase expression cassette, including the RSV promoter,  $\beta$ -galactosidase reporter gene

and SV40 polyA signal, was excised by Sal I and subsequently cloned into the pSub201 backbone by blunt end ligation (Samulski et al., 1987). Recombinant viral stocks were heated at 58°C for 60 minutes to inactivate contaminating helper adenovirus. Typical yields were

- 5  $5 \times 10^5$  to  $5 \times 10^9$  particles/ $\mu$ l based on DNA slot blot hybridization assays against plasmid standards. The level of adenoviral contamination, as based on a second reporter assay (Duan et al., 1997) for the recombinant adenovirus used for propagation (Ad.CMVAlkphos for AV.GFP3ori, and Ad.CMVLacZ for AV.Alkphos, Ad.CMVGFP for AV.LacZ), was less than one functional particle
- 10 per  $1 \times 10^{10}$  rAAV particles used for infection of 293 cells in the presence of adenovirus. Transfection with Rep/Cap encoding plasmids served as controls for antibody staining of Rep protein. Virus was dialyzed in PBS prior to *in vitro* or *in vivo* infections.

- Transduction of polarized airway epithelial cells and primary human
- 15 fibroblasts. rAAV infection of fully differentiated bronchial cells was performed as described in Duan et al. (1998). For infections from the apical surface of the airway cells, 5  $\mu$ l rAAV was mixed with 50  $\mu$ l of culture media and applied directly onto the apical compartment of Millicell inserts (MOI=10,000 particles/cell). During apical infection, the basolateral side of the Millicell was
- 20 continuously bathed in culture media. Gene transfer to the basal side was performed by inverting Millicell inserts and applying viral vector to the bottom of the supporting filter membrane in a 50  $\mu$ l volume for 2 hours. Subsequently, Millicell inserts were returned to the upright position, in the continued presence of the original viral inoculum plus an additional 450  $\mu$ l of media. For both
- 25 apical and basolateral infections, rAAV containing media was removed after 24 hours and replaced with either fresh culture media (for the basal side) or exposed to air (for the apical side). To test the effect of different agents on the efficiency of AAV transduction in polarized airway cells, 1  $\mu$ l of each solution was mixed with AAV prior to infection of airway epithelia. Agents were usually presented
- 30 during the 24 hours AAV infection period unless indicated otherwise. Most of the agents were dissolved in DMSO except for hydroxyurea (dissolved in phosphate buffered saline), H-Leu-Ala-OH (dissolved in 0.9% glacial acetic acid) and H-His-Ala-OH (dissolved in 50% methanol). The working concentrations of the agents were as follows: 0.1  $\mu$ M camptothecin, 10  $\mu$ M

etoposide, 5  $\mu$ g/ml aphidicolin, 40 mM hydroxyurea, 50  $\mu$ M genistein, 40  $\mu$ M LLnL and 4  $\mu$ M Z-LLL. When the ubiquitin ligase (E3) inhibitors (H-Leu-Ala-OH and H-His-Ala-OH) were used, airway cells were pretreated with a combination of both inhibitors at a final concentration of 2 mM for 60 minutes prior to infection, followed by the continued presence of inhibitor (0.2 mM) during the entire 24 hours infection period from the basolateral surface. Studies involving EGTA treatment were performed by transiently treating the apical membrane of polarized airway epithelia with 3 mM EGTA in water for 10 minutes (Duan et al., 1998). Following hypotonic EGTA treatment, cultures were washed twice with culture medium and infected with rAAV in the presence or absence of 40  $\mu$ M LLnL. Human primary fibroblast cells (P4) were maintained in 10% fetal bovine serum (FBS), 1% penicillin and streptomycin, and 89% DMEM. Infection with AV.GFP3ori was performed with 80% confluent fibroblasts at an MOI of 1000 DNA particles/cell in 2% FBS DMEM for 24 hours.

S<sup>35</sup> labeling of rAAV. The methionine residue in the capsid protein of rAV.GFP3ori was labeled during the generation of radioactive viral stocks according to a previously published protocol with modifications (Mizukami et al., 1996). Briefly, twenty 150 mm plates of subconfluent 293 cells were infected with Ad.LacZ (5 pfu/cell) for 1 hour followed by calcium phosphate transfection of pCisAV.GFP3ori (250  $\mu$ g) and pRepCap (750  $\mu$ g). Cells were incubated for an additional 10 hours, at which time the medium was changed to 2% FBS Methionine-free DMEM for 45 to 60 minutes. The medium was changed once again to labeling medium containing 15 mCi of S<sup>35</sup>-methionine per 400 ml of 2% FBS Methionine-free DMEM (final=1.49MBq/ml), and cells were pulsed for 1.5 hours at 37°C. Following labeling, L-methionine was added back to a final concentration of 30 mg/L, and cells were incubated for an additional 30 hours at 37°C. Cell lysates were prepared and virus was purified by isopycnic cesium chloride ultracentrifugation as described above. Typical specific activities of labeled virus preparations were  $5 \times 10^{-6}$  cpm/particle, which is slightly higher than the  $5.5 \times 10^{-7}$  cpm/particle specific activity reported by other investigators (Bartlet et al., 1999).

Viral binding/entry assays and in situ localization of viral particles. To assess the binding of rAAV to polarized bronchial epithelia cells, S<sup>35</sup>-labeled

AV.GFP3ori was applied to either the apical or basal surface (MOI=50,000 particles/cell), followed by incubation at 4°C for 60 minutes. Combined binding/entry of rAAV into differentiated airway epithelia was measured under the same conditions, except that the cultures were incubated at 37°C for an additional 2-24 hours before they were harvested. These combined viral binding/entry assays were performed under identical infection conditions to those used for functional studies of rAAV transduction with transgene expression as an endpoint. After washing three times in PBS, cells were lysed in situ by the addition of 5 ml of liquid scintillation cocktail at room temperature for 5 minutes, and the radioactivity was quantitated in a scintillation counter.

To analyze the subcellular localization of the rAAV particles within polarized human bronchial epithelial cells, infection was performed by applying S<sup>35</sup> labeled virus (MOI=50,000 particles/cell) to either the mucosal or serosal surface. At 2 hours post-infection, transwells were washed with medium three times and fixed in 4% paraformaldehyde overnight prior to cryoprotection and embedding for frozen sectioning. 10 µm frozen sections were overlaid with photoemulsion and developed for 5 weeks according to a previously published protocol (Duan et al., 1998).

Molecular analysis of rAAV viral genomes following infection of polarized airway epithelial cultures. The molecular state of bound and endocytosed virus was assayed at different times following rAAV infection. To examine the amount of virus attached to the cell surface, rAAV infection was performed at 4°C for 1 hour. Following binding, the extent of viral internalization was assessed by continuing incubations in the presence of virus at 37°C for 4-24 hours. Viral DNA was extracted according to a modified Hirt protocol and Southern blots performed with Hybond N+ nylon membrane (Amersham) (Duan et al., 1997). The 1.6 kb single stranded viral DNA, the 2.7 kb double stranded circular intermediate, and the 4.7 kb double stranded replication from viral genome were detected with a transgene EGFP specific probe at  $5 \times 10^6$  cpm/ml. Blots were washed at a stringency of  $0.2 \times \text{SSC}/0.1\% \text{SDS}$  at 55°C for 20 minutes twice. In studies aimed at evaluating viral internalization, virus attached to the cell surface was removed by trypsinization with 1 ml of buffer containing 0.5% trypsin, and 5.3 mM EDTA at 37°C for 10 minutes (500 µl buffer was added to the apical and basolateral

compartment of the Millicell inserts), followed by washing with ice-cold PBS twice. Externally bound AAV virus was determined by the intensity of the 1.6 kb viral genome band in Hirt DNA extracted from cells infected at 4°C for 60 minutes. The internalized virus was determined by the intensity of the 1.6 kb viral genome band in Hirt DNA extracted from trypsinized cells after infection at 37°C for 4 and 24 hours. The dynamic changes in the molecular structure of the internalized virus were assayed at 2, 10, 30 and 50 days after virus was removed from culture medium.

Detection of ubiquitinated AAV capsid proteins by immunoprecipitation.

To analyze the effect of the proteasome inhibitor on AAV ubiquitination, human primary fibroblasts were lysed at 6 hours post-viral infection in 1X RIPA buffer. Cell lysates were then cleared with 30  $\mu$ l Protein A-Agarose. The supernatant was incubated with 10  $\mu$ l of monoclonal anti-VP1, 2, and 3 antibody (Clone B1, ARP) followed by the addition of 30  $\mu$ l Protein A-Agarose. The pellets were washed 4 times with 1X RIPA buffer and resolved on a 10% SDS-PAGE. After transfer to a nitrocellulose filter, blots were probed with a 1:1000 dilution of anti-ubiquitin monoclonal antibody (clone P4D1, Santa Cruz, catalogue #sc-8017), followed by 1:500 HRP-conjugated secondary antibody (BMB). After the final washings, immunoreactivity was visualized using the ECL system (Amersham).

In vivo studies in mice. Animal studies were performed in accordance with the institutional guidelines of the University of Iowa. To determine the effect of the proteasome inhibitor on AAV mediated gene transfer in mouse lung, 6 week-old BALB/c mice were lightly anesthetized using a methoxyflurane chamber. AV.LacZ ( $5 \times 10^{10}$  particles) was administered alone or with 400  $\mu$ M Z-LLL in a 10  $\mu$ l instillation by nasal aspiration as described by Walters et al. (2000). To prevent unforeseen toxicity of DMSO solvent, the proteasome inhibitor Z-LLL was dissolved in ethanol as a 40 mM stock solution and was included in the viral inoculum at 1% final concentration. Viral infection controls in the absence of Z-LLL also contained a 1% final concentration of ethanol. Since studies in both primary cultured human airway cells and fibroblasts have demonstrated similar enhancement efficiency between 40  $\mu$ M LLnL and 4  $\mu$ M Z-LLL, and also due to the poor solubility of LLnL in ethanol (a low dose in DMSO had previously been administered to the trachea), only Z-LLL was tested



in this particular mouse lung study. The animals were euthanized at 2, 10 and 150 days post infection and PBS (10 ml) was instilled into the right ventricle, followed by removal of the lungs and heart as an intact cassette. The trachea was intubated and instilled at 10 cm of water pressure with the following solutions in order: PBS, 0.5% glutaraldehyde, 1 mM  $\text{MgCl}_2$ /PBS, and finally X-gal staining reagent for an overnight incubation at room temperature. The X-gal stained mouse lungs were then post fixed in 10% neutral buffered formalin for 48 hours at room temperature and cryopreserved in serial 10%, 20% and 30% sucrose/PBS solutions. Lungs (N=3 for each condition) were embedded in OCT (optimal cutting temperature; Baxter, Warrendale, PA) and 15  $\mu\text{m}$  serially sections were analyzed for gene transfer by calculating the percentage of positive cells in the airway epithelium. The diameter of the airway was recorded for classification ( $> 360 \mu\text{m}$ , 260-350  $\mu\text{m}$ , 160-250  $\mu\text{m}$ ,  $< 150 \mu\text{m}$ ) of results following morphometric analysis. Greater than 150 airway cross-sections were quantified for each experimental condition.

### Results

#### Molecular analysis of rAAV genomes in polarized airway epithelia.

Recent studies revealed a lack of AAV-2 receptor, heparin sulfate proteoglycan, and co-receptors, FGFR-1 and  $\alpha\text{V}\beta 5$  integrin, at the apical surface of differentiated airway epithelia (Duan et al., 1998; Duan et al., 1999; Hughes et al., 1993; Goldman et al., 1999). However, differences in the binding of radioactive virus at the apical and basolateral membranes were only 4-7 fold (basolateral  $>$  apical) (Duan et al., 1998). These differences in binding are insufficient to explain the 200-fold variance observed in the polarity of infection (basolateral  $>>$  apical) with rAAV-2 (Duan et al., 1998). These findings suggested that viral binding and/or uptake were not the sole limiting factors contributing to inefficient mucosal transduction in airway epithelia. To this end, the molecular state of rAAV DNA at 50 days following apical and basolateral infection of air-liquid interface cultured human bronchial epithelia was evaluated. At this time point, gene expression measured from an EGFP reporter was  $> 200$ -fold higher in basolaterally infected cultures (data not shown) (Duan et al., 1998). Hirt DNA from the cultures was evaluated by Southern blot hybridization with  $^{32}\text{P}$ -labeled EGFP probes. A significant amount of apically applied rAAV was able to infect airway cells. However, only single stranded

viral genomes (ssDNA) were detected at this time point (50 days). This result clearly suggests that rAAV can be endocytosed from the mucosal surface and that the endocytosed viral ssDNA was stably sequestered in some unknown subcellular compartment. In contrast, the majority of basolaterally applied rAAV was converted into double stranded forms that migrated at 2.8 kb and > 12 kb in 1% non-denaturing agarose gels. Consistent with previous reports (Sanlioglu et al., 1999; Duan et al., 1999), subsequent restriction enzyme mapping of Hirt DNA and Southern blots confirmed this 2.8 kb band to be a supercoiled, circular episomal molecule (data not shown). The identity of the > 12 kb band, which is significantly more intense following basolateral infection, is currently unknown but may represent episomal circular concatamers of the AAV genome. Taken together, these results suggest that inefficient molecular conversion of AAV viral DNA to circular genomes represents a significant obstacle for rAAV mediated gene transfer from the apical surface of the airway. Furthermore, circularization, not linear replication though self-priming, is the predominant pathway for rAAV gene conversion in polarized airway epithelia.

Proteasome inhibitors dramatically enhance rAAV infection in polarized airway epithelia. Given the fact that rAAV appears to remain latent within some cellular compartment(s) following apical infection in the airway, and that agents that alter the molecular conversion of the viral genome might enhance rAAV transduction in airway epithelia, several agents were tested in this regard, including DNA damaging agents (Alexander et al., 1994), DNA synthesis and topoisomerase inhibitors (Russell et al., 1995), and cellular tyrosine kinases inhibitors (Qing et al., 1997; Man et al., 1998). Application of camptothecin, etoposide, hydroxyurea, and genistein resulted a 10 to 60 fold enhancement in rAAV transduction from the basolateral surface. Interestingly, however, none of these agents facilitated rAAV transduction from the apical surface (data not shown). Since chemicals known to affect intra-nuclear events involved in rAAV transduction in other cell types (Sanlioglu et al., 1999) did not enhance rAAV apical infection in the airway, other agents affecting endocytic processing, such as the ubiquitin-proteasome pathway, were tested. Proteasome systems are known to modulate the intracellular processing of many foreign and endogenous molecules, including viruses such as HIV (Schwartz et al., 1998). Several specific, cell permeable, peptide aldehyde inhibitors of proteasome pathways

have recently been discovered (Rock et al., 1994; Fenteany et al., 1995). These inhibitors bind to the active sites of proteolytic enzymes within the proteasome core and reversibly block their function (Rubin et al., 1995). To test whether proteasomes represent an intracellular compartment that sequesters rAAV following infection, the tripeptidyl aldehyde proteasome inhibitor (a cysteine protease inhibitor) N-acetyl-L-leuciny-L-leucinal-L-norleucinal (LLnL, also called Calpain inhibitor I) was applied to polarized cultures of human bronchial epithelial cells at the time of rAAV infection. Surprisingly, a greater than 200 fold augmentation in transgene expression was obtained at 2 days post infection when 40  $\mu$ M LLnL was applied to the serosal surface along with rAAV. A similar result was achieved when another ubiquitin-proteasome pathway inhibitor, N-carbobenzoxyl-L-leuciny-L-leuciny-L-leucinal (Z-LLL, also called MG132) (Jensen et al., 1995), was tested (data not shown). However, the most important finding was that these proteasome inhibitors also substantially increased rAAV transduction from the mucosal surface (see below). When compared with other agents, proteasome inhibitors were found to be the most potent enhancers of rAAV transduction in airway epithelium.

Proteasome inhibitors augment rAAV transduction in airway epithelia in a polarized fashion. Although proteasome inhibitors appear to significantly increase the efficacy of rAAV transduction from the serosal surface, the route most germane to clinical application of gene delivery in the airway is the mucosal surface. To test the effect of proteasome inhibitors on rAAV transduction from apical membrane, a side-by-side kinetic comparison of rAAV transduction from both mucosal and serosal surfaces of airway epithelia following treatment with LLnL was performed. Co-administration of LLnL and rAAV to the mucosal surface resulted a sustained augmentation in AAV transduction, which peaked at 22 days post-infection. In contrast to mucosal infection, rAAV infection from the serosal surface in the presence of LLnL resulted only in a transient peak in gene expression at 72 hours post-infection, which returned to the levels equivalent to that of the untreated samples by 22 days. These results suggested that the proteasome inhibitor LLnL produces different augmentation profiles when AAV virus is applied to either the apical or the basolateral membranes. To exclude potential effects caused by polarized uptake of LLnL by airway epithelia, different combinations of rAAV and LLnL

administration from both apical and basolateral surfaces were tested. Similar augmentation patterns for AAV transduction were achieved, regardless of whether LLnL was applied to the same or opposite surface as rAAV during infections (data not shown).

5 To determine whether LLnL administration augmented rAAV transduction of particular airway cell types, a rAAV vector encoding the alkaline phosphatase gene (Alkphos) was utilized. Transduced cell types were evaluated by standard histochemical staining for Alkphos to address this question. In the absence of LLnL, rAAV preferentially transduced basal cells at 3 days following  
10 serosal application of virus. Consistent with previous findings utilizing AV.GFP3ori virus, co-administration of LLnL resulted in a dramatic increase in AV.Alkphos transduction. Interestingly, ciliated cell transduction was most significantly increased by treatment with LLnL at the time of rAAV infection. In contrast, basal cells were the least responsive to LLnL treatment. These  
15 findings indicated that the mechanisms of LLnL action may have some cell specific components, which differs in polarized (i.e., ciliated) and non-polarized (i.e., basal) cell types.

Optimization of LLnL enhanced rAAV transduction. With the aim of further improving the enhancement in rAAV transduction achieved in the  
20 presence of LLnL, several detailed kinetic studies were performed which altered the timing and number of LLnL administrations following rAAV infection. Several important conclusions arose from these studies. First, following basolateral infection, administration of LLnL once every three days increased length of peak transgene expression, despite the fact that by the end of 30 days  
25 levels were similar to that of cultures treated once at the time of infection. Second, continual administration of LLnL was toxic to cells and ablated transgene expression by 10 days. Third, re-infection of cultures with rAAV in the presence of LLnL at 7, 10 and 15 days resulted in a similar pattern of augmentation and, as expected, elevated the final level of transgene expression  
30 observed at 30 days (only data from the second infection at 15 days are shown). Most notably however, all the cultures infected from the basolateral side produced similar long-term transgene expression levels within 2 to 3 fold of each other, regardless of whether LLnL was administered.

Despite the fact that LLnL administration at the time of the viral infection augmented rAAV transduction from both the apical and basolateral surfaces, the kinetics of this induction were significantly different. Enhancement following basolateral infection was transient, while enhancement following apical infection was long-term. Furthermore, although induction with LLnL from the apical membrane was long-lasting, by 30 days the maximal level of transgene expression was only one eighth of that resulting from basal infection. The application of hypotonic EGTA solution has been shown to increase AAV transduction from the apical surface by 7 to 10 fold (Duan et al., 1998; Walters et al., 2000). Therefore the combined administration of EGTA and LLnL could provide yet a further increase in rAAV transduction from the apical surface. Interestingly, treatment of airway cultures with EGTA prior to infection with rAAV in the presence of LLnL gave a transient peak in transduction within the first three days, and a significantly increased (200-fold), prolonged level of transgene expression out to 30 days. This prolonged level of transgene expression, while comparable to rAAV infection from the basal surface, was much above the level observed in apically infected epithelia treated with EGTA alone. In summary, these results demonstrate that EGTA and LLnL have synergistic effects on rAAV transduction, allowing for transduction from the apical surface at levels normally only seen following basolateral infection.

Viral binding and internalization are not affected by LLnL treatment.

The action of LLnL has been typically attributed to its selective and reversible inhibition of the proteasome system. However, it was important to rule out any possible effect on viral binding and/or endocytosis. As has been found for type 1 herpes simplex virus (Everett et al., 1998), LLnL treatment had no significant effect on 4°C rAAV binding. Similarly, the uptake of  $S^{35}$  labeled rAAV for a 2 hour infection period at 37°C was not altered by LLnL treatment. Given these results, LLnL acts at points distal to virus binding and entry. Interestingly, at 24 hours post-infection a very significant decrease in the amount of intracellular radioactivity was observed in epithelia treated with LLnL, regardless of which surface was infected. Given the concordant increase in transgene expression at this time point, LLnL may be accelerating processing and routing of the virus to the nucleus, wherein uncoating and clearance of  $S^{35}$  labeled capsid proteins

occur. By this mechanism, S<sup>35</sup> isotope would be diluted into the culture medium and could explain the decrease in cell-associated counts.

LLnL enhances endosomal processing and nuclear trafficking of rAAV.

To test the hypothesis that LLnL increases trafficking of rAAV to the nucleus, in situ localization of the S<sup>35</sup>-labeled rAAV particles following infection from the apical and basolateral surfaces was performed in the presence and absence of LLnL. Since loss of intact radiolabeled capsid proteins occurred at 24 hours post-infection, a 2 hour time point was chosen for this analysis. Using photoemulsion overlay, the subcellular distribution of S<sup>35</sup>-labeled rAAV particles was evaluated by blinded morphometric analysis. The majority of viral particles localized to the cytoplasm in the absence of LLnL. This was the case regardless of whether infection was performed from the apical or basolateral surface. In contrast, LLnL treatment substantially changed the intracellular distribution of radiolabeled rAAV particles, resulting in a significant shift to nuclear associated grains. These results substantiated the findings from whole cell counts at 24 hours post-infection, which suggested that LLnL increases viral uncoating and the subsequent loss of S<sup>35</sup> isotope into the media.

LLnL augment rAAV transduction within a specific time frame after infection. Evidence thus far has suggested that LLnL may act to increase intracellular routing of rAAV to the nucleus. Additionally, LLnL action is independent of the epithelial surface to which it is administered (i.e., serosal application of LLnL augments mucosal infection and vice versa). This indicates that LLnL need not be endocytosed with AAV particles to enhance transduction. Thus, LLnL may act at a specific time following rAAV endocytosis but during endosomal processing. To provide functional support for this hypothesis, a kinetic analysis of LLnL action at various times after infection from the basolateral surface was performed. In these experiments, LLnL was added to the culture medium either at the time of AAV infection or at various time points after infection. Viral-mediated transgene expression was quantified at 24 hour intervals following infection. Augmentation was achieved regardless of whether LLnL was administrated at 0, 24, 48, and 72 hours after viral infection. However, addition of LLnL at 24 or 48 hours gave the strongest level of augmentation. The ability of LLnL to reduce AAV expression appeared to decline by 72 hour post-infection and was completely lost by 15 days after the

initial AAV infection (data not shown). Taken together, it appears that after rAAV enters the cell, it may be targeted to an intracellular compartment that is sensitive to proteasome inhibitor-facilitated liberation. In addition, the loss of an LLnL augmentation effect at 15 days post-infection suggests that enhanced transcription, translation, and/or stability of the transgene products do not likely contribute to the mechanism responsible for this observation.

Combined treatment of LLnL and EGTA prevents degradation of internalized rAAV. To further clarify the molecular mechanism(s) responsible for augmentation of rAAV transduction by LLnL, rAAV genomes in infected cells were analyzed by Southern blotting Hirt DNA. Consistent with studies using S<sup>35</sup> labeled virus, rAAV binding to either surface of polarized airway epithelia was not affected by LLnL treatment. Southern blotting also demonstrated 2 to 7 fold higher viral binding from the basal surface, which varied among different tissue samples (data not shown). The extent of virus internalization was compared after stripping surface bound virus with trypsin. Confirming previous results, a significant amount of rAAV was endocytosed from the apical surface during the infection period, although viral uptake was more active from basolateral surface. LLnL alone also did not substantially prevent enzymatic degradation of the internalized AAV viral DNA, indicating that enhanced viral trafficking into the nucleus might be more important in the observed augmentation by LLnL. However, treatment with both hypotonic EGTA and LLnL substantially increased the amount of virus internalized from apical surface. Since hypotonic EGTA treatment alone only slightly increased persistence of AAV DNA or AAV-mediated gene expression (Duan et al., 1998; Walters et al., 2000) following apical infection, the predominant mechanism responsible for the combined effects of EGTA and LLnL might be due to reduced degradation of the internalized virus and an increased rate of endocytosis. These synergistic effects of EGTA and LLnL augment rAAV transduction from the apical membrane more than 200-fold. Additionally, the conversion of single stranded viral genomes to linear replication or circular forms has been associated with enhanced AAV transduction by adenoviral early gene products or UV irradiation, respectively (Fisher et al., 1996; Sanlioglu et al., 1999; Duan et al., 1999). Southern blots of Hirt DNA from cultures co-infected with Ad.d1802 and rAAV showed LLnL enhanced AAV transduction

was clearly not mediated through the formation of linear replication intermediates (4.7 kb band) as seen in the presence of adenoviral E4orf6 protein produced by Ad.d1802 co-infection.

Ubiquitination of viral capsid proteins following rAAV infection in the  
5 airway alters the efficiency of transduction. Proteasome-dependent degradation of ubiquitinated molecules represents a major pathway for disposal of both endogenous and foreign proteins (Schwartz et al., 1999). Several distinct steps in the regulation of this pathway have been identified, including: activation of ubiquitin by its activating enzyme (E1), transfer of the activated ubiquitin to the  
10 ubiquitin carrier protein (E2), and subsequent delivery of the activated ubiquitin to the protein substance by ubiquitin ligase (E3). Ultimately, ubiquitinated proteins are degraded by the 26S proteasome through an ATP-dependent process. To test whether enhancement of rAAV transduction by proteasome inhibitors involves liberation of ubiquitinated virus from an endosomal  
15 compartment, the extent of ubiquitin side chains on AAV capsid proteins following infection was examined as well as whether treatment with proteasome inhibitors altered the extent of ubiquitination. AAV capsid proteins were immunoprecipitated using anti-VP 1,2, 3 antibody from rAAV infected human polarized airway cells and confluent human fibroblasts at 6 hours post-viral  
20 infection. Subsequent Western analysis with anti-ubiquitin specific antibodies demonstrated a significant increase in the cellular level of ubiquitinated AAV capsid in fibroblasts following proteasome treatment. Ubiquitination significantly increased the molecular weight of capsid proteins (63 kd, 73 kd, and 87 kd) to 220-250 kd and is consistent with the size change following  
25 ubiquitination for other molecules (Bregman et al., 1996). Unfortunately, the limited amount of virus retrievable from air-liquid interface cultured human airway cells precluded the ability to detect ubiquitinated capsid in this system (data not shown). Nonetheless, confluent primary fibroblasts also demonstrated augmentation (10-fold) of transgene expression following treatment with  
30 proteasome inhibitors. Thus, proteasome inhibitors increase rAAV transduction by decreasing the targeting and/or degradation of ubiquitinated AAV in the proteasome. The net result of such proteasome inhibition would be expected to increase the abundance of ubiquitinated viral capsid.



Because a technical limitation in polarized airway model prevented direct detection of ubiquitinated viral capsid, it was determined whether modulation of other steps in the ubiquitin proteasome pathway could also increase rAAV transduction similarly to that seen with proteasome inhibitors LLnL and Z-LLL.

- 5 Several dipeptides, such as H-Leu-Ala-OH and H-His-Ala-OH, are known to inhibit ubiquitin ligase E3 (Obin et al., 1999). Application of these ubiquitin ligase inhibitors indeed enhanced rAAV transduction from the basolateral surface of human airway cells. Taken together, data in both fibroblasts and polarized airway epithelia suggest that AAV capsid is ubiquitinated following  
10 endocytosis, and that this process is a barrier to rAAV transduction. The most plausible mechanism responsible for the augmentation of rAAV transduction by tripeptide proteasome inhibitors involves the prevention of ubiquitinated virus degradation and/or targeting to the proteasome.

Long-term enhancement of rAAV transduction by proteasome inhibitor

- 15 *in vivo*. To evaluate the potential utility of proteasome inhibitors for *in vivo* gene therapy, both the toxicity and efficacy of these agents for *in vivo* rAAV mediated gene transfer in the mouse lung was tested. To assess the toxicity of these proteasome inhibitors in mice, 10, 100, and 1000 fold higher effective doses of LLnL or Z-LLL were administered than used to induce gene transfer in polarized  
20 airway cells, using both intra-tracheal and systemic (IV) delivery. No toxicity was indicated by histologic evaluation of the lung and liver or was evidenced by the death of animals. To investigate whether these proteasome inhibitors could improve rAAV transduction *in vivo*, AV.LacZ ( $5 \times 10^{10}$  particles) was delivered either alone or in the presence of 400  $\mu$ M Z-LLL by intranasal administration.  
25 Mouse lungs were harvested at 3, 10 and 150 days post-infection to evaluate short and long term effects. Proteasome inhibitor treatment from basal surface, or in conjunction with EGTA from apical surface, resulted in pronounced, immediate enhancement on rAAV transduction, however, X-gal staining of the lung tissues at 3 and 10 days post infection demonstrated no detectable transgene  
30 expression in either proteasome inhibitor treated or untreated groups. In contrast, significant transduction was achieved at 150 days in Z-LLL treated samples. Targeted transgene expression was predominantly confined to the conducting airways, rather than in the parenchyma. Alveolar cells were rarely transduced. Although on average only about 5.88% of airway cells were

transduced by AV.LacZ, and LacZ positive cells were observed throughout the entire conducting airway, a characteristic transduction profile was evident. The transduction efficiency in larger bronchioles ( $> 350 \mu\text{m}$ ) reached a mean of  $10.36 \pm 1.63\%$  of the airway epithelium, while  $1.37 \pm 0.41\%$  of airways cells in the smaller bronchioles ( $< 150 \mu\text{m}$ ) expressed the  $\beta$ -galactosidase transgene. The range of transgene expression in distal and proximal airways was 0 to 4% and 5 to 18%, respectively. This transduction profile demonstrating a higher and more consistent transduction in larger airways likely reflects a more uneven delivery of virus to regions of the lung encompassing the smaller airways. Examination of cryo-sections from lungs infected by AV.LacZ alone revealed only 2 lacZ positive cells in a total of 315 airway sections (n=3 animals).

### Discussion

Inefficient gene transfer from the apical surface of the airway has been a major obstacle in numerous gene therapy approaches for cystic fibrosis utilizing recombinant adenovirus (Walters et al., 1999; Pickles et al., 1998), adeno-associated virus (Duan et al., 1998), retrovirus (Wang et al., 1998), and non-viral liposome vectors (Chu et al., 1999). It has been generally thought that inefficient viral mediated gene delivery through the apical membrane of airway epithelia is predominantly due to the lack of receptors or co-receptors on this surface.

Molecular analysis of rAAV infection in polarized airway epithelia has revealed several unique findings. First, there is conclusive evidence that the previously reported lack of known AAV-2 receptor and co-receptors (Duan et al., 1999) at the apical membrane of airway epithelia does not abrogate AAV infection. Although transduction (as determined by transgene expression) from the basolateral surface is 200-fold more efficient than from the apical membrane, quantitative and semi-quantitative analyses of viral endocytosis with either  $S^{35}$ -labeled virus or Southern blotting have demonstrated that viral uptake from the apical surface is only 2-7 fold less efficient than from the basolateral membrane. Therefore, it is reasonable to assume that previously unidentified alternative receptor/co-receptors and/or receptor-independent mechanism(s) might be involved in AAV uptake from the mucosal surface of the airway.

Polarity is widely recognized to significantly influence endosomal processing of many proteins, and distinct sorting mechanisms have been

described for the apical and basolateral compartments (Odorizzi et al., 1996; Rodriguez-Boulan et al., 1993). The lack of a direct correlation between the efficiency of viral uptake and transgene expression following basolateral and apical infection suggest that additional post-endocytic barriers exist for rAAV mediated gene transfer. Differences in the extent of AAV nuclear trafficking following basolateral versus apical routes of infection suggest that basal and apical cellular compartments possess distinct biologic properties that may influence the polarity of AAV transduction. Endosomal processing barriers to rAAV transduction may not be limited to polarized epithelial cells. In support of this notion, impaired intracellular trafficking of viral particles to the nucleus has been observed in NIH 3T3 cells. In addition, rAAV can remain in an inactive state for as long as 7 days in confluent primary fibroblast cells until rescued by UV irradiation to a functionally active state. Thus, post-endocytic barriers to infection exist in multiple cell types.

In the airway, the major rate-limiting steps in rAAV transduction from the mucosal surface appear to involve inefficient endosomal processing of the internalized virus. Regulated intracellular proteolysis through proteasomes plays a critical role in many physiological and pathological conditions (Schwartz et al., 1999; Kato, 1999). Recent identifications of many specific proteasome inhibitors has set the foundation for pharmacologic intervention in this cellular enzymatic system as a novel therapeutic approach. For example, several cell permeable synthetic tripeptide aldehydes (such as LLnL and Z-LLL used in this study) have been demonstrated to be promising cancer therapy agents or anti-inflammatory drugs (Goldberg et al., 1995; Kloetzel, 1998; Wojcik, 1999). Additionally, the proteasome has been suggested to have antiviral functions in HIV infection (Schwartz et al., 1998), implying that the inhibition of proteasome function could be beneficial in promoting transduction with recombinant viruses. Based on the molecular evidence that apical infection of rAAV in the airway is significantly limited by post-entry events, ubiquitin/proteasome pathways appear to be instrumental in this blockage. The proteasome is commonly known as a compartment for clearance of endogenous and foreign proteins. However, recent studies also suggested that the proteasome system is involved in regulating endocytosis (Bonifacino et al., 1998; Strous et al., 1999). From the standpoint of gene delivery, proteasome inhibitors have been shown to protect transfected

plasmid DNA from degradation (Coonrod et al., 1997). The results described herein clearly demonstrate that rAAV mediated gene transfer to the airway epithelia is also significantly enhanced by proteasome inhibitors. Furthermore, this enhancement is correlated with proteasome inhibitor stimulated viral trafficking to the nucleus. Although proteasome inhibitors increased long-term levels of AAV transduction from the apical surface, their effect on basolateral infection appeared predominantly to alter the rate, rather than the long-term levels, of transduction. These differences highlight fundamentally distinct pathways involved in rAAV transduction from apical and basolateral surfaces.

Several findings also support the notion that ubiquitination of virus following endocytosis may be a critical mechanism for sorting incoming AAV. First, treatment of airway epithelia with proteasome inhibitors known to block ubiquitin-dependent degradation of proteins enhances rAAV gene transfer. Second, inhibition of ubiquitin E3 ligase activity in airway epithelia also enhances transduction. Lastly, rAAV capsid proteins are ubiquitinated following infection in confluent human fibroblasts, and that the extent of this ubiquitination is increased by inhibition of ubiquitin-proteasome degradative pathways.

From an applied standpoint, one of the most important findings in this study is the persistent high level of rAAV transduction induced by proteasome inhibitor in mouse lung. Co-administration of Z-LLL with rAAV increased transgene expression from undetectable levels to 10.36 $\pm$ 1.63% of proximal bronchial epithelial cells at 150 days post-infection. This level of gene expression is thought to be sufficient for therapeutic correction of CFTR deficiency (Crystal, 1999). The feasibility of this strategy for clinical application is further supported by the lack of a detectable local or systemic toxicity following proteasome inhibitor administration to mice. Furthermore, preliminary studies in several other organs, e.g., heart skeletal muscle and liver, have suggested that ubiquitination of rAAV2 may occur in an organ-specific fashion. The application of proteasome inhibitors in skeletal and cardiac muscle had no effect on either short-term or long-term rAAV mediated gene transfer. However, application of Z-LLL in the liver led to a 7-fold increase in rAAV transduction at 1 month post-infection. These findings suggest that tripeptide

proteasome inhibitors could be used to increase gene transfer in organs other than the lung, depending on the cell biology of virus processing.

In conclusion, a significant barrier to apical infection in the airway with rAAV-2 lies at the level of endosomal processing and ubiquitination.

- 5 Modulation of the ubiquitin-proteasome system has revealed innovative strategies to enhance rAAV transduction from the mucosal surface of the airway for gene therapy of cystic fibrosis.

### Example 2

#### 10 Expression of the *LacZ* Gene in Lung Airway Epithelium and Liver *In vivo*

The *in vivo* activity of rAAV in the presence or absence of an agent of the invention in the lung or liver may be tested using the *LacZ* gene. A rAAV vector containing the *LacZ* gene, recombinant AV.LacZ (about  $5 \times 10^{10}$  particles), was administered to mouse lung either as virus alone in PBS or virus  
15 in combination with 40  $\mu\text{M}$  LLnL in PBS. Virus was directly instilled into C57Balb/c mice trachea with a 30 G needle in a total volume of 30  $\mu\text{l}$ . To insure the spread of the virus in mouse lung, 50  $\mu\text{l}$  air was pumped into lung through the same syringe immediately after virus was administered. Ninety days after  
20 infection, lungs were harvested intact and fixed in 4% paraformaldehyde followed by cryosection. AAV-mediated transgene expression was evaluated by 10  $\mu\text{m}$  tissue sections staining for LacZ.

Recombinant AV.LacZ (about  $5 \times 10^{10}$  particles) was also administered to mouse liver either as virus alone in PBS, virus in combination with 40  $\mu\text{M}$  Z-  
25 LLL in PBS, or virus in combination with 20  $\mu\text{M}$  LLnL in PBS. Virus was directly instilled into portal vein of the C57B6 mice. AAV-mediated LacZ transgene expression was evaluated by histology staining at 2 and 4 weeks post infection in frozen tissue sections.

### 30 Example 3

#### Methods to Determine Additional Agents Useful to Enhance rAAV Transduction

A. To screen for agents that enhance rAAV transduction, any number of cells can be used. A range of concentrations of the agent to be tested can be determined based on, for instance desirable profiles of the agent, desirable

toxicity profiles of the agent and/or concentration of the agents employed *in vivo*. The usefulness of the cell type chosen for the screen can be confirmed by testing compounds, e.g., proteasome inhibitors described in Example 1 such as LLnL and ZLL which are known to increase rAAV transduction. For example, a

5 AAV2 FLAG-Luc vector was employed to transduce HeLa, ferret fibroblasts, IB3 and Huh (liver) cells in the presence or absence of the proteasome inhibitor MG132. MG132 was confirmed to enhance AAV transduction in all cell types tested: HeLa cell transduction was enhanced about 500-fold at 80  $\mu$ M, and 200-fold at 40  $\mu$ M, MG132; ferret fibroblast cell transduction was enhanced about

10 200-fold at 20  $\mu$ M, and 17-fold at 4  $\mu$ M, MG132; IB3-1 cell transduction was enhanced about 30 to 70-fold at 20 to 80  $\mu$ M MG132; and Huh-7 cell transduction was enhanced about 15-fold at 20 to 80  $\mu$ M MG132. There was no difference in rAAV transduction efficiency in HeLa cells when either DMSO or ETOH was used as a vehicle for MG132.

15 B. HeLa cells were selected to screen for additional agents that enhance rAAV transduction, although any cell strain or line; or primary cells, may be employed. Agents were selected from various classes, such as anti-inflammatories (e.g., dexamethasone and cyclosporin A), NSAIDs (e.g., ibuprofen),  $\beta$ -adrenergics (e.g., albuterol), antibiotics (e.g., ciprofloxacin,

20 colison, gentamycin, tobramycin, and epoxomycin), lipid lowering agents (e.g., lovastatin, simvastatin and eicosapentaenoic acid), food additives (e.g., tannic acid), viral protease inhibitors (e.g., Norvir, Kaletra, and Viracept), chemotherapeutics (e.g., aclacinomycin A, doxorubicin, doxil, camptothecin, taxol and cisplatin) and protease inhibitors (e.g., chymostatin, bestatin and

25 chloroquine). The range of concentrations of the agents to be tested were selected based on solubility profiles, toxicity profiles and/or concentrations previously employed *in vivo*.

HeLa cells were infected for 2 hours with an MOI of 100 rAAV in the presence of agents, e.g., ritonavir (Norvir) (1, 10 and 100  $\mu$ M), cyclosporin A

30 (2.5, 25 and 250  $\mu$ g/ml), epoxomicin (1, 10 and 50  $\mu$ M), alcacinomycin A (5, 50 or 500  $\mu$ M), chymostatin (1, 10 and 100  $\mu$ M), bestatin (1, 10 and 100  $\mu$ M), doxorubicin (adriamycin) (0.1, 1 and 10  $\mu$ M), camptothecin (camptosar) (1, 10 and 100  $\mu$ M), eicosapentanoic acid (1, 10 and 100  $\mu$ M), tannic acid (2, 20, 200

and 2000  $\mu$ M), simvastatin, prodrug (2, 20 and 200  $\mu$ M), cisplatin (0.2, 2 and 20  $\mu$ g/mL), and chloroquine (4, 40 and 400  $\mu$ M). Forty-eight hours after infection, cells were harvested for analysis. rAAV transduction was measured by removing the media from the cell cultures, adding 100  $\mu$ L reporter lysis buffer (RLB) and freezing. The supernatant was thawed and transferred to microfuge tubes, freeze thawed an additional 2 times, clarified by centrifugation for 10 minutes and then analyzed for reporter gene expression on the luminometer. Protein was determined by Bradford analysis and results were expressed as relative light units per mg protein (RLU/mg). Data is presented in Figures 1A-E.

Doxorubicin, epoxomicin, and camptothecin all showed a dose-dependent increase in transduction at the dose ranges tested. At the doses tested doxorubicin and epoxomicin increased transduction efficiency up to 169-fold and 120-fold, respectively, camptothecin increased transduction efficiency by 15-fold, tannic acid increased transduction efficiency by 17-fold, cisplatin increased transduction efficiency by 16-fold, and simvastatin increased transduction efficiency by 4-fold.

It should be noted with respect to simvastatin and the lovastatin, that these drugs are formulated as prodrugs and conversion to the activated open ring forms was not confirmed which may have contribute to the negative results.

Similarly, the liposomal formulation of doxorubicin, doxil could not be confirmed to be bioavailable to cell culture cells. Thus, agents which initially screened as statistically negative may be reflective of formulations that are not readily bioavailable to cell culture cells or may be reflective of the limited dose range or exposure time.

Epoxomicin, a naturally occurring antibiotic isolated from Actinomycetes known to inhibit NF-KB-mediated signaling *in vivo* and *in vitro*, inhibits proteasomes by inhibiting a proteasome-specific chymotrypsin-like protease. Doxorubicin, an anti-tumor antibiotic which inhibits topoisomerase II and inhibits nucleic acid synthesis, is translocated by a 20S proteasome from the cytoplasm to the nucleus. Camptothecin, a reversible DNA topoisomerase inhibitor, down regulates topoisomerase via an ubiquitin/26S proteasome pathway. Simvastatin is an agent that modulates proteasome activity, tannic acid inhibits chymotrypsin-like activity and is a cancer chemopreventative, and cisplatin is a chemotherapeutic which crosslinks DNA.

C. To determine whether combinations of agents that enhance rAAV transduction efficiency have synergistic or additive effects when used in combination, cells were contacted with the proteasome modulator, doxorubicin, and the proteasome inhibitor Z-LLL or LLnL. Different AAV vectors were tested, including splicing vectors and pseudotyped rAAV. Viral stocks utilized were as follows: Av2RSVluc,  $5 \times 10^8$  particle/ $\mu$ l; Av2RSVlucCap5 (also referred to as Av2/5 CMVluc),  $2 \times 10^9$  particle/ $\mu$ l; Av2CMVluc,  $1.3 \times 10^9$  particle/ $\mu$ l; and Av2CMVlucCap5,  $1.1 \times 10^9$  particle/ $\mu$ l. Combinations of agents were compared to the agents used alone to determine the efficiency of transduction. LLnL was used at 40, 200 or 400  $\mu$ M, Z-LLL at 4  $\mu$ M and doxorubicin at 0.5 or 1  $\mu$ M when employed alone. When a combination of LLnL and doxorubicin was used, LLnL was used at 4, 10, 20, 40, 200 or 400  $\mu$ M and doxorubicin at 1 or 5  $\mu$ M. The apical surface of polarized airway epithelia, HeLa cells or ferret fibroblast was contacted with the agents and rAAV ( $5 \times 10^9$  particles per well).

The results showed that LLnL enhances transduction in HeLa, ferret fibroblast and polarized epithelial cells at 40  $\mu$ M and A549 cells at 200 to 400  $\mu$ M. Doxorubicin enhanced transduction in HeLa and ferret fibroblast cells at 1  $\mu$ M and A549 or polarized airway cells at 5  $\mu$ M, and enhanced transduction about 100 fold when ferret fibroblasts were infected with lacZ splicing vectors. Doxorubicin also enhanced AAV2 and AAV5 transduction to a greater extent than LLnL. Synergistic effects were noted when doxorubicin and LLnL were co-administered.

In the absence of agent administration, transduction from the apical surface of polarized epithelial cells was greater with AAV vectors with AAV5 capsid than AAV vectors with AAV2 capsid. In the presence of doxorubicin, a 200 to 600-fold induction was observed for AAV2 and AAV5 apical infection of polarized cells. Thus, agents of the invention can enhance rAAV transduction, including in serotype, pseudotype and multiple vector strategies.

D. Endotracheal administration of  $10^{11}$  AV2FLAG-luc rAAV particles to male Balb/c mice in conjunction with intravenous administration of Doxil (dosed in a range of 2, 10, or 20 mg/kg), a liposomal preparation of doxorubicin, to mice enhanced AV2FLAG-luc transduction by 2 logs by day 7 at the 20 mg/kg



dose of doxil. Specifically, at 20 mg/kg doxil, transduction was enhanced on the average of 67-fold by day 7 and 4-fold by day 30 (Figure 2). It is worth noting that doxil previously tested negative in cell line screening while the free compound doxorubicin tested positive in cell line screening (Figures 1A-E).

- 5 Liposomal formulations have desirable properties for *in vivo* use including their increased stability or circulation half life making them more bioavailable *in vivo*. Those same characteristics make liposomal formulations less desirable for *in vitro* screening as described above. Thus, one skilled in the art can design formulation strategies for agents of the invention to tailor them to the desired application. In addition to formulation design, one skilled in the art can tailor routes of delivery in order to maximize rAAV transduction efficiencies.

- In additional experiments, a pseudotyped rAAV vector encoding FVIII was tested in male Rag-1 mice. Rag-1 mice were used because as described in the art, normal mice produce inhibitors of human FVIII that can obscure protein detection in the serum. Rag-1 mice are known to be deficient in the pathways necessary to produce these inhibitors and thus will either produce no inhibitors, lower levels of inhibitors or have extended time periods for development of inhibitors. The rAAV vector was constructed containing serotype 5 capsid proteins and 5'-3' ITRs of AAV-2 flanking a heterologous transgene comprised of the minimal liver specific element HNF3/EBP and a human B-domain deleted FVIII gene (a second construct was identical except it contained a B-domain deleted canine FVIII gene). Animals were administered  $10^{12}$  rAAV vector particles intravenously via the lateral tail vein concurrently with 20 mg/kg of doxil at day 0. Circulating, bioavailable FVIII activity was measured from the serum at days 31, 53 and 90 by techniques known in the art including ELISA and Coatest. Data presented in Figure 3 demonstrate that animals not treated with doxil had barely detectable levels of FVIII in the range of 0.99 ng/ml for days 31 and 53 which decreased to 0.13 ng/ml by day 90. In contrast, animals dosed with 20 mg/kg of doxil had over 40 times the levels of FVIII protein. Interestingly, the decline in FVIII protein seen in animals not treated with doxil at day 90 (0.13 ng/ml) was not evident in animals treated with doxil (40.16 ng/ml) indicating that doxil not only enhanced rAAV transduction as evident at the shorter time period, but the agent of the invention also prolonged expression. In order to demonstrate that doxil was affecting rAAV transduction and not

merely affecting the FVIII protein translation or stability, RS-PCR was performed on liver tissue at the day 53 time point. The data presented for individual animals in Table 1 demonstrates that the increase in FVIII protein noted in animals treated with doxil correlates with the levels of mRNA detected.

5       The increase *in vivo* rAAV transduction produced by doxil was further confirmed utilizing the same vectors and protocol described above in male FVIII knockout mice tolerized to the human FVIII protein utilizing a cytoxin mediated tolerization strategy as described in the art. Animals were treated with weekly injection of 50 mg/kg cytoxin beginning at the time of rAAV vector  
10 delivery. Data presented in Table 2 confirmed the previously described results when tested by ELISA or Coatest at days 14 and 25, namely animals dosed with doxil demonstrated at least a ten-fold enhancement of rAAV transduction.

Table 1

Animal Number	Treatment	Molecules FVIII mRNA/cell	FVIII Protein (ng/mL)
#26	AAV2/5 HNF3/EBP	2.15	0.68
#27		0.91	<0.63
#28		1.98	0.97
#29		2.06	1.45
#30		2.45	0.77
#31		2.29	<0.63
#59	AAV2/5 HNF3/EBP FVIII + Doxil	65.47	31.85
#60		41.4	37.75
#61		99.43	51.9
#62		49.44	38.65
#63		43.9	40.55
#64		57.54	31.55
Animal Number	Treatment	Molecules FVIII mRNA/cell	FVIII Protein (ng/mL)
#26	AAV2/5 HNF3/EBP	2.15	0.68
#27		0.91	<0.63
#28		1.98	0.97
#29		2.06	1.45
#30		2.45	0.77
#31		2.29	<0.63
#59	AAV2/5 HNF3/EBP FVIII + Doxil	65.47	31.85
#60		41.4	37.75
#61		99.43	51.9
#62		49.44	38.65
#63		43.9	40.55
#64		57.54	31.55

Table 2. *In Vivo* Enhancement of FVIII rAAV Transduction

Day 14 Results

SampleAnimal # and Final Result (DF\*ng/mL) Coatest (mU/mL)

Group 1 Vehicle

801 < 0.63	0
804 < 0.63	0
805 < 0.63	0
847 < 0.63	0

Group 2 AAV2/5-HFN3/EBP-FVIII

816 < 0.63	0
817 < 0.63	0
818 0.92	0
819 < 0.63	0
820 < .63	0

	834 0.9	0
Group 2 AAV2/5-HFN3/EBP-FVIII + Doxil		
	870 60.45	171
	871 26.29	0
	872 12.395	14
	873 44.3	30
	874 12.135	122
	875 31.04	94

## 2.X.10, Day 25 FVIII ELISA

<u>Sample</u>	<u>Animal # and Final Result</u>
---------------	----------------------------------

## Group 1 Vehicle

806 < 0.63	0
807 < 0.63	0
808 < 0.63	0
849 < 0.63	0

## Group 2 AAV2/5-HFN3/EBP-FVIII

821 < 0.63	0
822 < 0.63	0
823 < 0.63	0
824 1.27	0
825 0.72	0
833 0.74	0

## Group 3 AAV2/5-HFN3/EBP-FVIII + Doxil (no spikes)

841 16.785	49.833
842 12.425	37.282
843 13.685	41.466
844 35.225	91.842
845 7.815	12.974
846 24.02	54.853

Thus, agents that interact with molecules in intracellular AAV trafficking pathways, such as proteasomes or molecules in the ubiquitin pathway, by binding to those molecules and/or inhibiting their activity, are useful to enhance

5 rAAV transduction.

Example 4Proteasome Involvement in rAAV-2 and rAAV-5 Transductionof Polarized Airway Epithelia *In vitro* and *In vivo*

10 Inhibition of the proteasome with small tripeptide inhibitors such as LLnL can significantly augment rAAV-2 transduction from the apical membrane

of both polarized human airway epithelia *in vitro* and mouse lung *in vivo* (Duan et al., 2000). As AAV-5 has been reported to have higher tropism for, and alternate receptors on, the apical membrane of airway epithelia, increased transduction of airway epithelia from the apical membrane with rAAV-5 might  
5 be due to altered proteasome involvement. Co-administration of a proteasome modulator and a proteasome inhibitor was found to augment transduction of both serotypes in a cell type dependent manner (Figures 4-6).

To better understand serotype-specific differences in airway transduction, the effect of proteasome inhibitors on rAAV-2 and rAAV-5 transduction in  
10 polarized human airway epithelial cultures and mouse lung was examined (Figure 8). A proviral construct containing 5' and 3' ITRs from AAV-2 flanking a transgene was packaged into both AAV-2 and AAV-5 capsid to generate AV2.RSVluc and AV2.RSVlucCap5 viruses which express the luciferase transgene. rAAV-2, but not rAAV-5, demonstrated a significant difference in  
15 transduction from the apical versus basolateral surface. Transduction with AV2.RSVluc was 36- and 103-fold greater from the basolateral membrane at 5 and 14 days post-infection, respectively. In contrast, AV2.RSVlucCap5 transduced epithelia from the apical and basolateral membranes with similar efficiencies at both time points.

20 LLnL augments AV2.RSVluc transduction from the apical and basolateral surfaces. However, application of LLnL selectively increased AV2.RSVlucCap5 transduction 12-fold only when virus was applied to the apical surface. These results suggest an interesting difference in the involvement of the proteasome for various AAV capsid entry pathways that are effected by  
25 cell polarity.

The proteasome inhibitor Z-LLL was found to induce long-term (5 month) transduction with rAAV-2 in mouse lung. To determine *in vivo* transduction efficiency of AV2.RSVlucCap5, mice were infected with  $6 \times 10^{10}$  particles of AV2.RSVlucCap5 by nasal aspiration alone (control) or in  
30 combination with 200  $\mu$ M Z-LLL, 200  $\mu$ M doxorubicin or 200  $\mu$ M Z-LLL and 200  $\mu$ M doxorubicin (12 mice per group). Co-administration of Z-LLL induced whole lung luciferase expression 17.2- and 2.1-fold at 14 (2 weeks) and 42 (6 weeks) days post-infection, respectively (Figure 9). Interestingly, luciferase expression was further reduced at 3 months post-infection (Figure 10).

Co-administration of doxorubicin induced whole lung luciferase expression at levels almost ten times higher than those for Z-LLL at 2 weeks. Doxorubicin also induced tracheal and bronchi luciferase expression at higher levels than Z-LLL at 2 weeks. At six weeks, a similar pattern was observed for  
5 Z-LLL and doxorubicin alone, however, luciferase levels were more than additive in trachea and bronchi in mice co-administered virus, Z-LLL and doxorubicin. By three months post-infection, the synergism was no longer observed. These observations suggest a striking difference in the kinetics and longevity of induction by Z-LLL between *in vivo* studies with rAAV-2 and  
10 rAAV-5. Since *in vivo* transduction is significantly more efficient with rAAV-5 compared to rAAV-2, altering proteasome activity may simply enhance the rate of transduction with rAAV-5. In the case of rAAV-2, this basal rate may be significantly reduced from the apical membrane *in vivo* rendering more sustained augmentation of transduction by proteasome inhibitors.

15 These results also highlight the use of different agents and vectors to achieve different results. For example, agents and vectors that result in a steady increase in transgene expression in particular cells over time may be useful for certain disorders or conditions while agents and vectors that result in a high burst of transgene expression may be useful for metabolic disorders such as  
20 hemophilia.

Ubiquitination and proteasome activity can influence a myriad of intracellular processes that control protein degradation and intracellular trafficking. The following examples are designed to identify the molecular mechanisms of rAAV transduction that are controlled by the  
25 ubiquitin/proteasome system. These studies may lead to a clearer understanding of pathways and/or molecules that influence rate-limiting steps in rAAV transduction and can also be used to identify further useful agents to enhance processing of rAAV (i.e., endosomal escape, trafficking to the nucleus, and uncoating) and hence transduction.

30

### Example 5

#### Endosomal Pathways for Serotypes of rAAV

To delineate the intracellular pathway(s) of rAAV trafficking in airway epithelial cell lines, the pathway of intracellular trafficking for type 2 and 5

rAAV is determined using co-localization techniques with fluorescently-labeled rAAV and intracellular endosomal markers, biochemical purification of various endosomal compartments, and inhibition of endosomal movement using exogenously-expressed specific dominant negative Rab proteins. Rabs are small GTPases that provide for programmed delivery of endosomal compartments to various subcellular domains, and facilitate membrane fusion through GTP-dependent mechanism. Single cell microinjection of fluorochrome-quenching antibodies was used to determine the endosomal compartment from which rAAV escapes based on a color changes of dually-labeled rAAV. rAAV2 and rAAV5 may traffic through multiple endocytic compartments (Late endosome [LE], golgi, perinuclear recycling endosome [PNRE]), but only one of these compartments is the point of exit into the cytoplasm.

#### A. Intracellular Accumulation of rAAV2

Previous studies have demonstrated that Cy3-labeled rAAV2 co-localizes with FITC-labeled transferrin but not FITC-labeled Dextran when visualized in HeLa cells (Bartlett et al., 2000; Duan et al., 1999; Sanlioglu et al., 2000). Although virus begins to accumulate in the nucleus by 1 hour post-infection, a significant amount accumulates in a perinuclear organization. Transferrin is known to traffic through the PNRE (also called pericentriolar recycling endosome), which is an intracellular warehouse for intracellular sorting of receptors. Thus, rAAV2 may also traffic through this compartment.

Rab proteins encompass a group of small GTPases that are well known for their importance in vesicular sorting and membrane fusion. Many of these Rab proteins have been extensively characterized as markers for various intracellular sorting pathways. GFP-Rab fusion proteins as intracellular markers by which to compare rAAV2 trafficking to the transferrin sorting pathway (Rab5→Rab4→Rab11) (Ren et al., 1998; Trischler et al., 1996).

#### Methods

Labeling. rAAV was labeled with a monovalent Cy3 fluorochrome as previously described in Duan et al. (1999) and Sanlioglu et al. (2000). Typically about 2 fluorochromes label the rAAV capsid with greater than 85% retention of functional activity. To facilitate quality control analysis of labeled rAAV, rAAV that expresses the luciferase genes was used. For all labeling procedures, rAAV is generated by triple transfection as previously described in Duan et al. (2001).

The labeling procedure was modified to include a G50 Sephadex gel-filtration step to isolate virus from free fluorochrome. Fractions were then assessed by slot blot and functional activity, and peak fractions were then analyzed by EM.

- Intracellular GFP-tagged endosomal markers. cDNAs that express N-terminal GFP-tagged proteins that mark various intracellular compartments including Rab4, 5, 7, 9, and 11 endosomes, golgi, and the proteasome were obtained, as well as dominant negative constructs for each of these Rabs that prevents GTP hydrolysis (a function required for endosomal fusion mediated by each Rab) (Table 3).

10

Table 3

Construct	Protein Expressed	Endosomal Compartment and Use	cDNA Source (Ref)
Rab5-GFP	GFP-tagged Rab5a	Marks Early Endosome	Sonnichsen et al. (2000)
dnRab5	Rab5a(S34N)	Block Movement out of Early Endosome	Li et al. (1993)
Rab5-HA	HA-tagged Rab5a	Immunoaffinity Isolation of Rab5 Endosomes	
Rab4-GFP	GFP-tagged Rab4	Block Movement into the Rab4 compartment	Sonnichsen et al. (2000)
dnRab4	Rab4(S22N)	Immunoaffinity Isolation of Rab4 Endosomes	Sonnichsen et al. (2000)
Rab4-HA	HA-tagged Rab4	Immunoaffinity Isolation of Rab4 Endosomes	
Rab11-GFP	GFP-tagged Rab11a	Marks the PNRE	Sonnichsen et al. (2000)
dnRab11	Rab11a(S25N)	Block Movement through the PNRE	
Rab11-HA	HA-tagged Rab11a	Immunoaffinity Isolation of Rab11 Endosomes	
Rab7-GFP	GFP-tagged Rab7	Marks the Late Endosome to Lysosome pathway	Bucci et al. (2000)
dnRab7	Rab7(T22N)	Block Movement through the late endosome	Bucci et al. (2000)
Rab7-HA	HA-tagged Rab7	Immunoaffinity Isolation of Rab7 Endosomes	



Construct	Protein Expressed	Endosomal Compartment and Use	cDNA Source (Ref)
Rab9-GFP	GFP-tagged Rab9	Marks Rab7 Late Endosome to Golgi Movement	Barbero et al. (2002)
dnRab9	Rab(S21N)	Blocks endosomal movement to the golgi	Iversen et al. (2001)
Rab9-HA	HA-tagged Rab9	Immunoaffinity Isolation of Rab9 Endosomes	
TGN38-GFP	GFP-tagged TGN38	Marks the trans-golgi network	Girotti et al. (1996)
TGN38-HA	HA-tagged TGN38	Immunoaffinity Isolation trans-golgi network	
LMP2-GFP	GFP-tagged LMP2	Marks the proteasome subunit LMP2	Reits et al. (1997)

#### Co-localization of Cy3-rAAV2 with GFP-labeled Rab compartments.

HeLa cells were transfected with GFP-tagged Rab4, Rab5, and Rab11 expression constructs using standard protocols and lipofectamine/DNA complexes. At 48 hours following transfection, HeLa cells were infected with Cy3-rAAV2 at an MOI of 50,000 particles/cell on glass coverslips at 4°C for 1 hour. Cells were then washed extensively and either fixed for analysis or shifted to 37°C for 1 hour. Samples were then evaluated by confocal microscopy for the co-localization of Cy3 and GFP signal.

#### 10 Results and Conclusions

GFP-tagged Rab5 and Rab4 show similar patterns of distribution in HeLa cells at 48 hours post-transfection consistent with their overlapping distribution within the early endosomal recycling compartment (Trischler et al., 1999). In contrast, Rab11-GFP, which marks the PNRE, demonstrated a very unique distribution within the cell. Co-localization experiments with Cy3-rAAV2 and Rab11-GFP demonstrate a large percentage of overlap at 1 hour following infection. However, as expected, no overlap in signal was detected with bound Cy3-rAAV prior to initiated endocytosis at 37°C. These findings suggest that rAAV2 traffics through the Rab11 compartment. In HeLa cells, this compartment predominantly demarcates the PNRE. However, some overlap exists with trans-golgi as Rab11 has also been shown to control movement from the PNRE to the golgi. The Golgi-specific marker TGN-38 is employed to

evaluate this possibility. Although a large extent of overlap between Cy3 and Rab11 signals was observed, specific intracellular and intranuclear domains contained regions of no overlap in signal. The intracellular domains are other potential endosomal compartments through which rAAV2 may migrate (i.e., late endosome, golgi, lysosome).

**B. Localization of rAAV with Rab5 and Rab11**

Endosomal purification techniques were employed to evaluate the trafficking patterns of rAAV and the effect to which proteasome inhibitors alter the manner in which virus moves through the cell.

**10 Methods**

Density gradients. Density gradient centrifugation was used to isolate mixed populations of endosomes according to their size and buoyant density. Iodixanol is used as the medium for fractionation since it can provide an iso-osmotic condition with low viscosity over a wide range of density.

Vesicular isolation. Confluent monolayers of IB2, HeLa, or A549 cells grown on one 150 mm dish were incubated with 0.8 mg/ml biotin-transferrin (Sigma Co., St. Louis, MO) or AV2Luc (MOI = 10,000) in prewarmed MEM supplemented with 10 mM Hepes for 30 minutes at 37°C. The cells were harvested by trypsinization (which removes external, membrane-bound rAAV2 (Duan et al., 2001; Duan et al., 2000), washed in ice-cold PBS three times, and harvested into ice-cold homogenization buffer (0.25 M sucrose, 10 mM triethanolamine, 1 mM EDTA, 1 mM PMSF, 100 µg aprotinin). Cells were then homogenized in a Duall tissue grinder and centrifuged at 1000 x g at 4°C for 10 minutes. The supernatant, which contains intracellular vesicular compartments and membranes, but not the nuclei, was designated the post-nuclear supernatant (PNS). The PNS was subsequently combined with 60% iodixanol solution to obtain a final concentration of 32% and then loaded into an SW55Ti centrifuge tube and overlaid with two-step gradients of 24% and 20% iodixanol. All iodixanol solutions were prepared in homogenization buffer. Samples were centrifuged at 30,500 rpm for 1 hour at 4°C. Fractions were collected from the top to bottom of the centrifuge tube at 4°C (320-500 µl/fraction) since vesicular fractions migrate at the interphase between 24%/20% iodixanol.

Western blot analysis. 50 µl of each fraction was loaded on SDS-PAGE gel and Western blotted for Rab5 (Santa Cruz Biotechnology), Rab11

(Transduction Laboratories), and/or biotin-transferrin (Zymed Laboratories). Western blots were developed using ECL chemiluminescence using HRP conjugated streptavidin or secondary antibodies.

- TaqMan PCR quantification of viral DNA. PCR primers and the
- 5 Taqman probe for AV2Luc DNA quantification were selected using the Primer Express software program. The forward primer, P1 (5'-TTTTTGAAGCGAAGGTTGTGG-3'; SEQ ID NO:1), and the reverse primer, P2 (5'-CACACACAGTTCGCCTCTTTG -3'; SEQ ID NO:2), were chosen to amplify a 32-bp fragment in the promoter region of AV2Luc DNA. The
- 10 Taqman probe (5'-ATCTGGATACCGGGAAAACGCTGGGCGTTAAT-3'; SEQ ID NO:3) was designed following the general rules outlined by the manufacturer. The Taqman probe carried a 5' reporter dye, 6-carboxy fluorescein (FAM), and a 3' quencher dye, 6-carboxy tetramethyl rhodamine, and was synthesized by Genosys. The 25 µl PCR mixture consisted of 10 µl
- 15 AV2Luc gradient sample, primers P1 and P2 (final concentration 500 nM), Taqman probe (final concentration 100 nM), and 12.5 µl Taqman Universal Master Mix (PE Applied Biosystems). For AV2Luc DNA amplification, 1 cycle at 50°C for 2 minutes and 1 cycle at 95°C for 10 minutes were followed by a two-step PCR procedure consisting of 15 seconds at 95°C and 1 minutes at 60°C
- 20 for 40 cycles. Amplification, data acquisition, and analysis were performed using the ABI Prism 7700 Sequence Detector System (PE applied Biosystems). All standard dilutions of purified AV2Luc, controls, and samples from the subcellular fractionation were run in duplicate, and the average value of the copy number was used to quantify AV2Luc. The standard curve for AV2Luc was
- 25 accepted when the slope was between -3.74 and -3.32 and the coefficient of correlation was > 0.990.

### Results and Conclusions

- Subcellular fractionation of purified endosomes was shown by isolating intact endosomes containing preloaded biotin-transferrin. As expected,
- 30 transferrin immunoreactivity co-fractionates with the Rab5 and Rab11 compartments as detected by Western blotting (fraction 3 and 4). The remaining immunoreactivity in the bottom of the tube represents lysed endosomes and free Rabs or transferrin in the PNS. The addition of free biotin-transferrin to the PNS of unloaded cells does not lead to detectable immunoreactivity in peak vesicular

fractions (data not shown).

To investigate whether this method could be used to isolate viral-containing endosomes, similar evaluations were performed on AV2Luc-infected Hela cells (MOI=10,000). Peak Rab5/Rab11 positive vesicular fractions (#2-4) co-isolate with internalized rAAV genomes, following a 30 minute infection at 37°C. Approximately 50% of rAAV DNA was contained within the endosomal fraction. There was also a significant portion of rAAV DNA in the PNS at the bottom of the tube. This likely represents either free rAAV that has exited the endosome or endosomal lysis during the processing. However, without the use of more refined methods proposed in the experimental plan, the interpretation that vector remaining in the PNS had exited the endosome should be interpreted cautiously.

#### C. Use of HA-tagged Rab Proteins for Purification

Based on a previous report describing the immuno-affinity isolation of Rab5 and Rab11 endosomal compartments to study transferrin movement through cells (Trischler et al., 1999), a novel approach was developed to immuno-isolate numerous endosomal compartments using HA-tagged Rab marker proteins. These HA-tagged constructs as described below, partition to the endogenous sites of their Rab counterparts as well as our ability to immuno-isolate the Rab5 compartment.

#### Methods

N-terminal HA-tagged Rabs were generated by PCR for Rab5, Rab7, and Rab11 using a forward primer containing the HA epitope. A CMV-driven plasmid expression construct was employed to express HA-Rab5 and HA-Rab11 in Hela cells following lipofectamine transfection. At 72 hours post-transfection, endosomal fractions were purified and various fractions from the Iodixanol gradient were evaluated by Western blotting for HA, Rab5, and Rab11. Mixed populations of endosomes were then used for the immuno-affinity isolation strategy described below.

Immuno-affinity isolation of HA-tagged Rab5 endosomal compartments. Rab5 endosomes were isolated based on a previous method (Trischler et al., 1999) with modifications. Hela cells were transfected with HA-Rab5 expression plasmid and peak vesicular fractions (#3, 4, and 5) were combined from the Iodixanol gradient and immuno-affinity-purified using Dynabeads M-500

(DynaL Inc) bound to anti-HA antibodies. Secondary antibody (40 µg anti-rabbit) was conjugated to Dynabeads (200 µl containing  $4 \times 10^8$  beads/ml) in 0.1 M borate buffer (pH 9.5) for 24 hours at 25°C with slow rocking. The beads were then placed into the magnet for 3 minutes to remove the supernatant and washed three times in 0.1% (w/v) BSA/PBS for 5 minutes at 4°C. A final wash in 0.2 M Tris (pH 8.5)/BSA was performed for 24 hours. Finally, the beads were resuspended in BSA/PBS and conjugated to 4 µg primary anti-HA antibody per  $10^7$  beads O/N at 4°C and washed in BSA/PBS. Vesicular fractions (300 µl) from  $2 \times 10^7$  cells expressing the various HA-tagged Rabs were mixed with 700 µl coated beads in PBS containing 2 mM EDTA, 5% BSA, and protease inhibitors. The mixture was then incubated for 6 hours at 4°C with slow rocking, followed by magnetic capture and washing in the same tube three times (15 minutes each). Beads and enriched endosomes were then resuspended in PBS for Western blotting to assess enrichment of the Rab5 compartment.

## 15 Results and Conclusions

Exogenously-expressed HA-Rab5 and HA-Rab11 partition in an Iodixanol gradient to fractions typically containing the endosome. To assess the co-localization of endogenous Rab counterparts with the exogenously-expressed HA-tagged fusion, Western blots of peak vesicular fractions using anti-HA, anti-Rab5, and anti-Rab11 were performed. HA immunoreactivity was only seen in endosomes from cells transfected with the HA-tagged Rabs. This immunoreactivity coincided with the peak immunoreactivity for each of the Rab proteins. These results demonstrated that the tagged Rabs properly incorporate into endosomes and partition with the endogenous membrane-bound Rab counterparts.

Using an immuno-affinity isolation strategy with anti-HA bound Dynabeads beads, the peak endosomal fraction from HA-Rab5-transfected HeLa cells (#4) was used for Rab5 endosomal isolation. Immuno-isolation was performed in the presence of 1° anti-HA and 2° anti-rabbit antibodies or with 2° anti-rabbit antibody alone as a control for specificity. The results demonstrate approximately 30% immuno-isolation of Rab5-containing vesicles using the HA-Rab5 marker and undetectable contamination when 2° anti-rabbit antibody was used alone.

## D. Dual Fluorochrome Labeling of rAAV to Follow Endosomal Escape

One of the most challenging but important aspects of intracellular trafficking of rAAV is determining the exact endosomal compartment from which virions exit into the cytoplasm. Proteasome inhibitors may modulate this aspect of the rAAV life cycle by either changing the rate of endosomal escape and/or the compartment from which rAAV enters into the cytoplasm.

#### Methods

To study endosomal escape, single-cell imaging and microinjection of quenching antibodies against one of two fluorochromes on a dual-labeled rAAV capsid were performed. The Alexa Fluor system from Molecular Probes was chosen as a system for which multiple fluorochromes could be linked to the rAAV capsid at similar efficiencies. Three dyes (Alexa Fluor® 488 [green], Alexa Fluor® 568 [Red] and Alexa Fluor® 647 [blue]) were selected as useful in this regard. Preferably, dual labeling of rAAV does not change the infection pattern. Also preferably, microinjection of quenching antibodies against Alexa-488 (Molecular Probes) can shift fluorescence of dual-labeled rAAV. The general approach to assess endosomal escape is to inject the cytoplasm of living cells with anti-Alexa-488 following infection with rAAV that is dual labeled with Alexa-488 and one of the other dyes. Alexa-488/568 dual-labeled rAAV, a shift in fluorescence of virus from yellow to red (i.e., quenching of the green fluorochrome) indicates movement of virus into the cytoplasm. This approach is used in combination with GFP-tagged endosomal compartments and/or dominant negative Rabs to evaluate the compartment from which rAAV moves into the cytoplasm.

Alexa labeling of rAAV. The monovalent Alexa succinimidyl ester reactive dye (Alexa-488 and/or Alexa-568) was dissolved in 50 µl of 1 M bicarbonate.  $0.5 \times 10^{12}$  particles (determined by slot blot) of purified AV2Luc in 0.5 ml Hepes buffer was added to the reaction mixture and incubated for 2 hours. When dual labeling was performed, equal molar amounts of the two fluorochromes was used and the reaction time was extended to 3 hours. The labeled rAAV2 was separated from the free dye by exclusion chromatography. The fractions were tested for infectious titers on HeLa cells using luciferase assays. The 5 peak fractions were then combined and used for fluorescent imaging studies. Imaging studies were performed.

#### Results and Conclusions

Assessment of functional particles demonstrated that greater than 85% activity was retained following label with Alexa dyes (data not shown). This was similar to results observed with Cy3 labeling. Results from Hela cells infected with Alex-568-labeled rAAV2 demonstrated a significant overlap in signal with the GFP-tagged Rab11 compartment. The distribution observed was very similar to that seen with Cy3-labeled rAAV2. From these studies, it was concluded that Alexa-labeling of rAAV can be performed, and it was slightly more sensitive than Cy3-labeling. In these studies, approximately 3-4 fluorochromes were labeled on each rAAV capsid. To investigate whether dual labeling procedures could also be adapted to efficiently label rAAV, studies were conducted that compared dual Alexa-488/568 and Alexa-568-labeled rAAV2 following a 1 hour infection of Hela cells. These studies, which demonstrate overlap in the Alexa-488/568 signal, as compared to Alexa-568 alone, confirm that the predominance of rAAV virions are dual-labeled when both dyes are added to the conjugation reaction.

To begin to develop assays for visualizing endosomal release of rAAV into the cytoplasm, it was determined single cell injection of Anti-Alexa-488 could quench green fluorescence from dual-labeled Alexa-488/568 once rAAV entered into the cytoplasm. Results from these experiments are shown in Figure 17C and depict the fluorescence of Alexa-488/568 dual-labeled AV2Luc in Hela cells at 2 hour post-infection following injection with Anti-Alexa-488. Three cells are shown in the field, of which two were microinjected with antibody (closed arrowheads). From this study, it is obvious that the level of Alexa-488 fluorescence is significantly quenched by injection of anti-Alexa-488 while leaving red channel fluorescence of Alexa-568 intact. In contrast, fluorescence of both fluorochromes remains quite high in uninjected cells (open arrow). The remaining Alexa-488 fluorescence in injected cells is interpreted as virus still remaining in the endosomal compartment protected from antibody binding. These findings suggest that a significant portion of rAAV may be free in the cytoplasm by two hrs post-infection.

#### E. Intracellular Trafficking Patterns of rAAV-2 Demonstrate Significant Cell-Type Specificity

To further investigate the intracellular mechanisms of rAAV-2 transduction that might vary between cell types, immunofluorescent localization

of Cy3-rAAV-2 was performed following transduction of HeLa and IB3 cells. Despite the fact that rAAV-2 enters these two cell types with similar efficiency, HeLa cells are much more transducible with rAAV-2 than IB3 cells. However, IB3 cells demonstrate a much higher responsiveness to tripeptidyl proteasome inhibitor induction of transduction than HeLa cells. These differences in transduction may be reflected by variations in the intracellular trafficking patterns of rAAV-2 between HeLa and IB3 cells.

#### Methods

Luciferase-expressing rAAV2 was labeled with Cy3 and purified by column chromatography. Rab11, Rab7, and Rab9 were cloned into a pEGFP-C3 vector such that N-terminal EGFP-Rab fusions were generated. IB3 and HeLa cells were transfected with various EGFP-tagged Rabs using lipofectamine and infected with Cy3-labeled rAAV-2 at 4°C for 30 minutes with an MOI of 10,000 particles/cell. Cells were then washed and shifted to 37°C for 30 minutes to 2 hours. Cells were fixed and evaluated by fluorescent microscopy.

#### Results

Fluorescent microscopy was used to evaluate the primary vesicular compartments in which Cy3-labeled rAAV-2 accumulated following infection of HeLa and IB3 cells. A substantial degree of co-localization of Cy3-AAV-2 and EGFP-Rab11 was observed in HeLa cells from 30 minutes to 2 hours post-infection. This pattern, however, was not observed in IB3 cells. In contrast, the Cy3-labeled rAAV-2 was primarily co-localized with EGFP-Rab9 in IB3 cells. In HeLa cells, the degree of co-localization of Cy3-AAV and EGFP-Rab9 was not predominant. These findings suggest that rAAV-2 traffics through a diversity of intracellular compartments in a cell type specific manner.



### Example 6

#### Altered Trafficking of rAAV

Proteasome-modulating agents act to increase rAAV transduction through one or more of the following mechanisms: 1) increasing the rate at which rAAV accumulates in the primary compartment through which it emerges to the cytoplasm without changing the pathway of intracellular trafficking; 2) altering the pathway of rAAV intracellular trafficking in a manner that leads to more efficient accumulation in a compartment through which it emerges to the cytoplasm; 3) increasing the efficiency at which rAAV breaks out of the endosomal compartment; and/or 4) enhancing the rate of nuclear trafficking of free rAAV in the cytoplasm.

Several lines of evidence suggest that proteasome inhibitors may act to enhance rAAV transduction by increasing the rate of viral transport to the nucleus (Duan et al., 2000) and/or enhancing viral processing of the capsid (Yan et al., 2002). First, proteasome inhibitors such as the tripeptides LLnL and Z-LLL enhance transduction of both rAAV2 or rAAV5, viruses without enhancing 1) endocytosis of virus, 2) stability of viral DNA within the cell, or 3) promoter activity which drives transgene expression (Duan et al., 2000; Yan et al., 2002). Second, proteasome inhibitors can be added up to a week following infection of polarized human airway epithelia and still enhance transduction (i.e., gene expression). Third, viral capsids for type 2 and type 5 show enhanced ubiquitination *in vivo* in the presence of proteasome inhibitors, and purified virus can also be ubiquitinated *in vitro* (Yan et al., 2002). Together, these findings strongly suggest that modulating proteasome activity enhances rAAV transduction for at least two serotypes and that the mechanism of enhancement involves some aspect of intracellular viral processing.

#### A. Proteasome Inhibitors Increase Transport of rAAV2 and rAAV2/5 cell to the Nucleus

A large number of various classes of proteasome inhibitors were screened to identify those that had the largest effect. Two classes of compounds (the tripeptidyl aldehyde LLnL and an anthracycline derivative doxorubicin), and their ability to induce rAAV2 and rAAV2/5 transduction in two airway cell lines (IB3 and A549) are described below.

### Methods

LLnL and Z-LLL are two tripeptidyl aldehydes shown to inhibit calpains, cathepsins, cysteine proteases as well as the chymotrypsin-like protease activity of proteasomes (Wagner et al., 2002; Donkor, 2000; Sasaki et al., 1990).

5 Doxorubicin has also been shown to inhibit chymotrypsin-like protease activity of proteasomes (Kiyomiya et al., 2002). Both classes of proteasome inhibitors bind tightly to the proteasome complex. Dose response curves for these two proteasome-modulating agents were evaluated on IB3, A549, HeLa, and primary fibroblasts. The responses were consistent for a number of cell lines and for

10 three different promoters driving luciferase expression. For one set, CMV-driven luciferase constructs with an AAV2-based genome were employed that were packaged into AV2 or AV5 capsids. Cells were infected at various doses of AV2Luc and AV2/5Luc (MOIs 100 to 1000 particles/cell). At the time of infection, cells were treated with various concentrations of LLnL or Doxorubicin

15 and gene expression was assayed at 24 hours post-infection. The effect of proteasome inhibitors on nuclear uptake of virus was evaluated using a previously-described protocol for fractionating viral DNA in the cytoplasm and nucleus (Xiao et al., 2002). Viral DNA content in the cytoplasmic and nuclear fractions was then evaluated by slot blot hybridization against a Luciferase DNA

20 probe.

### Results and Conclusions

Results from this analysis demonstrated that both LLnL and Dox can significantly augment rAAV2 and rAAV2/5 transduction in two independent airway cell lines (Figure 11). Although the trends were similar between these

25 two cell lines and the two serotypes of rAAV, several features of the induction are worth noting. First, transduction in IB3 cells was most significantly inducible (> 200-fold) by LLnL, while A549 cells required much higher concentration of LLnL to achieve 10-fold lower levels of induction. Hence, IB3 cells appear to be particularly sensitive to LLnL induction of rAAV. Second,

30 rAAV transduction in both cell lines was highly inducible (200-fold) by Dox.

Given previous findings in polarized human airway epithelial cells that treatment with LLnL increased movement of rAAV to the nucleus (Duan et al., 2000), it was determined whether LLnL and Dox treatment at the time of infection also enhanced rAAV movement to the nucleus. Subcellular

fractionation of nuclei and cytoplasmic extracts from rAAV2-infected IB3 cells, demonstrated that both Dox and LLnL significantly increased the fraction of viral DNA in the nuclear compartment (Figure 12A and B). These findings suggest that these two proteasome-modulating agents act to increase rAAV  
5 transduction by mobilizing virus to the nucleus. In summary, these findings support a growing body of work that the ubiquitin/proteasome system acts in some manner to control intracellular processing of rAAV and its movement to the nucleus.

10 B. LLnL and Dox Act through Distinct Mechanisms to Modulate the Proteasome and Enhance rAAV Transduction.

To test the hypothesis that LLnL and Dox might augment rAAV transduction through distinct mechanistic interactions with the proteasome, their effects on rAAV transduction were assessed when added in combination. If each of these drugs acted to augment transduction by distinct mechanistic interactions  
15 with the proteasome, then their cumulative effect would be greater than either individually.

Methods

Hela, A549, IB3, and primary fetal fibroblasts were evaluated for AV2Luc and AV2/5Luc transduction in the presence of LLnL, Dox, or LLnL +  
20 Dox at various concentrations. The data shown is from Hela and A549 cells at the most optimal dose combination that induces rAV2Luc transduction to a greater extent than each compound alone.

Results and Conclusions

Cooperative inhibition of the proteasome by multiple proteasome  
25 inhibitors can provide increased augmentation in rAAV transduction (Figure 13). The observation that combined Dox and LLnL treatment enhances rAAV transduction greater than either compound alone does not, in and of itself, prove that the mechanisms of induction are independent of one another. There are several potential reasons why such drugs might cooperatively enhance rAAV  
30 transduction. First LLnL and/or Dox might alter endosomal routing of rAAV, enhance endosomal escape, and/or mobilize rAAV in the cytoplasm to the nuclear pore. Each of these compounds might affect any one or more of these processes to differing extents and allow for additive or synergistic effects on rAAV transduction. Hela cells appear to provide a greater additive effects of

Dox and LLnL on rAAV transduction than A549 cells. Furthermore, it should be noted that in primary fetal fibroblasts, no additive effect on transduction is seen (data not shown). In this cell line, Dox most significantly enhances transduction of rAAV2 and rAAV5, and LLnL provides no additional induction despite the fact it induced transduction 10-fold by itself. These interesting cell-specific differences also imply that certain cellular processes that alter rAAV transduction may be uniquely controlled by LLnL and Dox interactions with the proteasome.

10

### Example 7

The mechanism(s) by which proteasome inhibitors augment rAAV transduction from the apical membrane of airway epithelia may be reflected in the biologic differences in intracellular trafficking in apical and basolateral compartments. Co-infection studies from the apical and basolateral membranes of epithelia with two different fluorochrome-labeled rAAV viruses were used to directly visualize how polarity alters intracellular trafficking, as endocytic pathways from the apical and basolateral membranes of polarized airway epithelia may differentially utilize the ubiquitin/proteasome system to modulate vesicular trafficking and processing of rAAV. Endosomal trafficking pathways for rAAV2 and rAAV5 identified using cell lines and polarized airway models may be *in vivo* using human and mouse bronchial xenograft models with recombinant adenoviruses expressing either GFP-tagged intracellular markers or dominant negative Rab proteins.

15

20

#### A. Epithelial Polarity and the Ubiquitin/Proteasome System Uniquely Affect

25

#### rAAV transduction from Apical and Basolateral Membranes

30

Of particular importance to understanding the intracellular barriers to rAAV transduction from the apical membrane is an appreciation of how epithelial polarity alters intracellular trafficking of virus from the apical and basolateral membranes. It was previously reported that rAAV2 transduces from the basolateral membrane of polarized human airway epithelia 200-fold more effectively than from the apical membrane (Duan et al., 1998). Interestingly, this reduced transduction from the apical membrane correlated with the partitioning of high-affinity heparan sulfate proteoglycan (HSPG) AAV2 receptor to the basolateral membrane, but did not correlate with a substantial

difference in viral endocytosis from the apical vs basolateral membranes (Duan et al. 1999, Duan et al., 2000). These findings suggest that an unidentified alternative apical receptor for AAV2 may be present on the apical surface of human airway epithelia which leads to endocytosis but also to poor intracellular processing of rAAV2 in the absence of applied proteasome inhibitors (Duan et al., 2000). In contrast, rAAV5 has been suggested to infect the apical surface of airway epithelia more effectively than rAAV2 due to its use of an alternative receptor that resides on both the apical and basolateral surfaces (Walters et al., 2001; Zabner et al., 2000). This finding raises the possibility that the different receptors for rAAV2 and rAAV5 may also utilize different endosomal processing pathways.

#### Methods

Polarized human airway epithelia were generated as previously described in Duan et al. (1998), Duan et al. (2000), and Duan et al. (1998). Both AV2Luc and pseudotyped AV2/5Luc viruses were utilized in these studies. Infections were performed by applying equal amounts of virus, in 500  $\mu$ l of cell culture media, to the apical or basolateral membrane in the presence of LLnL (40  $\mu$ M) for 16 hours as previously described in Duan et al. (1998). After infection, the epithelia were washed and re-fed with media lacking LLnL or virus and harvested for luciferase assays at 5 and 14 days post-infection.

#### Results and Conclusions

Comparison of AV2Luc and AV2/5Luc transduction from the apical and basolateral membrane of airway epithelia yielded several interesting findings (Figure 14). First, these studies confirmed previous findings demonstrating a > 200 fold higher efficiency of rAAV2 transducing from the basolateral as compared to the apical membrane. Second, they also demonstrated a slightly higher level of transduction from the apical membrane with AV2/5Luc as compared with AV2Luc, although the difference was not as great as previously reported by Zabner et al. (2000). Third, only rAAV2 demonstrated a polarity of infection from the apical and basolateral membranes. Lastly, only apical transduction for both AAV serotypes was enhanced by the addition of the proteasome inhibitor LLnL. Thus, the data suggest a common link between rAAV transduction and the proteasome independent of the receptor entry pathway.

B. rAAV Gene Conversion is not a Rate-Limiting Step in Transduction of Polarized Airway Epithelium from the Apical Membrane

Thus far the data suggests that inhibition of the proteasome increases the ability of rAAV to migrate to the nucleus and express its encoded gene. Since  
5 rAAV is a single-stranded DNA virus which packages + or - strands, it must convert its genome to duplex double-stranded form in order to express encoded transgenes. If proteasome inhibition also affects this process, the mechanism of action could be more complicated than proposed. Since increased nuclear  
10 uptake of virus in the presence of proteasome inhibitors will undoubtedly also increase genome conversion of rAAV, differentiating between a direct proteasome inhibitor effect on the level of conversion enzymes and increased nuclear transport of virus or viral genome, e.g., via cytoskeletal components such as microtubules or microfilaments.

To address whether second strand synthesis might also be rate-limiting in  
15 the airway epithelia and enhanced by the proteasome inhibition, self-complementary AAV vectors (scAAV, also known as double-stranded AAV or dsAAV) that do not require second strand synthesis were used. These viruses which contain half-length genomes (< 2.5kb) have been shown to package either two annealed single-strand genomes ( = i.e., dsAAV) or replication form (Rf)  
20 monomer genomes composed of a covalently joined end ( ≡ i.e., scAAV) (McCarty et al., 2001). Since scAAV vectors have been shown to not require second strand synthesis to express an encoded transgene, their onset of gene expression is much more rapid. scAAV vectors and full-length AAV vectors were employed to demonstrate that intracellular processing, and not second  
25 strand synthesis, is the primary rate-limiting step in apical transduction of human airway epithelia.

Methods

A set of viral vectors was prepared of half-genome length was prepared. Four GFP-based viruses were generated for this analysis (AV2eGFP,  
30 scAV2eGFP, AV2/5eGFP, and scAV2/5eGFP that had either 4.7 kb or 2.4 kb length genomes packaged into AAV2 or AAV5 capsids. The data AAV2 capsid viruses were identical to data for rAAV5 viruses. Functional confirmation of scAAV/dsAAV structure was performed by analysis of gene conversion and gene expression rates in Hela cells, sensitivity of transduction in Hela cells to the

DNA synthesis inhibitor hydroxyurea (HU), and by denaturing NaHO gel electrophoresis. Polarized airway epithelia were infected with the various vector constructs from the apical membrane in the presence and absence of applied LLnL at the time of infection. Gene expression was monitored by quantitative morphometry of GFP fluorescence at various post-infection time points.

#### Results and Conclusions

Evaluation of full-length rAAV and scAAV vectors on Hela cells demonstrated the previously reported faster rate of onset and higher levels of gene expression for scAV2eGFP as compared to AV2eGFP (Figure 15A) (McCarty et al., 2001). Furthermore, pretreatment of Hela cells with 5mM HU significantly decreased gene expression from AV2eGFP but not scAV2eGFP virus (Figure 15B). These findings support the notion that scAAV vectors do not require DNA synthesis to express encoded transgenes (McCarty et al., 2001). Furthermore, molecular characterization of Hirt DNA from infected Hela cells demonstrated a much higher percentage of full-length scAV2eGFP genomes (2.4 kb) at 24 hours post-infection as compared to AV2eGFP, which was predominantly single-stranded migrating at 1.6 kb in a native gel (Figure 15C). Additionally, denaturing NaHO gel analysis of viral DNA demonstrated that approximately 75% was Rf (data not shown). Given the Hirt DNA analysis, we assume the remainder is likely dsAAV. In contrast to the clear enhancement of gene expression seen with scAV2eGFP vector on Hela cells, results from analysis of scAV2eGFP and full-length AV2eGFP vector on airway epithelia demonstrated no discernable difference in apical transduction in the presence or absence of proteasome inhibitor (Figures 16-17). Although data is only shown for rAAV2 serotypes, the results were identical for rAAV2/5. These findings strongly suggest that second strand synthesis is not the major rate-limiting step in rAAV transduction of human airway epithelia. Additionally, the finding that LLnL did not alter the profile of expression between scAV2eGFP and full-length AV2eGFP viruses also suggests that this proteasome inhibitor does not alter the rate of second strand synthesis in airway epithelia.

#### C. Proteasome Inhibitors Enhance the Efficacy of rAAV-Mediated Functional Correction of CFTR in Polarized Human Airway Epithelia

As described below, combined administration of LLnL and Dox synergistically act to augment rAAV transduction from the apical membrane of

human polarized airway epithelia to a level which can restore near normal levels of CFTR-mediated chloride current. Furthermore, analysis of type 5 and type 2 rAAV vectors in mouse lung using these approaches suggest species-specific differences in both the synergistic response to proteasome inhibitors and the optimal AAV serotype when compared to human airway epithelia (Figure 18).

#### Methods

Several vectors were used for this analysis including, AV2.Luc, AV2/5Luc, scAV2eGFP, AV2LacZdonor, AV2LacZacceptor, AV2tgCF, AV2/5tgCF, AV2CF83, and AV2/5CF83. AV2LacZdonor and AV2LacZacceptor virus are two *trans*-splicing vectors that reconstitute LacZ expression following intermolecular recombination and have been previously described in Duan et al. (2001). These vectors were used to establish the utility of combined proteasome inhibitor treatment to augment delivery using this approach. AV2tgCF is the current clinically-used AAV2-based full-length CFTR vector in which expression of CFTR is driven off the ITR (Aitken et al., 2001; Wagner et al., 2002). AV2/5tgCF virus has the identical proviral structure to AV2tgCF but is packaged into AAV5 capsid. AV2CF83 and AV2/5CF83 viruses have an additional 83 bp minimal promoter inserted into the AV2tgCF proviral genome to increase gene expression and are packaged into AAV2 and AAV5 capsids, respectively. All the CFTR vectors used in the current study were provided by Target Genetics Incorporated. Infections of polarized human CF and non-CF airway epithelia were all performed from the apical membrane at a dose of 10,000 particles/cell for 24 hours in the presence of Dox and LLnL.

*In vivo* Assessment of Gene Transfer in Mouse Lung. *In vivo* gene delivery to the lung of BL6 mice was performed by nasal inhalation of  $1 \times 10^{11}$  particles of AV2Luc or AV2/5Luc in the presence of proteasome inhibitor (200  $\mu$ M Z-LLL and/or 200  $\mu$ M Dox) as previously described in Duan et al. (2000). For *in vivo* studies, it is necessary to use the tripeptide Z-LLL was employed in place of LLnL because solubility in ethanol is much higher for Z-LLL. LLnL and Z-LLL perform similarly to augment rAAV in human polarized airway epithelia (Duan et al., 2000). For *in vivo* use, the concentration of tripeptide proteasome inhibitor is 5 to 10-fold higher to augment rAAV transduction and LLnL is insoluble in ethanol at 200  $\mu$ M. Mouse lung and tracheas were harvested separately for analysis at various post-infection time points and



assayed for luciferase activity as previously described in Duan et al. (2000). Data presented here shows only 14-day time points for comparison to studies with human polarized airway epithelia (Figure 19).

Functional assays for CFTR complementation. Complementation of CFTR chloride transport abnormalities in polarized CF airway epithelia was performed as previously described in Liu et al. (2002). Short circuit currents of epithelia were measured in Ussing chambers at 15 days following a 24 hour apical infection in the presence of Dox and LLnL. CFTR-mediated transport of chloride was interpreted as the increase in current generated following addition of 0.1 mM IBMX/10  $\mu$ M Forskolin to the luminal bath of epithelia equilibrated with low luminal chloride and 100  $\mu$ M amiloride. All CFTR-mediated current was reversibly blocked by the addition of 100  $\mu$ M bumetanide to the basolateral bath.

#### Results and Conclusion

Experiments evaluating the affect of LLnL and/or Dox treatment of polarized airway epithelia demonstrated a dramatic synergistic affect on transduction efficiency with rAAV transduction. As seen in Figure 15, enhancement of transduction from the apical surface increased 10 and 100-fold in the presence of LLnL and Dox, respectively. Remarkably, the combined addition of Dox and LLnL at the time of infection enhanced transduction 1000-fold with both full-length AV2Luc (Figure 17A) or self-complementary scAV2eGFP (Figure 17B-E). This high level of augmentation was also capable of facilitating high level dual vector *trans*-splicing reconstitution of LacZ (Figure 17F). Expression of the reconstituted LacZ gene product was only seen in epithelia co-infected with both AV2LacZdonor and AV2LacZacceptor viruses.

CFTR complementation studies in CF polarized airway epithelia using CFTR rAAV vectors, which compared both AAV2 and AAV5 capsid-mediated transduction in the presence and absence of optimal proteasome inhibitor combinations (Dox and LLnL), demonstrated several interesting findings (Figure 19). First, it was evident that rAAV2 capsid vectors performed as well or slightly better than rAAV5 in the absence of proteasome inhibitor. These findings are similar to those previously discussed using luciferase vectors (Figure 19) but differ from one previous report (Zabner et al., 2000). Second, as

seen with luciferase-based vectors, rAAV2-mediated CFTR delivery performed dramatically better in the presence of proteasome inhibitors than that seen with rAAV5. These findings suggest that in the presence of proteasome inhibitors, rAAV2 capsid-based vectors are perhaps the better vector for gene therapy of CF. Third, there was a tangible increase in correction seen with the AV2CF83 minimal promoter as compared to the current clinical vector AV2tgCF that utilizes the ITR as a promoter. Cumulatively, these findings demonstrate the need to circumvent intracellular barriers by modulating the proteasome to achieve functional expression of CFTR and support the current clinical observations with AV2tgCF (also called tgAAVCF) that substantial vector DNA can be found in airway epithelia without RT PCR detectable mRNA (Aitken et al., 2001). Thus far, results have demonstrated a direct correlation of CFTR functional correction with mRNA expression from the vectors.

Studies comparing transduction of rAAV2 and rAAV2/5 vectors and the effect of Dox and Z-LLL on transduction in mouse lung have demonstrated several notable differences to those seen in human polarized airway model. First, AV2/5 vectors perform substantially better (100-fold) in mouse lung and trachea as compared to AV2 vectors. This finding in mice supports several other reports in the field comparing AV2 to AV2/5 (Aurichio et al., 2002; Zabner et al., 2000), but is notably different than observations in polarized human airway epithelia that demonstrate near equivalent transduction with these two serotypes. Second, Z-LLL and Dox both substantially increased transgene expression from AV2/5 vectors to a level of 10 and 100-fold induction, respectively. Third, the lack of synergism in the induction of AV2/5 vectors when both Dox and Z-LLL were given at the time of infection. In fact, the combination of the two drugs appeared to inhibit overall transduction (Figure 19).

These differences between rAV2 and rAV2/5 transduction in mouse and human airways are relevant to evaluating mechanisms of proteasome involvement in rAAV transduction in the airway for several reasons. First, the mouse is extensively used as a preclinical model and knowledge about differences in transduction biology between humans is made. Second, tripeptidyl aldehyde (i.e., LLnL and Z-LLL) and anthracycline derivatives (i.e., Dox) may enhance intracellular processing of rAAV through overlapping yet distinct mechanisms. Hence, the lack of synergism in the induction of rAAV

transduction in the mouse airway may provide clues as to the mechanism of action of these compounds.

### Example 8

#### 5 *In vitro* and *In vivo* Activities of Additional Proteasome Modulators

Based on results with doxorubicin, a small number of FDA approved anthracyclines were tested for their relative *in vitro* and *in vivo* activities on AAV transduction. HeLa cells were infected with 100 ppc AAV2FLAG-Luc for 2 hours in the presence of different anthracyclines, e.g., doxorubicin, 10 daunarubicin (Cerubidine), epirubicin (Ellence™), and idarubicin (Idamycin®), and cells harvested 48 hours later. The anthracyclines were pharmaceutical grade, and prepared according to the manufacturer's instructions. Prior to use, the agents were diluted in sterile water to an equal mass, e.g., 0.6 µg/mL, 3 µg/mL and 6 µg/mL. The results are shown in Figure 20. For example, 3 µg/mL 15 idamycin increased luciferase expression by over 5000-fold while doxorubicin increased luciferase expression by 58-fold. Generally, the potency was as follows: idarubicin > daunarubicin > epirubicin > doxorubicin.

Six groups of ten, five-to-seven week-old, Balb/c mice (5 male and 5 female per group) were employed in a comparison of the relative *in vivo* potency 20 and safety of different anthracycline derivatives at a single dose after intranasal delivery. Treatment was administered as shown in Table 4. Animals were followed for seven days post dose.

Table 4

Group	R <sub>x</sub>	rAAV Treatment (Dose in DRP)	Proteasome Modulator	Proteasome Modulator Dose (% of HDE)	Route of Administration (rAAV/Inhibit or)	Day of Sacrifice
1	No R <sub>x</sub> control	Vehicle	Vehicle	0	Intranasal/ Intranasal	7
2	Vector control	1 x 10 <sup>12</sup> AAV2-GFP + 1 x 10 <sup>11</sup> AAV2-Luc	Vehicle	0	Intranasal/ Intranasal	7
3	Test 1	1 x 10 <sup>12</sup> AAV2-GFP + 1 x 10 <sup>11</sup> AAV2-Luc	Doxorubicin	10	Intranasal/ Intranasal	7

Group	R <sub>x</sub>	rAAV Treatment (Dose in DRP)	Proteasome Modulator	Proteasome Modulator Dose (% of HDE)	Route of Administration (rAAV/Inhibitor)	Day of Sacrifice
4	Test 2	1 x 10 <sup>12</sup> AAV2-GFP + 1 x 10 <sup>11</sup> AAV2-Luc	Idamycin	10	Intranasal/Intranasal	7
5	Test 3	1 x 10 <sup>12</sup> AAV2-GFP + 1 x 10 <sup>11</sup> AAV2-Luc	Doxil	10	Intranasal/Intranasal	7
6	Positive control	1 x 10 <sup>12</sup> AAV2-GFP + 1 x 10 <sup>11</sup> AAV2-Luc	Doxil	75	Intranasal/Intravenous	7

The dose of modulator was based on the Human Dose Equivalent (HDE) and is summarized below in Table 5. For intranasal dose administration, the dose was held constant at 10% of the HDE. For the intravenous positive control (Doxil), a dose of 10 mg/kg (75%) of the HDE was used. This represented the lowest dose that gave a 10% increase in mean and median luciferase expression in earlier studies.

Table 5. Human dose equivalent calculations

Drug	Drug Concentration (mg/mL)	Human dose (mg/m <sup>2</sup> )	10% Human Dose (mg/m <sup>2</sup> )	10% of Human dose in mg/kg for a mouse (dose mg/m <sup>2</sup> x 3)	10% of human dose per 20 gram mouse (mg)	Volume of stock drug (mL) per mouse
Adriamycin	2	40-75	7.5	2.5 mg/kg	0.05 mg	0.025 mL
Idamycin	1	10-12	1.2	0.4 mg/kg	0.008 mg	0.008 mL
Doxil	2	10-40	4.0	1.3 mg/kg	0.026 mg	0.013 mL

- 10 Dose calculation: Animal (mouse) dose in mg/kg x 3 (mouse km) = dose in mg/m<sup>2</sup>.  
mg per mouse = Dose in mg/kg x 0.02 kg mouse

15 Safety endpoints included morbidity and mortality, clinical observations, body weights, gross necropsy observations and histopathology. Transduction endpoints included luciferase and GFP analysis.

On the day of sacrifice, the left lung was clamped off at the level of the extrapulmonary bronchi, removed and frozen on dry ice. The left lung was homogenized and processed for luciferase expression using Promega's luciferase

assay system (Madison, WI). Luminescence was measured using the Berthold AutoLumat LB953 instrument. Samples were normalized for total protein using Pierce's Coomassie Plus Protein Assay Reagent (Rockford, IL).

Intranasal administration of doxorubicin and idamycin at 10% HDE were both associated with early mortality of some animals, ruffled hair coats and sick mice. In addition, those animals that survived also lost considerable body weight over the week. The intranasally doxil treated mice did better than the doxorubicin- or idamycin-treated animals in that there was no early mortality and they appeared clinically normal. However, they also lost weight. The intravenously doxil treated mice fared the best.

Intranasal treatment of doxorubicin and idamycin resulted in increased luciferase expression (Figure 21 and Table 6). Treatment with doxil at a 10% HDE (both intravenously and intranasally) resulted in an average increase in luciferase expression by 49- and 74-fold, respectively, 7 days post-dose.

15

Table 6. Fold increase in luciferase expression

Rx.	Average	Standard Deviation	Fold Increase
Vehicle - M	1.28E+03	4.05E+02	
Vehicle - F	1.32E+03	6.64E+02	
Vehicle	1.30E+03	5.19E+02	
No Rx - M	7.28E+03	5.01E+03	1
No Rx - F	3.56E+03	1.27E+03	1
No Rx	5.63E+03	4.12E+03	1
Doxorubicin (10% HDE) - M	*4.21E+06	*2.06E+06	578
Doxorubicin (10% HDE) - F	5.44E+05	4.00E+05	153
Doxorubicin (10% HDE)	1.77E+06	2.13E+06	314
Idamycin (10% HDE) - M	8.11E+05	2.81E+05	111
Idamycin (10% HDE) - F	2.02E+05	1.05E+05	57
Idamycin (10% HDE)	5.06E+05	3.80E+05	90
Doxil (10% HDE) - M	6.68E+05	2.57E+05	92
Doxil (10% HDE) - F	1.65E+05	7.15E+04	46
Doxil (10% HDE)	4.16E+05	3.19E+05	74
Doxil (75% HDE iv) - M	3.16E+05	2.69E+05	43
Doxil (75% HDE iv) - F	2.31E+05	1.21E+05	65
Doxil (75% HDE iv)	2.73E+05	2.02E+05	49

\*Average and standard deviation were calculated from two numbers

References

- Afione et al., J. Virol., 70:3235 (1996).
- Aitken et al., Hum. Gene Ther., 12:1907 (2001).
- 5 Alexander et al., Hum. Gene Ther., 7:841 (1996).
- Alexander et al., J. Virol., 68:8282 (1994).
- Animal Cell Culture (R. I. Freshney, Ed., 1987).
- Aurichio et al., J. Clin. Invest., 110:499 (2002).
- Aurichio et al., Hum. Mol. Genetics, 10:3075 (2001).
- 10 Bantel-Schaal et al., J. Virol., 73:939 (1999).
- Bantel-Schaal et al., J. Virol., 76:2340 (2002).
- Barbero et al., J. Cell Biol., 156:511 (2002).
- Bartlett et al., Hum. Gene Ther., 9:1181 (1998).
- Bartlett et al., J. Virol., 74:2777 (2000).
- 15 Bartlett et al., Nat. Biotechnol., 17:181 (1999).
- Basak et al., J. Virol., 63:3164 (1989).
- Basak et al., Virology, 186:368 (1992).
- Benson et al., J. Virol., 74:9184 (2000).
- Berg et al., J. Biol. Chem., 273:21883 (1998).
- 20 Bertran et al., Ann. N.Y. Acad. Sci., 850:163 (1998).
- Blacklow, Parvoviruses and Human Disease, J. R. Pattison, ed., pp. 165-174 (1988).
- Blau et al., Virology, 210:91 (1995).
- Blommaert et al., Eur. J. Biochem., 243:240 (1997).
- 25 Bonifacino et al., Ann. Rev. Cell Dev. Biol., 14:19 (1998).
- Bregman et al., Proc. Natl. Acad. Sci. USA, 93:11586 (1996).
- Britten et al., Radiat. Res., 148:308 (1997).
- Bucci et al., Mol. Biol. Cell, 11, 467 (2000).
- Ceresa et al., Mol. Cell Biol., 18:3862 (1998).
- 30 Chao et al., Mol. Ther., 2:619 (2000).
- Chen et al., J. Cell Biol., 101:85 (1985).
- Chiorini et al., J. Virol., 68:797 (1994).
- Chiorini et al., J. Virol., 71:6823 (1997).
- Chiorini et al., J. Virol., 73:1309 (1999).

- Chorini et al., J. Virol., 73:4293 (1999).
- Chu et al., Hum. Gene Ther., 10:25 (1999).
- Clayson et al., Mol. Cell Biol., 8:3391 (1988).
- Conforti et al., Cell Adhes. Commun., 1:279 (1994).
- 5 Conrad et al., Gene Ther., 3:658 (1996).
- Coonrod et al., Gene Ther., 4:1313 (1997).
- Crystal et al., J. Clin. Invest., 104:1491 (1999).
- Current Protocols in Immunology (J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach and W. Strober, eds., 1991).
- 10 Current Protocols in Molecular Biology (F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Siedman, J. A. Smith, and K. Struhl, eds., 1987).
- Current Protocols in Protein Science (John E. Coligan et al., eds., Wiley and Sons, 1995).
- 15 Davidson et al., Proc. Natl. Acad. Sci. USA, 97:3428 (2000).
- Duan et al., Am. J. Respir. Cell Mol. Biol., 18:750 (1998).
- Duan et al., Hum. Gene Ther., 10:1553 (1998).
- Duan et al., Hum. Gene Ther., 10:1553 (1999).
- Duan et al., Hum. Gene Ther., 9:2761 (1998).
- 20 Duan et al., J. Clin. Invest., 105:1573 (2000).
- Duan et al., J. Virol., 72:8568 (1998).
- Duan et al., J. Virol., 73:10371 (1999).
- Duan et al., J. Virol., 73:161 (1999).
- Duan et al., Virus Res., 48:41 (1997).
- 25 Engelhard et al., J. Clin. Invest., 90:2598 (1992).
- Engelhardt et al., Development, 121:2031 (1995).
- Engelhardt et al., Nat. Genet., 2:240 (1992).
- Engelhardt et al., Nat. Genet., 4:27 (1993).
- Everett et al., EMBO J., 17:161 (1998).
- 30 Fenteany et al., Science, 268:726 (1995).
- Ferrari et al., J. Virol., 70:3227 (1996).
- Fisher et al., J. Virol., 70:520 (1996).
- Flotte et al., Gene Ther., 2:357 (1995).
- Flotte et al., Hum. Gene Ther., 7:1145 (1996).

- Flotte et al., Proc. Natl. Acad. Sci. USA, 90:10613 (1993).
- Flotte et al., Proc. Natl. Acad. Sci. USA, 93:10163 (1993).
- Folli et al., Gastroenterology, 113:954 (1997).
- Fuller et al., Cell, 38:65 (1984).
- 5 Gao et al., Proc. Natl. Acad. Sci. USA, 99:11854 (2002).
- Gene Transfer Vectors for Mammalian Cells (J. M. Miller and M. P. Calos eds. 1987).
- Gibson et al., J. Cell Biol., 143:81 (1998).
- Girotti et al., J. Cell Sci., 109:2915 (1996).
- 10 Goldberg et al., Chem. Biol., 2:503 (1995).
- Goldenthal et al., J. Histochem. Cytochem., 36:391 (1988).
- Goldman et al., Gene Ther., 3:811 (1996).
- Goldman et al., J. Virol., 69:5951 (1995).
- Gommerman et al., J. Biol. Chem., 272:30519 (1997).
- 15 Gottlieb et al., J. Cell Biol., 120:695 (1993).
- Griffiths et al., Cell, 52:329 (1988).
- Halbert et al., J. Virol., 71:5932 (1997).
- Halbert et al., J. Virol., 74:1524 (2000).
- Halbert et al., J. Virol., 75:6615 (2001).
- 20 Handbook of Experimental Immunology, (D. M. Weir and C. C. Blackwell, Eds.).
- Hansen et al., J. Virol., 74:992 (2000).
- Hansen et al., J. Virol., 75:4080 (2001).
- Hansen et al., Mol. Ther., 4:289 (2001).
- 25 Hildinger et al., J. Virol., 75:6199 (2001).
- Hirt, J. Mol. Biol., 26:365 (1967).
- Hoggan et al., Proceedings of the Fourth Lepetit Colloquium, pp. 41-47, North Holland, Amsterdam.
- Horowitz, Fundamental Virology, Fields et al., eds., pp. 771-816 (1985).
- 30 Hughes et al., Lab Invest., 69:173 (1993).
- Iqbal et al., J. Med. Chem., 38, 2276 (1995).
- Iversen et al., Mol. Biol. Cell, 12:2099 (2001).
- Janson et al., Hum. Gene Ther., 13:1391 (2002).
- Jeggo et al., Int. J. Radiat. Biol., 66:573 (1994).



- Jensen et al., Cell, **83**:129 (1995).
- Jiang et al., J. Cell Biol., **143**:645 (1998).
- Kao et al., J. Biol. Chem., **273**:25450 (1998).
- Kaplitt et al., Nat. Genet., **8**:148 (1994).
- 5 Kato, Hum. Mutat., **13**:87 (1999).
- Kay et al., Nat. Genetics, **24**:257 (2000).
- Kloetzel, Gene Ther., **5**:1297 (1998).
- Kondo et al., Am. J. Physiol., **261**:L106 (1991).
- Kotin et al., Proc. Natl. Acad. Sci. USA, **87**:2211 (1990).
- 10 Lebkowski et al., Mol. Cell Biol., **8**:3988 (1988).
- Lee et al., Ch. 10 in Proteosomes: TheWorld of Regulatory Proteolysis,  
Hut et al., eds (2000).
- Li et al., J. Biol. Chem., **268**:24475 (1993).
- Li et al., J. Virol., **72**:2055 (1998).
- 15 Li et al., J. Virol., **72**:8806 (1998).
- Lim et al., Proc. Natl. Acad. Sci. USA, **95**:10146 (1998).
- Linden et al., Proc. Natl. Sci. USA, **93**:11288 (1996).
- Mah et al., J. Virol., **72**:9835 (1998).
- Martys et al., J. Biol. Chem., **271**:10953 (1996).
- 20 Memmo et al., J. Cell Sci., **111**:425 (1998).
- Meresse et al., J. Cell Sci., **108**:3349 (1995).
- Mingozzi et al., J. Virol., **76**:10497 (2002).
- Minutes of Recombinant DNA Advisory Committee Meeting of June  
14015, 2002. Hum. Gene Ther., **12**:2129 (2001).
- 25 Miramatsu et al., Virology, **221**:208 (1996).
- Mizukami et al., Virology, **217**:124 (1996).
- Mu et al., J. Biol. Chem., **270**:13503 (1995).
- Muzyczka et al., In: BN Fields, DM Knipe, PM Howley, eds., Virology,  
New York,: Raven Press, 2327-2360 (2001).
- 30 Muzyczka, Curr. Top. Microbiol. Immunol., **158**, 97 (1992).
- Naim et al., J. Cell Biol., **129**:1241 (1995).
- Obin et al., J. Biol. Chem., **274**:11789 (1999).
- Odorizzi et al., J. Cell Biol., **135**:139 (1996).
- Odorizzi et al., J. Cell Biol., **137**:1255 (1997).

- Oligonucleotide Synthesis (M. J. Gait Ed., 1984).
- Paillard, Hum. Gene Ther., **10**:337 (1999).
- Park et al., Proc. Natl. Acad. Sci. USA, **89**:11416 (1992).
- Parker et al., J. Virol., **74**:1919 (2000).
- 5 Peters et al., Embo J., **13**:3296 (1994).
- Pickles et al., J. Virol., **72**:6014 (1998).
- Ponnazhagan et al., Hum. Gene Ther., **8**:275 (1997).
- Powell et al., Am. J. Respir. Cell Mol. Biol., **19**:563 (1998).
- Prasad et al., Virology, **214**:360 (1995).
- 10 Protein Purification: Principles and Practice (Robert K. Scopes, Springer-Verlag, 1994).
- Prydz et al., J. Cell Biol., **119**:259 (1992).
- Qing et al., J. Virol., **71**:5663 (1997).
- Qing et al., J. Virol., **75**:8968 (2001).
- 15 Qing et al., J. Virol., **77**:2741 (2003).
- Qing et al., Nat. Med., **5**:71 (1999).
- Qing et al., Proc. Natl. Acad. Sci. USA, **94**:10879 (1997).
- Rabinowitz et al., J. Virol., **76**:791 (2002).
- Rabinowitz et al., Virology, **278**:301 (2000).
- 20 Recchia et al., Proc. Natl. Acad. Sci. USA, **96**:2615 (1999).
- Reits et al., EMBO J., **16**:6087 (1997).
- Ren et al., PNAS USA, **95**:6187 (1998).
- Rock et al., Cell, **78**:761 (1994).
- Rodriguez et al., J. Virol., **65**:494 (1991).
- 25 Rodriguez-Boulan et al., J. Cell Sci. Suppl., **17**:9 (1993).
- Rose, Comprehensive Virology, **3**: 1 (1974).
- Rose, Comprehensive Virology, **3**:1 (1974).
- Rubin et al., Curr. Biol., **5**:854 (1995).
- Russell et al., Proc. Natl. Acad. Sci. USA, **91**:8915 (1994).
- 30 Russell et al., Proc. Natl. Acad. Sci. USA, **92**:5719 (1995).
- Rutledge et al., J. Virol., **72**:309 (1998).
- Sambrook, Fritsch, and Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989).
- Samulski et al., EMBO J., **10**:3941 (1991).

- Samulski et al., EMBO J., 11:1228 (1992).
- Samulski et al., J. Virol., 61:3096 (1987).
- Samulski, In Press, 2003.
- Sanlioglu et al., Gene Ther., 6:1427 (1999).
- 5 Sanlioglu et al., Human Gene Therapy, 10:591 (1999).
- Sanlioglu et al., Virology, 74:9184 (2000).
- Sato et al., J. Biochem. (Tokyo), 119:887 (1996).
- Schwartz et al., Annu. Rev. Med., 50:57 (1999).
- Schwartz et al., J. Virol., 72:3845 (1998).
- 10 Seglen, Methods Enzymol., 96:737 (1983).
- Seisenberger et al., Science, 294:1029 (2001).
- Sharma et al., Am. J. Respir. Cell Mol. Biol., 19:30 (1998).
- Shiomi et al., Mutat. Res., 314:167 (1994).
- Snyder et al., Nat. Genet., 16:270 (1997).
- 15 Sonnichsen et al., J. Cell Biol., 149:901 (2000).
- Srivastava et al., J. Virol., 45:555 (1983).
- Strouss et al., J. Cell Sci., 112:1417 (1999).
- Summerford et al., J. Virol., 72:1438 (1998).
- Summerford et al., Nat. Med., 5:78 (1999).
- 20 Teramoto et al., J. Virol., 72:8904 (1998).
- Thompson et al., Mol. Cell Biol., 10:6160 (1990).
- Thompson et al., Proc. Natl. Acad. Sci. USA, 91:6855 (1994).
- Tomkinson et al., Mutat. Res., 407:1 (1998).
- Tugizov et al., J. Gen. Virol., 77:61 (1996).
- 25 Vihinen-Ranta et al., J. Virol., 72:802 (1998).
- Wacher et al., J. Pharma. Sci., 87, 1322 (1998).
- Wagner et al., Hum. Gene Ther., 13:1349 (2002).
- Wagner et al., Laryngoscope, 109:266 (1999).
- Waite et al., Clin. Immunol. Immunopathol., 86:81 (1998).
- 30 Walters et al., J. Biol. Chem., 274:10219 (1999).
- Walters et al., J. Biol. Chem., 276:20610 (2001).
- Walters et al., J. Virol., 74:535 (2000).
- Wang et al., J. Virol., 72:3455 (1998).
- Wang et al., J. Virol., 72:9818 (1998).

- Weber et al., Mol. Cell Biol., 8:1137 (1988).
- Westerveld et al., Nature, 310:425 (1984).
- Wickham et al., J. Virol., 70:6831 (1996).
- Wickham et al., Nat. Biotechnol., 14:1570 (1996).
- 5 Wills et al., Epithelial transport: a guide to methods and experimental analysis, 1<sup>st</sup> ed., Chapman & Hall, London; New York (1996).
- Wojcik, Drug Discovery Today, 4:188 (1999).
- Xiao et al., J. Virol., 70:8098 (1996).
- Xiao et al., J. Virol., 71:941 (1997).
- 10 Xiao et al., J. Virol., 72:10222 (1998).
- Xiao et al., J. Virol., 73:3994 (1999).
- Xiao et al., J. Virol., 76:11505 (2002).
- Yan et al., J. Virol., 76:2043 (2002).
- Yang et al., J. Virol., 73:9468 (1999).
- 15 Yang et al., J. Virol., 76:7651 (2002).
- Young et al., J. Virol., 74:3953 (2000).
- Yukawa et al., Atherosclerosis, 141:125 (1998).
- Zabner et al., Gene Ther., 3:458 (1996).
- Zabner et al., J. Clin. Invest., 100:1144 (1997).
- 20 Zabner et al., J. Virol., 70:6994 (1996).
- Zabner et al., J. Virol., 74:3652 (2000).
- Zhang et al., Am. J. Physiol., 270:C1326 (1996).
- Zhang et al., Hum. Gene Ther., 9:635 (1998).
- Zhang et al., J. Clin. Invest., 96:2997 (1995).
- 25 Zwacka et al., Nat. Med., 4:698 (1998).

All publications, patents and patent applications are incorporated herein by reference. While in the foregoing specification, this invention has been described in relation to certain preferred embodiments thereof, and many details

30 have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details herein may be varied considerably without departing from the basic principles of the invention.

**WHAT IS CLAIMED IS:**

1. A method to enhance recombinant adeno-associated virus (rAAV)  
transduction of a mammalian cell, comprising: contacting the mammalian  
5 cell with at least one rAAV and at least two agents in an amount effective  
to additively or synergistically enhance rAAV transduction.
2. The method of claim 1 wherein the rAAV comprises a marker gene or a  
selectable gene.  
10
3. The method of claim 1 further comprising contacting the cell with an  
agent that alters single strand to double strand rAAV genome conversion.
4. The method of claim 1 further comprising contacting the cell with an  
15 agent that alters cellular uptake of rAAV.
5. The method of claim 1 wherein the agents enhance transduction by at  
least 2 fold relative to transduction of a corresponding mammalian cell  
contacted with the rAAV and one of the agents or transduction of a  
20 corresponding mammalian cell contacted with the at least one rAAV but  
not contacted with the agents.
6. The method of claim 1 wherein the agents enhance transduction by at  
least 4 fold relative to transduction of a corresponding mammalian cell  
25 contacted with the rAAV and one of the agents or transduction of a  
corresponding mammalian cell contacted with the at least one rAAV but  
not contacted with the agents.
7. The method of claim 1 wherein the agents enhance transduction by at  
30 least 10 fold relative to transduction of a corresponding mammalian cell  
contacted with the rAAV and one of the agents or transduction of a  
corresponding mammalian cell contacted with the at least one rAAV but  
not contacted with the agents.

8. The method of claim 1 wherein one of the agents is a chemotherapeutic, a lipid lowering agent, an antibiotic or a food additive.
9. The method of claim 1 wherein one rAAV comprises a first recombinant DNA molecule comprising linked:
- 5
- i) a first DNA segment comprising a 5' inverted terminal repeat (ITR) of AAV;
  - ii) a second DNA segment comprising a heterologous DNA; and
  - iii) a third DNA segment comprising a 3' ITR of AAV.
- 10
10. The method of claim 9 further comprising a second rAAV comprising a second recombinant DNA molecule comprising linked:
- i) a first DNA segment comprising a 5' ITR of AAV, and
  - ii) a second DNA segment comprising a heterologous DNA which
  - 15 has sequences that are different than the sequences in the second DNA segment of the first recombinant DNA molecule; and
  - iii) a third DNA segment comprising a 3' ITR of AAV.
11. The method of claim 10 wherein the second DNA segment of the first recombinant DNA molecule comprises a portion of an open reading
- 20
- frame for a gene product, optionally operably linked to at least one transcriptional regulatory element, and a splice donor site 3' to the portion of the open reading frame, and wherein the second DNA segment of the second recombinant DNA molecule comprises a splice acceptor
- 25
- site 5' to the remainder of an open reading frame, which together with the second DNA segment of the first recombinant DNA molecule encodes a functional gene product.
12. The method of claim 11 wherein the transcriptional regulatory element is
- 30
- a promoter.
13. The method of claim 11 wherein the transcriptional regulatory element is an enhancer.

14. The method of claim 10 wherein the second DNA segment of the first recombinant DNA molecule comprises an enhancer and the second DNA segment of the second recombinant DNA molecule comprises an open reading frame encoding a functional gene product.
- 5
15. The method of claim 10 wherein the second DNA segment of the first recombinant DNA molecule comprises a promoter and the second DNA segment of the second recombinant DNA molecule comprises an open reading frame encoding a functional gene product.
- 10
16. The method of claim 1 wherein the cell is a lung cell, an epithelial cell, a liver cell, a muscle cell, a hematopoietic cell, a heart cell, or a neuronal cell.
- 15
17. The method of claim 11, 14 or 15 wherein the expression of the functional gene product is enhanced.
18. The method of claim 9 wherein the second DNA segment encodes a functional gene product.
- 20
19. The method of claim 11, 14, 15 or 18 wherein the functional gene product is a therapeutic peptide or polypeptide or a prophylactic peptide or polypeptide.
- 25
20. The method of claim 19 wherein the functional polypeptide is cystic fibrosis transmembrane conductance regulator,  $\beta$ -globin,  $\gamma$ -globin, tyrosine hydroxylase, glucocerebrosidase, aryl sulfatase A, factor VIII, dystrophin or erythropoietin.
- 30
21. The method of claim 1 wherein one of the agents is epoxomicin, doxorubicin, doxil, daunorubicin, idarubicin, epirubicin, aclarubicin camptothecin, simvastatin, tannic acid, cisplatin, LLnL or Z-LLL.

22. The method of claim 1 wherein the cell is a human cell, canine cell, murine cell, rat cell or rabbit cell.
23. The method of claim 1 wherein the cell is contacted with at least one agent before the cell is contacted with the virus.
24. The method of claim 1 wherein the cell is contacted with the virus before the cell is contacted with at least one agent.
25. The method of claim 1 wherein at least one of the agents modulates microfilaments or microtubules.
26. The method of claim 1 wherein at least one of the agents modulates rAAV endocytosis.
27. The method of claim 1 wherein at least one of the agents modulates rAAV trafficking in the cell.
28. The method of claim 1 wherein at least one of the agents modulates rAAV processing in the cell.
29. The method of claim 1 wherein at least one of the agents modulates rAAV nucleic acid degradation in the cell.
30. The method of claim 1 wherein at least one of the agents modulates rAAV protein degradation in the cell.
31. The method of claim 1 wherein at least one of the agents modulates rAAV transport to the nucleus.
32. The method of claim 1 wherein at least one of the agents modulates viral genome transport to the nucleus.



33. A method to inhibit or treat a condition associated with aberrant expression of an endogenous gene product, comprising: contacting a mammal at risk of or having the condition, with an effective amount of at least one agent that enhances AAV transduction and an effective amount at least one rAAV comprising a transgene encoding at least a portion of a functional gene product, the expression of which in the mammal inhibits or treats at least one symptom of the condition, wherein the agent is a chemotherapeutic, a lipid lowering agent, an antibiotic or a food additive.
34. The method of claim 33 wherein the aberrant expression is the lack of or reduced expression of the endogenous gene product.
35. The method of claim 33 wherein one rAAV comprises a first recombinant DNA molecule comprising linked:
- iv) a first DNA segment comprising a 5' ITR of AAV;
  - v) a second DNA segment comprising a heterologous DNA; and
  - vi) a third DNA segment comprising a 3' ITR of AAV.
36. The method of claim 35 further comprising a second rAAV comprises a second recombinant DNA molecule comprising linked:
- ii) a first DNA segment comprising a 5' ITR of AAV, and
  - ii) a second DNA segment comprising a heterologous DNA which has sequences which are different than the sequences in the second DNA segment of the first recombinant DNA molecule;
- and
- iii) a third DNA segment comprising a 3' ITR of AAV.
37. The method of claim 36 wherein the second DNA segment of the first recombinant DNA molecule comprises a portion of an open reading frame for a gene product, optionally linked to a transcriptional regulatory element, and a splice donor site 3' to the portion of the open reading frame, wherein the second DNA segment of the second recombinant DNA molecule comprises a splice acceptor site 5' to the remainder of an

open reading frame, which together with the second DNA segment of the first recombinant DNA molecule encodes a functional gene product.

38. The method of claim 37 wherein the transcriptional regulatory element is a promoter.
39. The method of claim 36 wherein the second DNA segment of the first recombinant DNA molecule comprises an enhancer and the second DNA segment of the second recombinant DNA molecule comprises an open reading frame encoding a functional gene product.
40. The method of claim 36 wherein the second DNA segment of the first recombinant DNA molecule comprises a promoter and the second DNA segment of the second recombinant DNA molecule comprises an open reading frame encoding a functional gene product.
41. The method of claim 33 wherein the expression of the transgene is enhanced.
42. The method of claim 33 wherein the transgene encodes cystic fibrosis transmembrane conductance regulator,  $\beta$ -globin,  $\gamma$ -globin, tyrosine hydroxylase, glucocerebrosidase, aryl sulfatase A, factor VIII, dystrophin or erythropoietin.
43. A method to enhance rAAV transduction of a mammalian cell, comprising: contacting the mammalian cell with at least one rAAV and at least one agent that alters rAAV endocytosis, rAAV trafficking or processing in intracellular compartments, viral nucleic acid or protein degradation, nuclear transport of virus or viral genome, effective to enhance rAAV transduction, with the proviso that the agent is not an inhibitor of proteasome proteolytic activity.
44. The method of claim 43 wherein the rAAV comprises a marker gene or a selectable gene.

45. The method of claim 43 further comprising contacting the cell with an agent that alters single strand to double strand rAAV genome conversion.
- 5 46. The method of claim 43 wherein further comprising contacting the cell with an agent that alters cellular uptake of rAAV.
47. The method of claim 43 wherein one of the agents is a chemotherapeutic, a lipid lowering agent, an antibiotic or a food additive.
- 10 48. The method of claim 43 wherein the cell is a lung cell, an epithelial cell, a liver cell, a heart cell, a hematopoietic cell, a muscle cell or a neuronal cell.
- 15 49. The method of claim 43 wherein the rAAV expresses a therapeutic or prophylactic gene product.
50. The method of claim 43 wherein the cell is a human cell, canine cell, murine cell, rat cell or rabbit cell.
- 20 51. The method of claim 43 wherein at least one agent modulates microfilaments or microtubules.
52. The method of claim 43 wherein at least one agent modulates rAAV endocytosis.
- 25 53. The method of claim 43 wherein at least one agent modulates rAAV trafficking in the cell.
- 30 54. The method of claim 43 wherein at least one agent modulates rAAV processing in the cell.
55. The method of claim 43 wherein at least one agent modulates rAAV nucleic acid degradation in the cell.

56. The method of claim 43 wherein at least one agent modulates rAAV protein degradation in the cell.
- 5 57. The method of claim 43 wherein at least one agent modulates rAAV transport to the nucleus.
58. The method of claim 43 wherein at least one agent modulates viral genome transport to the nucleus.
- 10 59. The method of claim 43 wherein at least one agent modulates subcellular localization of proteosomes.
- 15 60. The method of claim 33 or 43 wherein at least one agent is epoxomicin, doxorubicin, doxil, daunorubicin, idarubicin, epirubicin, aclarubicin, simvastatin or tannic acid.
- 20 61. Use of two or more agents that enhance rAAV transduction of a mammalian cell for the preparation of a medicament to additively or synergistically enhance rAAV transduction in a mammal in need of rAAV mediated gene therapy.
- 25 62. Use of a chemotherapeutic, a lipid lowering agent, an antibiotic or a food additive for the preparation of a medicament to enhance transduction of at least one rAAV comprising a transgene encoding at least a portion of a functional gene product in a mammal.
- 30 63. Use of at least one agent that alters rAAV endocytosis, rAAV trafficking or processing in intracellular compartments, viral nucleic acid or protein degradation, nuclear transport of virus or viral genome for the preparation of a medicament to enhance transduction of at least one rAAV comprising a transgene encoding at least a portion of a functional gene product in a mammal, with the proviso that the agent is not an inhibitor of proteosome proteolytic activity.

64. The use of any one of claims 61 to 63 wherein the medicament further comprises rAAV.
- 5 65. The use of claim 64 wherein the medicament comprises at least two different rAAV.
66. The use of claim 62 or 63 wherein the mammal has a condition associated with aberrant expression of an endogenous gene product that is
- 10 capable of being inhibited or treated with the transgene

Figure 1A:




Figure 1B.




Figure 1C.






Figure 1D .





Figure 1E . f






Figure 2.




Figure 3.

8/27





Fig 4

A



B





Fig 5

A



B







Fig. 6

A



B



C





Figure 7.








Fig 9A




Fig 9B




Fig. 10




Figure 11




Fig. 12




Fig. 13




Fig 14






Fig. 15




Fig 16




Fig. 17




Fig 18




Fig 19


Figure 20 A

# Transduction Modifier Screening

WO 2004/090145

25/27

PCT/US2004/010045



# Transduction Modifier Screening

Sample	AVG RLU/mg	Stdev	Fold Change
Vehicle	2.95E+03	9.01E+02	
AAV2 FLAG-Luciferase	1.11E+05	3.77E+04	1.00
MG-132 20 $\mu$ M	1.43E+06	1.72E+06	12.90
DOXOrubicin 6 $\mu$ g/mL	2.10E+07	4.57E+06	189.36
DOXOrubicin 3 $\mu$ g/mL	6.55E+06	1.15E+05	58.99
DOXOrubicin 0.6 $\mu$ g/mL	2.55E+05	1.30E+05	2.30
Daunorubicin 6 $\mu$ g/mL	3.17E+08	1.41E+08	2855.65
Daunorubicin 3 $\mu$ g/mL	2.40E+07	2.72E+06	216.42
Daunorubicin 0.6 $\mu$ g/mL	4.09E+05	6.41E+04	3.69
Ellence 6 $\mu$ g/mL	1.06E+08	4.85E+07	952.50
Ellence 3 $\mu$ g/mL	1.33E+07	2.70E+06	120.13
Ellence 0.6 $\mu$ g/mL	3.81E+05	1.78E+05	3.43
Idamycin 6 $\mu$ g/mL	3.87E+04	2.00E+04	0.35
Idamycin 3 $\mu$ g/mL	5.99E+08	1.91E+08	5396.31
Idamycin 0.6 $\mu$ g/mL	5.30E+07	1.48E+07	477.76

Average luciferase expression in males, females and group.




Fig 20



(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
21 October 2004 (21.10.2004)

PCT

(10) International Publication Number  
**WO 2004/090145 A3**

(51) International Patent Classification<sup>7</sup>: C12N 15/864,  
A61K 48/00

John, F. [US/US]; 8 Laredo Court, Iowa City, Iowa 52246  
(US).

(21) International Application Number:  
PCT/US2004/010045

(74) Agents: STEFFEY, Charles, E. et al.; Schwegman, Lund-  
berg, Woessner & Kluth P.A., P.O. Box 2938, Minneapolis,  
Minnesota 55402 (US).

(22) International Filing Date: 31 March 2004 (31.03.2004)

(25) Filing Language: English

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(26) Publication Language: English

(30) Priority Data:  
60/459,323 31 March 2003 (31.03.2003) US  
60/512,347 16 October 2003 (16.10.2003) US

(71) Applicants (for all designated States except US): UNI-  
VERSITY OF IOWA RESEARCH FOUNDATION  
[US/US]; Oakdale Research Center, 100 Oakdale Campus  
#214 TIC, Iowa City, Iowa 52242-5000 (US). TAR-  
GETED GENETICS CORPORATION [US/US]; 1100  
Olive Way, Suite 100, Seattle, Washington 98101 (US).

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-  
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

(71) Applicant and


(72) Inventor: MUNSON, Keith, L. [US/US]; 29 Eturia Street,  
#308, Seattle, Washington 98109 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): ENGELHARDT,

[Continued on next page]

(54) Title: COMPOUNDS AND METHODS TO ENHANCE RAAV TRANSDUCTION



(57) Abstract: Agents and methods to alter rAAV transduction are provided.



**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**(88) Date of publication of the international search report:**

24 February 2005

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/010045

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12N15/864 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/75365 A (ENGELHARDT JOHN F ; UNIV IOWA RES FOUND (US); DUAN DONGSHENG (US)) 14 December 2000 (2000-12-14)	1-66
Y	discussion on page 82 ff. page 79, line 1 - page 80, line 3; claims 82,83	33-60, 62-64,66
X	DUAN D ET AL: "Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus" JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 105, no. 11, June 2000 (2000-06), pages 1573-1587, XP002962239 ISSN: 0021-9738	1-66
Y	cited in the application abstract; figures 2,9	33-60, 62-64,66
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

10 December 2004

Date of mailing of the international search report

10.01.05

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Griesinger, I

## INTERNATIONAL SEARCH REPORT

 International Application No  
 PCT/US2004/010045

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TERAMOTO S ET AL: "Factors influencing adeno-associated virus-mediated gene transfer to human cystic fibrosis airway epithelial cells: Comparison with adenovirus vectors" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 11, November 1998 (1998-11), pages 8904-8912, XP002154339 ISSN: 0022-538X abstract; figure 9 -----	1-66
Y	MENG LIHAO ET AL: "Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 18, 31 August 1999 (1999-08-31), pages 10403-10408, XP002168150 ISSN: 0027-8424 abstract -----	33-60, 62-64,66
Y	KIYOMIYA KEN-ICHI ET AL: "The role of the proteasome in apoptosis induced by anthracycline anticancer agents" INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 20, no. 6, June 2002 (2002-06), pages 1205-1209, XP002310166 ISSN: 1019-6439 abstract -----	33-60, 62-64,66
A	ARCAMONE F M: "From the pigments of the actinomycetes to third generation antitumor anthracyclines" BIOCHIMIE (PARIS), vol. 80, no. 3, March 1998 (1998-03), pages 201-206, XP002310167 ISSN: 0300-9084 abstract -----	33-60, 62-64,66
A	ELLIOTT P J ET AL: "RECENT ADVANCES IN UNDERSTANDING PROTEASOME FUNCTION" CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, vol. 5, no. 2, 1999, pages 484-490, XP001070303 ISSN: 1367-6733 page 484, right-hand column, paragraph 3 - page 486, right-hand column, last paragraph ----- -/--	1-66

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/010045

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	YAN Z ET AL: "Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 12, 6 June 2000 (2000-06-06), pages 6716-6721, XP002162085 ISSN: 0027-8424 abstract; figure 1 -----	9-15, 35-40
A	EP 1 153 612 A (KITASATO INST ; NIPPON KAYAKU KK (JP); TSURUO TAKASHI (US)) 14 November 2001 (2001-11-14) abstract page 5, line 28 - page 7, line 22 -----	61-66
P,X	YAN ZIYING ET AL: "Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia." JOURNAL OF VIROLOGY, vol. 78, no. 6, March 2004 (2004-03), pages 2863-2874, XP002296726 ISSN: 0022-538X abstract -----	1-66

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US2004/010045

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0075365	A	14-12-2000	AU 5869400 A	28-12-2000
			CA 2376400 A1	14-12-2000
			EP 1190249 A2	27-03-2002
			JP 2003501068 T	14-01-2003
			WO 0075365 A2	14-12-2000
EP 1153612	A	14-11-2001	CA 2362426 A1	17-08-2000
			EP 1153612 A1	14-11-2001
			CN 1339970 T	13-03-2002
			WO 0047230 A1	17-08-2000

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US2004/010045

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 1-60 could be understood to be directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,  
no additional fees are to be refunded.

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
  
1-32, 61, 65 (all claims completely), claims 33-60, 62-64  
66 (all claims partially)
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.